<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women - Taithongchai, A - 2023 | Cochrane Library</title> <meta content="Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women - Taithongchai, A - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014592.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women - Taithongchai, A - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014592.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD014592.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women" name="citation_title"/> <meta content="Annika Taithongchai" name="citation_author"/> <meta content="King's College Hospital" name="citation_author_institution"/> <meta content="annika.taithongchai@nhs.net" name="citation_author_email"/> <meta content="Eugenie E Johnson" name="citation_author"/> <meta content="Sharif I Ismail" name="citation_author"/> <meta content="Royal Sussex County Hospital" name="citation_author_institution"/> <meta content="Evelyn Barron-Millar" name="citation_author"/> <meta content="Newcastle University" name="citation_author_institution"/> <meta content="Ashleigh Kernohan" name="citation_author"/> <meta content="Newcastle University" name="citation_author_institution"/> <meta content="Ranee Thakar" name="citation_author"/> <meta content="Croydon University Hospital NHS Trust" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD014592.pub2" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/07/11" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014592.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014592.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014592.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Estrogens [therapeutic use]; *Pelvis; Pessaries; *Postmenopause; Urinary Bladder" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014592.pub2&amp;doi=10.1002/14651858.CD014592.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014592.pub2&amp;doi=10.1002/14651858.CD014592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014592.pub2&amp;doi=10.1002/14651858.CD014592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014592.pub2&amp;doi=10.1002/14651858.CD014592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014592.pub2&amp;doi=10.1002/14651858.CD014592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014592.pub2&amp;doi=10.1002/14651858.CD014592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014592.pub2&amp;doi=10.1002/14651858.CD014592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014592.pub2&amp;doi=10.1002/14651858.CD014592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014592.pub2&amp;doi=10.1002/14651858.CD014592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014592.pub2&amp;doi=10.1002/14651858.CD014592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014592.pub2&amp;doi=10.1002/14651858.CD014592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014592.pub2&amp;doi=10.1002/14651858.CD014592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014592.pub2&amp;doi=10.1002/14651858.CD014592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014592.pub2&amp;doi=10.1002/14651858.CD014592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014592.pub2&amp;doi=10.1002/14651858.CD014592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014592.pub2&amp;doi=10.1002/14651858.CD014592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014592.pub2&amp;doi=10.1002/14651858.CD014592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014592.pub2&amp;doi=10.1002/14651858.CD014592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014592.pub2&amp;doi=10.1002/14651858.CD014592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014592.pub2&amp;doi=10.1002/14651858.CD014592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014592.pub2&amp;doi=10.1002/14651858.CD014592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014592.pub2&amp;doi=10.1002/14651858.CD014592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014592.pub2&amp;doi=10.1002/14651858.CD014592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="7LavyS58";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD014592\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD014592\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014592\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014592\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ko","th","ms","ja","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD014592.pub2",title:"Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women",firstPublishedDate:"Jul 11, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Incontinence Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7LavyS58&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014592.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014592.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD014592.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD014592.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014592.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD014592.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD014592.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD014592.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD014592.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD014592.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2726 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD014592.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/full#CD014592-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/full#CD014592-sec-0123"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/full#CD014592-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/full#CD014592-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/full#CD014592-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/full#CD014592-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/full#CD014592-sec-0045"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/full#CD014592-sec-0116"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/appendices#CD014592-sec-0128"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/supinfo/CD014592-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/supinfo/CD014592-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/information#CD014592-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Annika Taithongchai</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/information#CD014592-cr-0005">Eugenie E Johnson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/information#CD014592-cr-0006">Sharif I Ismail</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/information#CD014592-cr-0007">Evelyn Barron-Millar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/information#CD014592-cr-0008">Ashleigh Kernohan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014592.pub2/information#CD014592-cr-0009">Ranee Thakar</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/information/en#CD014592-sec-0135">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 11 July 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD014592.pub2">https://doi.org/10.1002/14651858.CD014592.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD014592-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014592-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD014592-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014592-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014592-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD014592-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD014592-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD014592-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD014592-abs-0001" lang="en"> <section id="CD014592-sec-0001"> <h3 class="title" id="CD014592-sec-0001">Background</h3> <p>Pelvic organ prolapse (POP) is the descent of a woman's uterus, bladder, or rectum into the vagina. It affects 50% of women over 50 years old who have given birth to at least one child, and recognised risk factors are older age, higher number of births, and higher body mass index. This review assesses the effects of oestrogen therapy, alone or in combination with other treatments, on POP in postmenopausal women. </p> </section> <section id="CD014592-sec-0002"> <h3 class="title" id="CD014592-sec-0002">Objectives</h3> <p>To assess the benefits and harms of local and systemic oestrogen therapy in the management of pelvic organ prolapse symptoms in postmenopausal women, and to summarise the principal findings of relevant economic evaluations. </p> </section> <section id="CD014592-sec-0003"> <h3 class="title" id="CD014592-sec-0003">Search methods</h3> <p>We searched the Cochrane Incontinence Specialised Register (up to 20 June 2022), which includes CENTRAL, MEDLINE, two trials registers, and handsearching of journals and conference proceedings. We also checked the reference lists of relevant articles for additional studies. </p> </section> <section id="CD014592-sec-0004"> <h3 class="title" id="CD014592-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs), quasi‐RCTs, multi‐arm RCTs, and cross‐over RCTs that evaluated the effects of oestrogen therapy (alone or in combination with other treatments) versus placebo, no treatment, or other interventions in postmenopausal women with any grade of POP. </p> </section> <section id="CD014592-sec-0005"> <h3 class="title" id="CD014592-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data from the included trials using prespecified outcome measures and a piloted extraction form. The same review authors independently assessed the risk of bias of eligible trials using Cochrane's risk of bias tool. Had data allowed, we would have created summary of findings tables for our main outcome measures and assessed the certainty of the evidence using GRADE. </p> </section> <section id="CD014592-sec-0006"> <h3 class="title" id="CD014592-sec-0006">Main results</h3> <p>We identified 14 studies including a total of 1002 women. In general, studies were at high risk of bias in terms of blinding of participants and personnel, and there were also some concerns about selective reporting. Owing to insufficient data for the outcomes of interest, we were unable to perform our planned subgroup analyses (systemic versus topical oestrogen, parous versus nulliparous women, women with versus without a uterus). </p> <p>No studies assessed the effects of oestrogen therapy alone versus no treatment, placebo, pelvic floor muscle training, devices such as vaginal pessaries, or surgery. However, we did identify three studies that assessed oestrogen therapy in conjunction with vaginal pessaries versus vaginal pessaries alone and 11 studies that assessed oestrogen therapy in conjunction with surgery versus surgery alone. </p> </section> <section id="CD014592-sec-0007"> <h3 class="title" id="CD014592-sec-0007">Authors' conclusions</h3> <p>There was insufficient evidence from RCTs to draw any solid conclusions on the benefits or harms of oestrogen therapy for managing POP symptoms in postmenopausal women. Topical oestrogen in conjunction with pessaries was associated with fewer adverse vaginal events compared with pessaries alone, and topical oestrogen in conjunction with surgery was associated with reduced postoperative urinary tract infections compared with surgery alone; however, these findings should be interpreted with caution, as the studies that contributed data varied substantially in their design. </p> <p>There is a need for larger studies on the effectiveness and cost‐effectiveness of oestrogen therapy, used alone or in conjunction with pelvic floor muscle training, vaginal pessaries, or surgery, for the management of POP. These studies should measure outcomes in the medium and long term. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD014592-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014592-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD014592-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014592-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014592-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD014592-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD014592-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD014592-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD014592-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD014592-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD014592-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD014592-abs-0002" lang="en"> <h3>Does oestrogen therapy help to treat pelvic organ prolapse in postmenopausal women?</h3> <p><b>Key messages</b> </p> <p>• Although 14 studies met the inclusion criteria for this review, no studies addressed our comparisons of greatest interest, so we are uncertain about the effects of oestrogen therapy on pelvic organ prolapse in postmenopausal women. </p> <p>• Further research is needed to assess the effects of oestrogen therapy, alone or in combination with other treatments, on pelvic organ prolapse in postmenopausal women. </p> <p><b>What is pelvic organ prolapse?</b> </p> <p>Pelvic organ prolapse is when a woman's uterus (womb), bladder, or rectum moves down from its normal position into the vagina. It is a common condition, affecting 50% of women over 50 years old who have had at least one child. Between 6% and 12% of women who have had a hysterectomy (surgical removal of the uterus) will experience pelvic organ prolapse. Women who are older, who have had more children, and who are overweight are more likely to have pelvic organ prolapse. Women with pelvic organ prolapse may have the feeling of "something coming down" into the vagina, or other symptoms that can negatively affect their quality of life and body image, such as discomfort during sex or urinary problems. </p> <p><b>What did we want to find out?</b> </p> <p>Many clinicians prescribe oestrogen therapy (a type of hormonal therapy) to treat pelvic organ prolapse, sometimes in combination with other treatments such as a pessary (a device inserted into the vagina to provide support) or surgery. However, the benefits of this approach are unclear. We wanted to find out whether using oestrogen therapy, either alone or together with other treatments, could improve the symptoms of pelvic organ prolapse in women after their menopause. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that investigated the effects of oestrogen therapy, either alone or in combination with other treatments such as pessaries or surgery, on postmenopausal women. We compared and summarised the results of these studies and rated our confidence in the results based on aspects such as methods and number of participants. </p> <p><b>What did we find?</b> </p> <p>We found 14 studies involving a total of 1002 women. Ten studies recruited women with different severities of pelvic organ prolapse. There were differences across studies in terms of the location of pelvic organ prolapse, the number of children the women had had, whether the women had had a hysterectomy, and the type of oestrogen therapy being investigated. </p> <p><b>Main results</b> </p> <p>Although we identified 14 eligible studies, no studies addressed our main comparisons of interest (oestrogen therapy alone compared with no treatment, compared with pelvic floor muscle exercises, compared with surgery, or compared with devices such as vaginal pessaries). Four studies evaluated oestrogen therapy alongside vaginal pessaries compared with vaginal pessaries alone, and 10 studies evaluated oestrogen therapy alongside surgery compared with surgery alone. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>The evidence is very uncertain because of concerns about the studies' methods. The women were often aware of the treatments they were receiving, which may have affected the results. Additionally, many studies included few women. </p> <p><b>How up to date is this evidence?</b> </p> <p>The evidence is up to date to 20 June 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD014592-sec-0123" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD014592-sec-0123"></div> <h3 class="title" id="CD014592-sec-0124">Implications for practice</h3> <section id="CD014592-sec-0124"> <p>The available evidence suggests that topical oestrogen may reduce the risk of minor adverse vaginal events when used in conjunction with pessaries for pelvic organ prolapse (POP). In addition, when used in conjunction with surgery for POP, topical oestrogen may reduce the risk of early urinary tract infections. There is no evidence of significant harm or adverse events attributable to vaginal oestrogen. However, these findings should be interpreted with caution, as the studies that contributed data varied substantially in their design. Therefore, we are unable to provide evidence‐based recommendations regarding the use of oestrogen for treating POP, either alone or in conjunction with surgery or support pessaries, as the evidence is uncertain. </p> </section> <h3 class="title" id="CD014592-sec-0125">Implications for research</h3> <section id="CD014592-sec-0125"> <p>Topical oestrogen may play an adjunctive role in the treatment of POP when used alongside surgery or support pessaries. The data appear to imply that minor adverse vaginal events related to support pessaries are less common among women who are also using topical oestrogen. There is a need for sufficiently powered studies to assess appropriate outcomes over a longer time frame. No studies investigated whether oestrogen can improve the long‐term integrity of surgical repair or prolonged use of pessaries. Short‐term complications following surgical repair are insignificant compared to the burden of longer‐term failure of the procedure (prolapse recurrence). </p> <p>The data suggest that preoperative use of topical oestrogen may reduce the risk of early postoperative urinary tract infection. It seems logical that preoperative use of topical oestrogen would improve the vaginal tissue quality to provide a better substrate for suture placement for surgical repair and improve postoperative tissue healing. However, many of the outcome measures in the included studies, such as vaginal epithelial thickness, are surrogate outcomes for tissue quality. If preoperative oestrogen does improve tissue quality as hypothesized, then postoperative use until full healing may also provide further benefits. Meaningful studies demonstrating the mode of effect of preoperative oestrogen on long‐term surgical outcomes should be adequately powered and randomised, comparing tissue quality between oestrogenised and non‐oestrogenised groups and subsequent long‐term surgical outcomes. </p> <p>In addition, there is a need to develop appropriate measures for assessing adherence to oestrogen therapy and reasons for discontinuation. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD014592-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD014592-sec-0008"></div> <div class="table" id="CD014592-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Oestrogen therapy alone versus no treatment or placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oestrogen therapy alone versus no treatment or placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women with POP </p> <p><b>Setting:</b> primary or secondary care </p> <p><b>Intervention:</b> oestrogen therapy </p> <p><b>Comparison:</b> no treatment or placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with oestrogens</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no treatment or placebo</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subjective improvement or cure of POP symptoms</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement or cure of associated sexual symptoms</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Objective improvement or cure of POP symptoms</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Generic quality of life measures</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant adherence to intervention</b><br/>Follow‐up: various time points </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Minor adverse effects: vaginal events</b><br/>Follow‐up: longest time point reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major adverse events</b><br/>Follow‐up: longest time point reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>POP:</b> pelvic organ prolapse. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD014592-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oestrogen therapy alone versus pelvic floor muscle training</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oestrogen therapy alone versus pelvic floor muscle training</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women with POP </p> <p><b>Setting:</b> primary or secondary care </p> <p><b>Intervention:</b> oestrogen therapy </p> <p><b>Comparison:</b> pelvic floor muscle training </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with oestrogens</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with PFMT</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subjective improvement or cure of POP symptoms</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement or cure of associated sexual symptoms</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Objective improvement or cure of POP symptoms</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Generic quality of life measures</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant adherence to intervention</b><br/>Follow‐up: various time points </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Minor adverse effects: vaginal events</b><br/>Follow‐up: longest time point reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major adverse events</b><br/>Follow‐up: longest time point reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>PFMT:</b> pelvic floor muscle training; <b>POP:</b> pelvic organ prolapse. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD014592-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oestrogen therapy alone versus devices such as vaginal pessaries</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oestrogen therapy alone versus devices such as vaginal pessaries</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women with POP </p> <p><b>Setting:</b> primary or secondary care </p> <p><b>Intervention:</b> oestrogen therapy </p> <p><b>Comparison:</b> devices such as vaginal pessaries </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with oestrogens</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no treatment or placebo</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subjective improvement or cure of POP symptoms</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement or cure of associated sexual symptoms</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Objective improvement or cure of POP symptoms</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Generic quality of life measures</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant adherence to intervention</b><br/>Follow‐up: various time points </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Minor adverse effects: vaginal events</b><br/>Follow‐up: longest time point reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major adverse events</b><br/>Follow‐up: longest time point reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>POP:</b> pelvic organ prolapse. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD014592-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Oestrogen therapy alone versus surgery</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oestrogen therapy alone versus surgery</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women with POP </p> <p><b>Setting:</b> primary or secondary care </p> <p><b>Intervention:</b> oestrogen therapy </p> <p><b>Comparison:</b> surgery </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with oestrogens</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no treatment or placebo</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subjective improvement or cure of POP symptoms</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement or cure of associated sexual symptoms</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Objective improvement or cure of POP symptoms</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Generic quality of life measures</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant adherence to intervention</b><br/>Follow‐up: various time points </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Minor adverse effects: vaginal events</b><br/>Follow‐up: longest time point reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major adverse events</b><br/>Follow‐up: longest time point reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>POP:</b> pelvic organ prolapse. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD014592-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD014592-sec-0009"></div> <p>For a glossary of terms, see <a href="./appendices#CD014592-sec-0129">Appendix 1</a>. </p> <section id="CD014592-sec-0010"> <h3 class="title" id="CD014592-sec-0010">Description of the condition</h3> <p>Pelvic organ prolapse (POP) is common, affecting 50% of women aged over 50 years who have given birth to at least one child (<a href="./references#CD014592-bbs2-0045" title="DeLanceyJO . Anatomy and biomechanics of genital prolapse. Clinical Obstetrics and Gynecology1993;36(4):897-909.">DeLancey 1993</a>). POP is defined by the International Continence Society (ICS) and the International Urogynecological Association (IUGA) as the "descent of one or more of the anterior vaginal wall, posterior vaginal wall, the uterus (cervix) or the apex of the vagina [...correlated with] relevant POP symptoms" (<a href="./references#CD014592-bbs2-0059" title="HaylenBT , MaherCF , BarberMD , CamargoSF , DandoluV , DigesuA , et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for pelvic organ prolapse (POP). International Urogynecology Journal2016;27(2):165-94.">Haylen 2016</a>). Symptoms can include a bothersome vaginal lump or bulge, and can impact on urinary, bowel, and sexual health. Research has shown that the condition adversely impacts women's quality of life and body image (<a href="./references#CD014592-bbs2-0065" title="JelovsekJE , BarberMD . Women seeking treatment for advanced pelvic organ prolapse have decreased body image and quality of life. American Journal of Obstetrics and Gynecology2006;194(5):1455-61.">Jelovsek 2006</a>). There are a number of recognised risk factors for POP, including older age, increasing number of births (parity), higher body mass index (BMI), and vaginal delivery (<a href="./references#CD014592-bbs2-0094" title="VergeldtTF , WeemhoffM , IntHoutJ , KluiversKB . Risk factors for pelvic organ prolapse and its recurrence: a systematic review. International Urogynecology Journal2015;26(11):1559-73.">Vergeldt 2015</a>). Age is a particularly important risk factor for POP; both the incidence and prevalence of the condition increase with age (<a href="./references#CD014592-bbs2-0086" title="SalvatoreS , RademakersK , DeLanceyJ , IgawaY , KoelblH , LaterzaRM , et al. Pathophysiology of urinary incontinence, faecal incontinence and pelvic organ prolapse. In: AbramsP , CardozoL , WaggA , WeinA , editors(s). Incontinence: 6th International Consultation on Incontinence. Bristol (UK): ICI-ICS. International Continence Society, 2017:361-496. [ISBN: 978-0-9569607-3-3]">Salvatore 2017</a>). Additionally, 6% to 12% of women who have undergone a hysterectomy will develop prolapse (<a href="./references#CD014592-bbs2-0072" title="MaherC , BaesslerK , BarberM , CheonC , ConstenE , CooperK , et al. Pelvic organ prolapse surgery. In: AbramsP , CardozoL , WaggA , WeinA , editors(s). Incontinence: 6th International Consultation on Incontinence. Bristol (UK): ICI-ICS. International Continence Society, 2017:1855-993. [ISBN: 978-0-9569607-3-3]">Maher 2017</a>). Nonetheless, the aetiology is often multifactorial (<a href="./references#CD014592-bbs2-0047" title="DietzHP . The aetiology of prolapse. International Urogynecology Journal2008;19(10):1323-9.">Dietz 2008</a>). </p> <p>As well as affecting women's quality of life, POP has considerable resource implications that impact the health care system. The estimated annual cost of managing POP in 2005 was over EUR 144.2 million in Germany, more than EUR 83 million in France, and just over EUR 81 million in England (<a href="./references#CD014592-bbs2-0092" title="SubramanianD , SzwarcenszteinK , MauskopfJA , SlackMC . Rate, type, and cost of pelvic organ prolapse surgery in Germany, France, and England. European Journal of Obstetrics, Gynecology and Reproductive Biology2009;144(2):177-81.">Subramanian 2009</a>). </p> </section> <section id="CD014592-sec-0011"> <h3 class="title" id="CD014592-sec-0011">Description of the intervention</h3> <p>There are various conservative and surgical options for treating POP (<a href="./references#CD014592-bbs2-0056" title="HagenS , StarkD . Conservative prevention and management of pelvic organ prolapse in women. Cochrane Database of Systematic Reviews2011, Issue 12. Art. No: CD003882. [DOI: 10.1002/14651858.CD003882.pub4]">Hagen 2011</a>; <a href="./references#CD014592-bbs2-0076" title="MowatA , MaherD , BaesslerK , Christmann-SchmidC , HayaN , MaherC . Surgery for women with posterior compartment prolapse. Cochrane Database of Systematic Reviews2018, Issue 3. Art. No: CD012975. [DOI: 10.1002/14651858.CD012975]">Mowat 2018</a>). When deciding on the most appropriate option, factors to consider include the woman's preference, age, comorbidities, lifestyle factors, type of prolapse, and previous pelvic floor surgery (<a href="./references#CD014592-bbs2-0078" title="National Institute for Health and Care Excellence (NICE). Urinary incontinence and pelvic organ prolapse in women: management NICE guideline [NG123]. Published: 2 April 2019; last updated: 24 June 2019. Available at nice.org.uk/guidance/ng123 (accessed 26 June 2022).">NICE 2019</a>). Conservative management includes lifestyle modifications (such as weight loss, minimising heavy lifting, and preventing or treating constipation; <a href="./references#CD014592-bbs2-0078" title="National Institute for Health and Care Excellence (NICE). Urinary incontinence and pelvic organ prolapse in women: management NICE guideline [NG123]. Published: 2 April 2019; last updated: 24 June 2019. Available at nice.org.uk/guidance/ng123 (accessed 26 June 2022).">NICE 2019</a>), pelvic floor muscle training (PFMT) for mild or moderate POP (<a href="./references#CD014592-bbs2-0056" title="HagenS , StarkD . Conservative prevention and management of pelvic organ prolapse in women. Cochrane Database of Systematic Reviews2011, Issue 12. Art. No: CD003882. [DOI: 10.1002/14651858.CD003882.pub4]">Hagen 2011</a>, <a href="./references#CD014592-bbs2-0078" title="National Institute for Health and Care Excellence (NICE). Urinary incontinence and pelvic organ prolapse in women: management NICE guideline [NG123]. Published: 2 April 2019; last updated: 24 June 2019. Available at nice.org.uk/guidance/ng123 (accessed 26 June 2022).">NICE 2019</a>), and vaginal pessaries (small mechanical devices placed in the vagina to provide support; <a href="./references#CD014592-bbs2-0038" title="BuggeC , AdamsEJ , GopinathD , StewartF , DembinskyM , SobiesuoP , et al. Pessaries (mechanical devices) for pelvic organ prolapse in women. Cochrane Database of Systematic Reviews2020, Issue 11. Art. No: CD004010. [DOI: 10.1002/14651858.CD004010.pub4]">Bugge 2020</a>). </p> <p>Clinicians commonly prescribe oestrogen‐only hormone replacement therapy (or oestrogen therapy) to treat POP. This therapy consists of either natural or synthetic oestrogens, and can be administered either systemically, through oral tablets, transdermal skin patches, or subcutaneous implants; or locally, through vaginal creams, tablets, or rings or pessaries impregnated with oestrogen (<a href="./references#CD014592-bbs2-0091" title="StevensonJC . Type and route of estrogen administration. Climacteric2009;12(Suppl 1):86-90.">Stevenson 2009</a>). Locally applied oestrogens result in less systemic absorption and hence a lower incidence of systemic side effects. When administered for the treatment of vaginal atrophy, there is no evidence of a difference between the various topical preparations with regard to efficacy or side‐effect profile (<a href="./references#CD014592-bbs2-0068" title="LethabyA , AyelekeRO , RobertsH . Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews2016, Issue 8. Art. No: CD001500. [DOI: 10.1002/14651858.CD001500.pub3]">Lethaby 2016</a>). </p> <p>Clinicians can prescribe oestrogen therapy as a standalone option or in conjunction with other treatments. Oestrogen therapy alongside PFMT can strengthen the vaginal wall, improve sensation (<a href="./references#CD014592-bbs2-0079" title="North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause2007;14(3 Pt 1):355-369.">North American Menopause Society 2007</a>), and possibly improve pelvic floor muscle function (<a href="./references#CD014592-bbs2-0088" title="SipiläS , TaaffeDR , ChengS , PuolakkaJ , ToivanenJ , SuominenH . Effects of hormone replacement therapy and high-impact physical exercise on skeletal muscle in post-menopausal women: a randomized placebo-controlled study. Clinical Science2001;101:147-157.">Sipilä 2001</a>). When used with vaginal pessaries, oestrogen therapy can help prevent or treat vaginal atrophy (a thinning, drying, and inflammation of the vaginal walls that can occur if a woman's body has less oestrogen) before pessary insertion (<a href="./references#CD014592-bbs2-0078" title="National Institute for Health and Care Excellence (NICE). Urinary incontinence and pelvic organ prolapse in women: management NICE guideline [NG123]. Published: 2 April 2019; last updated: 24 June 2019. Available at nice.org.uk/guidance/ng123 (accessed 26 June 2022).">NICE 2019</a>). If conservative treatments for POP fail, or if a woman declines these treatments, she may be offered surgery (<a href="./references#CD014592-bbs2-0078" title="National Institute for Health and Care Excellence (NICE). Urinary incontinence and pelvic organ prolapse in women: management NICE guideline [NG123]. Published: 2 April 2019; last updated: 24 June 2019. Available at nice.org.uk/guidance/ng123 (accessed 26 June 2022).">NICE 2019</a>). Surgical methods include anterior and posterior vaginal wall repair, hysterectomy or hysteropexy for uterine prolapse, and sacrospinous fixation or sacrocolpopexy for apical prolapse (<a href="./references#CD014592-bbs2-0073" title="MaherCF , BaesslerKK , BarberMD , CheongC , ConstenEC , CooperKG , et al. Surgical management of pelvic organ prolapse. Climacteric2019;22(3):229-35.">Maher 2019</a>). Surgery has a 30% POP recurrence rate (<a href="./references#CD014592-bbs2-0080" title="OlsenAL , SmithVJ , BergstromJO , CollingJC , ClarkAL . Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstetrics and Gynecology1997;89(4):501-6.">Olsen 1997</a>), and an estimated 11.5% of women who have POP surgery will have repeat POP surgery within 15 to 20 years (<a href="./references#CD014592-bbs2-0071" title="LøwensteinE , MøllerLA , LaigaardJ , GimbelH . Reoperation for pelvic organ prolapse: a Danish cohort study with 15–20 years' follow-up. International Urogynecology Journal2018;29(1):119-24.">Løwenstein 2018</a>). Repeat surgery most frequently involves the anterior compartment (cystocele). Some of these surgeries use native tissue and others involve the insertion of mesh. However, health authorities in several countries have suspended procedures involving vaginal mesh owing to concerns over long‐term complications. Like any operation, POP surgical procedures involve a risk of anaesthetic, thrombotic, cardiovascular, and surgical complications, as well as failure and recurrence (<a href="./references#CD014592-bbs2-0078" title="National Institute for Health and Care Excellence (NICE). Urinary incontinence and pelvic organ prolapse in women: management NICE guideline [NG123]. Published: 2 April 2019; last updated: 24 June 2019. Available at nice.org.uk/guidance/ng123 (accessed 26 June 2022).">NICE 2019</a>). One key objective of prescribing preoperative local oestrogen is to improve vaginal tissues for surgery to avoid tearing or reduce infection. One feasibility study published in 2020 showed that a randomised controlled trial (RCT) designed to evaluate the efficacy of this approach would be feasible, with high fidelity (<a href="./references#CD014592-bbs2-0095" title="VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141.">Verghese 2020</a>). </p> </section> <section id="CD014592-sec-0012"> <h3 class="title" id="CD014592-sec-0012">How the intervention might work</h3> <p>The female genital tract is sensitive to oestrogen. After the menopause, there is a reduction in circulating oestrogen, which leads to atrophy, loss of vaginal folds (rugae), vaginal dryness, weakening and thinning of vaginal epithelium and pelvic‐supporting fascia and ligaments, and changes in vaginal pH (<a href="./references#CD014592-bbs2-0046" title="DelanceyJO . Fascial and muscular abnormalities in women with urethral hypermobility and anterior vaginal wall prolapse. American Journal of Obstetrics and Gynecology2002;187(1):93-8.">DeLancey 2002</a>; <a href="./references#CD014592-bbs2-0077" title="NaumovaI , Castelo-BrancoC . Current treatment options for postmenopausal vaginal atrophy. International Journal of Women's Health2018;10:387-95.">Naumova 2018</a>; <a href="./references#CD014592-bbs2-0098" title="WhitesideJL , BarberMD , ParaisoMF , WaltersMD . Vaginal rugae: measurement and significance. Climacteric2005;8(1):71-5.">Whiteside 2005</a>). Oestrogen therapy can improve many of these issues (<a href="./references#CD014592-bbs2-0077" title="NaumovaI , Castelo-BrancoC . Current treatment options for postmenopausal vaginal atrophy. International Journal of Women's Health2018;10:387-95.">Naumova 2018</a>). The exact mechanism of oestrogen therapy in the treatment of POP is unclear, but experts believe that collagen degradation in the pelvic floor connective tissue decreases in the presence of oestrogen (<a href="./references#CD014592-bbs2-0036" title="Bodner-AdlerB , AlarabM , Ruiz-ZapataAM , LattheP . Effectiveness of hormones in postmenopausal pelvic floor dysfunction – International Urogynecological Association research and development – committee opinion. International Urogynecology Journal2020;31(8):1577-82. [DOI: 10.1007/s00192-019-04070-0]">Bodner‐Adler 2020</a>). </p> <p>When used with other therapies, oestrogen could improve their efficacy to reduce POP symptoms and also minimise their associated side effects by optimising the strength of pelvic organ supporting ligaments, muscles, and the vaginal epithelium. For example, thinner vaginal tissues are more susceptible to trauma from the friction of a pessary, and locally applied oestrogen could improve the elasticity, strength, and moistness of the vaginal wall and reduce pessary‐related complications (<a href="./references#CD014592-bbs2-0070" title="LindahlSH . Reviewing the options for local estrogen treatment of vaginal atrophy. International Journal of Women's Health2014;6:307-12.">Lindahl 2014</a>). </p> </section> <section id="CD014592-sec-0013"> <h3 class="title" id="CD014592-sec-0013">Why it is important to do this review</h3> <p>The incidence of POP will likely increase as the population continues to age (<a href="./references#CD014592-bbs2-0094" title="VergeldtTF , WeemhoffM , IntHoutJ , KluiversKB . Risk factors for pelvic organ prolapse and its recurrence: a systematic review. International Urogynecology Journal2015;26(11):1559-73.">Vergeldt 2015</a>). Therefore, evidence is needed to guide clinicians in optimising the management of postmenopausal women with POP. Many clinicians prescribe oestrogens in daily clinical practice to treat POP, sometimes in conjunction with other therapies such as pessaries or surgery, without clear supporting evidence. With this review, we aimed to synthesise information from RCTs to confirm the appropriateness of current practice, ensure that the management of POP with oestrogens is evidence‐based, and highlight the potential need for future research. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD014592-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD014592-sec-0014"></div> <p>To assess the benefits and harms of local and systemic oestrogen therapy in the management of pelvic organ prolapse symptoms in postmenopausal women, and to summarise the principal findings of relevant economic evaluations. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD014592-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD014592-sec-0015"></div> <section id="CD014592-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD014592-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included RCTs and quasi‐RCTs (studies where allocation to groups is not strictly random, e.g. by day of the week), including multi‐arm and cross‐over trials. </p> </section> <section id="CD014592-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included studies that enrolled postmenopausal women (at least one year since last menses) with any grade or type of POP. We considered trials with a mix of postmenopausal and premenopausal women if there were separate data for postmenopausal women. </p> </section> <section id="CD014592-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included studies that used any compound containing natural or synthetic oestrogen in any form or dose, for any length of time. We had planned to analyse systemic and local routes of administration via subgroup analyses. </p> <p>We had planned to prepare summary of findings tables for the following comparisons.</p> <p> <ul id="CD014592-list-0001"> <li> <p>Oestrogen therapy alone versus no treatment or placebo</p> </li> <li> <p>Oestrogen therapy alone versus PFMT</p> </li> <li> <p>Oestrogen therapy alone versus devices such as vaginal pessaries</p> </li> <li> <p>Oestrogen therapy alone versus surgery</p> </li> </ul> </p> <p>We were also interested in analysing the following comparisons.</p> <p> <ul id="CD014592-list-0002"> <li> <p>Oestrogen therapy in conjunction with PFMT versus PFMT alone</p> </li> <li> <p>Oestrogen therapy in conjunction with vaginal pessaries versus vaginal pessaries alone</p> </li> <li> <p>Oestrogen therapy in conjunction with surgery versus surgery alone</p> </li> </ul> </p> </section> <section id="CD014592-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p><a href="./appendices#CD014592-sec-0130">Appendix 2</a> presents the definitions of abbreviations for outcome measurement tools. </p> <section id="CD014592-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD014592-list-0003"> <li> <p>Participant‐reported subjective improvement or cure of POP symptoms, measured with tools such as a visual analogue scale (VAS; <a href="./references#CD014592-bbs2-0093" title="UlrichD , Guzman RojasR , DietzHP , MannK , TrutnovskyG . Use of a visual analog scale for evaluation of bother from pelvic organ prolapse. Ultrasound in Obstetrics and Gynecology2014;43(6):693-7.">Ulrich 2014</a>) or the Patient Global Impression of Improvement (PGI‐I; <a href="./references#CD014592-bbs2-0089" title="SrikrishnaS , RobinsonD , CardozoL . Validation of the patient global impression of improvement (PGI-I) for urogenital prolapse. International Urogynecology Journal2010;21(5):523-8.">Srikrishna 2010</a>) </p> </li> </ul> </p> </section> <section id="CD014592-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD014592-list-0004"> <li> <p>Improvement or cure of associated urinary symptoms, measured by validated questionnaires such as the King's Health Questionnaire (KHQ; <a href="./references#CD014592-bbs2-0066" title="KelleherCJ , CardozoLD , KhullarV , SalvatoreS . A new questionnaire to assess the quality of life of urinary incontinent women. BJOG1997;104(12):1374-9.">Kelleher 1997</a>), the International Consultation on Incontinence Questionnaire‐Urinary Incontinence Short Form (ICIQ‐UI‐SF; <a href="./references#CD014592-bbs2-0031" title="AveryK , DonovanJ , PetersTJ , ShawC , GotohM , AbramsP . ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourology and Urodynamics2004;23(4):322-30.">Avery 2004</a>), or the International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms Modules (ICIQ‐FLUTS; <a href="./references#CD014592-bbs2-0037" title="BrookesST , DonovanJL , WrightM , JacksonS , AbramsP . A scored form of the Bristol female lower urinary tract symptoms questionnaire: data from a randomized controlled trial of surgery for women with stress incontinence. American Journal of Obstetrics and Gynecology2004;191(1):73-82.">Brookes 2004</a>) </p> </li> <li> <p>Improvement or cure of associated bowel symptoms, measured by validated questionnaires such as KHQ (<a href="./references#CD014592-bbs2-0066" title="KelleherCJ , CardozoLD , KhullarV , SalvatoreS . A new questionnaire to assess the quality of life of urinary incontinent women. BJOG1997;104(12):1374-9.">Kelleher 1997</a>) </p> </li> <li> <p>Improvement or cure of associated sexual symptoms, measured by validated questionnaires such as the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire, International Urogynecological Association‐Revised (PISQ‐IR; <a href="./references#CD014592-bbs2-0042" title="ConstantineML , PaulsRN , RogersRR , RockwoodTH . Validation of a single summary score for the prolapse/incontinence sexual questionnaire – IUGA revised (PISQ-IR). International Urogynecology Journal2017;28(12):1901-7.">Constantine 2017</a>) </p> </li> <li> <p>Objective improvement or cure of POP symptoms, measured by validated instruments such as the Pelvic Organ Prolapse Symptom Score (POP‐SS; <a href="./references#CD014592-bbs2-0054" title="HagenS , GlazenerC , SinclairL , StarkD , BuggeC . Psychometric properties of the pelvic organ prolapse symptom score. BJOG2009;116(1):25-31.">Hagen 2009</a>), the International Consultation on Incontinence Questionnaire Vaginal Symptoms Module (ICIQ‐VS; <a href="./references#CD014592-bbs2-0081" title="PriceN , JacksonSR , AveryK , BrookesST , AbramsP . Development and psychometric evaluation of the ICIQ vaginal symptoms questionnaire: the ICIQ-VS. BJOG2006;113(6):700-12.">Price 2006</a>), the Pelvic Organ Prolapse Quantification System (POP‐Q; <a href="./references#CD014592-bbs2-0039" title="BumpRC , MattiassonA , BøK , BrubakerLP , DeLanceyJO , KlarskovP , et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. American Journal of Obstetrics and Gynecology1996;175(1):10-7.">Bump 1996</a>), or the Australian Pelvic Floor Questionnaire (APFQ; <a href="./references#CD014592-bbs2-0032" title="BaesslerK , O'NeillSM , MaherCF , BattistuttaD . Australian pelvic floor questionnaire: a validated interviewer-administered pelvic floor questionnaire for routine clinic and research. International Urogynecology Journal2009;20(2):149-58.">Baessler 2009</a>) </p> </li> <li> <p>Condition‐specific quality of life, measured by prolapse‐specific quality of life questionnaires such as Pelvic Floor Distress Inventory (PFDI; <a href="./references#CD014592-bbs2-0034" title="BarberMD , KuchibhatlaMN , PieperCF , BumpRC . Psychometric evaluation of 2 comprehensive condition-specific quality of life instruments for women with pelvic floor disorders. American Journal of Obstetrics and Gynecology2001;185(6):1388-95.">Barber 2001</a>), the Pelvic Floor Impact Questionnaire (PFIQ; <a href="./references#CD014592-bbs2-0034" title="BarberMD , KuchibhatlaMN , PieperCF , BumpRC . Psychometric evaluation of 2 comprehensive condition-specific quality of life instruments for women with pelvic floor disorders. American Journal of Obstetrics and Gynecology2001;185(6):1388-95.">Barber 2001</a>), the Prolapse Quality of Life Questionnaire (P‐QOL; <a href="./references#CD014592-bbs2-0048" title="DigesuGA , KhullarV , CardozoL , RobinsonD , SalvatoreS . P-QOL: a validated questionnaire to assess the symptoms and quality of life of women with urogenital prolapse. International Urogynecology Journal2005;16(3):176-81.">Digesu 2005</a>), or the electronic Personal Assessment Questionnaire Pelvic Floor (ePAQ‐PF; <a href="./references#CD014592-bbs2-0083" title="RadleySC , JonesGL , TanguyEA , StevensVG , NelsonC , MathersNJ . Computer interviewing in urogynaecology: concept, development and psychometric testing of an electronic pelvic floor assessment questionnaire in primary and secondary care. BJOG2006;113(2):231-8.">Radley 2006</a>) </p> </li> <li> <p>Generic quality of life or health status, measured by generic quality of life questionnaires such as the Quality of Life Inventory (QOLI; <a href="./references#CD014592-bbs2-0052" title="FrischMB . Quality of Life Inventory Handbook: A Guide for Laypersons, Clients, and Coaches. Minneapolis, MN: NCS Pearson and Pearson, 2009.">Frisch 2009</a>), the Global Quality of Life Scale (GQOL; <a href="./references#CD014592-bbs2-0063" title="HylandME , SodergrenSC . Development of a new type of global quality of life scale, and comparison of performance and preference for 12 global scales. Quality of Life Research1996;5(5):469-80.">Hyland 1996</a>), or the Assessment of Quality of Life (AQoL; <a href="./references#CD014592-bbs2-0057" title="HawthorneG , RichardsonJ , OsborneR . The assessment of quality of life (AQoL) instrument: a psychometric measure of health-related quality of life. Quality of Life Research1999;8(3):209-24.">Hawthorne 1999</a>) </p> </li> <li> <p>Psychological or emotional well‐being outcome measures and ability to cope with daily activities, measured by generic quality of life questionnaires such as the Quality of Life Questionnaire (QLQ; <a href="./references#CD014592-bbs2-0051" title="EvansDR , BurnsJE , RobinsonWE , GarrettOJ . The quality of life questionnaire: a multidimensional measure. American Journal of Community Psychology1985;13(3):305-22.">Evans 1985</a>) </p> </li> <li> <p>Participant adherence to the intervention, including discontinuation of pessary use and declining surgical procedures </p> </li> <li> <p>Reduction in minor adverse events</p> <ul id="CD014592-list-0005"> <li> <p>Urinary tract infection (UTI)</p> </li> <li> <p>Vaginal events: vaginal itching, abrasion, ulcer, vaginitis, rash, bleeding, pain, vaginosis </p> </li> <li> <p>Urinary storage events: urinary retention, de novo urinary incontinence</p> </li> <li> <p>Sexual adverse events: dyspareunia or partner discomfort during intercourse</p> </li> </ul> </li> <li> <p>Major adverse events</p> <ul id="CD014592-list-0006"> <li> <p>Endometrial hyperplasia</p> </li> <li> <p>Thromboembolism</p> </li> <li> <p>Grade II Clavien‐Dindo complications (e.g. surgical site infection, haemorrhage, blood loss) </p> </li> </ul> </li> <li> <p>Surgical outcomes</p> <ul id="CD014592-list-0007"> <li> <p>Operative time</p> </li> <li> <p>Mesh exposure</p> </li> </ul> </li> </ul> </p> <section id="CD014592-sec-0023"> <h6 class="title">Timing of outcome assessment</h6> <p>We intended to assess outcomes at six months, 12 months, five years, and 10 years, except minor adverse events, major adverse events, and surgical outcomes, which we measured at the latest time point reported by study authors. </p> </section> <section id="CD014592-sec-0024"> <h6 class="title">Minimum important difference for outcomes</h6> <p>We determined the reported minimum important difference (MID) based on specific symptom and quality of life questionnaires. Some reported MIDs relate to surgical and non‐surgical management of prolapse. We looked for reported MIDs in the effect of oestrogen(s), either alone or alongside another treatment, or other treatment for POP. For example, a relevant MID would be the desired change resulting from the administration of local oestrogen cream either alongside pessary use for POP, or before and after surgery for POP. We found the following MIDs for various outcome measurement tools. </p> <p> <ul id="CD014592-list-0008"> <li> <p>ICIQ‐UI‐SF: a reduction of four points following non‐surgical intervention (<a href="./references#CD014592-bbs2-0069" title="LimR , LiongML , LimKK , LeongWS , YuenKH . The minimum clinically important difference of the international consultation on incontinence questionnaires (ICIQ-UI SF and ICIQ-LUTSqol). Urology2019;133:91-5.">Lim 2009</a>) </p> </li> <li> <p>KHQ: a change from baseline of five points following an intervention (<a href="./references#CD014592-bbs2-0067" title="KelleherCJ , PleilAM , ReesePR , BurgessSM , BrodishPH . How much is enough and who says so? The case of the King's Health Questionnaire and overactive bladder. BJOG2004;111(6):605-12.">Kelleher 2004</a>) </p> </li> <li> <p>POP‐SS: a reduction of 1.5 points or more (<a href="./references#CD014592-bbs2-0055" title="HagenS , GlazenerC , CookJ , HerbisonP , Toozs-HobsonP . Further properties of the pelvic organ prolapse symptom score: minimally important change and test-retest reliability (Abstract 175). Neurourology and Urodynamics2010;29(6):1055-6.">Hagen 2010</a>) </p> </li> <li> <p>PFDI: an improvement of eight points in the stress subscale for non‐surgical treatments (<a href="./references#CD014592-bbs2-0035" title="BarberMD , SpinoC , JanzNK , BrubakerL , NygaardI , NagerCW , et al, Pelvic Floor Disorders Network. The minimum important differences for the urinary scales of the pelvic floor distress inventory and pelvic floor impact questionnaire. American Journal of Obstetrics and Gynecology2009;200(5):580.e1-7.">Barber 2009</a>) </p> </li> <li> <p>PFIQ: an improvement of 16 points in the urinary impact questionnaire for non‐surgical treatment (<a href="./references#CD014592-bbs2-0035" title="BarberMD , SpinoC , JanzNK , BrubakerL , NygaardI , NagerCW , et al, Pelvic Floor Disorders Network. The minimum important differences for the urinary scales of the pelvic floor distress inventory and pelvic floor impact questionnaire. American Journal of Obstetrics and Gynecology2009;200(5):580.e1-7.">Barber 2009</a>) </p> </li> <li> <p>AQOL: 0.06 utility points over time (<a href="./references#CD014592-bbs2-0058" title="HawthorneG , OsborneR . Population norms and meaningful differences for the Assessment of Quality of Life (AQoL) measure. Australian and New Zealand Journal of Public Health2005;29(2):136-42.">Hawthorne 2005</a>) </p> </li> <li> <p>APFQ: one point after POP surgery (<a href="./references#CD014592-bbs2-0033" title="BaesslerK , MowatA , MaherCF . The minimal important difference of the Australian pelvic floor questionnaire. International Urogynaecology Journal2019;30(1):115-22.">Baessler 2019</a>) </p> </li> <li> <p>PISQ‐IR: 0.31 following surgery for POP (<a href="./references#CD014592-bbs2-0082" title="PruijssersB , van derVaartL , MilaniF , RooversJP , VollebregtA , van derVaartH . Minimal clinically important difference (MCID) for the pelvic organ prolapse-urinary incontinence sexual function questionnaire – IUGA revised (PISQ-IR). Journal of Sexual Medicine2021;18(7):1265-70.">Pruijssers 2021</a>) </p> </li> <li> <p>PISQ: an improvement of six points (<a href="./references#CD014592-bbs2-0074" title="MamikMM , RogersRG , QuallsCR , MorrowJD . The minimum important difference for the pelvic organ prolapse-urinary incontinence sexual function questionnaire. International Urogynecology Journal2014;25(10):1321-6.">Mamik 2014</a>) </p> </li> </ul> </p> <p>We found no MIDs for PGI‐I, ICIQ‐FLUTS, PISQ‐IR, ICIQ‐VS, P‐QOL, QOLI/GQOL, or QLQ. Available MID data for ePAQ‐PF are for surgical treatment of urinary incontinence only. </p> </section> <section id="CD014592-sec-0025"> <h6 class="title">Main outcomes for summary of findings tables</h6> <p> <ul id="CD014592-list-0009"> <li> <p>Subjective improvement or cure of POP symptoms (at 12 months)</p> </li> <li> <p>Improvement or cure of associated sexual symptoms (at 12 months)</p> </li> <li> <p>Objective improvement or cure of POP symptoms (at 12 months)</p> </li> <li> <p>Generic quality of life measures (at 12 months)</p> </li> <li> <p>Participant adherence to intervention (at 12 months)</p> </li> <li> <p>Minor adverse effects: vaginal events (at latest time point reported)</p> </li> <li> <p>Major adverse events (at latest time point reported)</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD014592-sec-0026"> <h3 class="title">Search methods for identification of studies</h3> <p>When searching for eligible studies, we imposed no restrictions on language, publication date, or publication status. </p> <section id="CD014592-sec-0027"> <h4 class="title">Electronic searches</h4> <section id="CD014592-sec-0028"> <h5 class="title">Search for clinical effectiveness studies</h5> <p>We identified relevant trials from the Cochrane Incontinence Specialised Register. For more details of the search methods used to build the Specialised Register, see the Group's <a href="http://incontinence.cochrane.org/resources/specialised-register" target="_blank">webpages</a>, which provide details of the Register's <a href="https://incontinence.cochrane.org/sites/incontinence.cochrane.org/files/public/uploads/cig_archied_specialised_register_1994-2007_0.pdf" target="_blank">development</a> (from inception) and the <a href="https://incontinence.cochrane.org/sites/incontinence.cochrane.org/files/public/uploads/cig_search_strategies_april_to_may_2018.pdf" target="_blank">most recent searches</a> performed to populate the Register. To summarise, the Register contains trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE In‐Process, MEDLINE Epub Ahead of Print, <a href="https://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>, the World Health Organization International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">WHO ICTRP</a>), and handsearching of journals and conference proceedings. </p> <p>The date of the most recent search was 20 June 2022.</p> <p><a href="./appendices#CD014592-sec-0131">Appendix 3</a> presents the terms we used to search the Cochrane Incontinence Specialised Register. </p> </section> <section id="CD014592-sec-0029"> <h5 class="title">Search for economic evaluations</h5> <p>We performed additional searches for the brief economic commentary (BEC). We searched the UK National Health Service Economic Evaluation Database (NHS EED) on the Centre for Reviews and Dissemination (CRD) <a href="https://www.crd.york.ac.uk/CRDWeb/" target="_blank">website</a> (covering from the earliest record in NHS EED, dating from 1968, up to and including 31 December 2014, when their coverage ended). </p> <p>As NHS EED is no longer actively updated, we performed additional searches of the following databases to identify eligible studies added to these databases from 1 January 2015. </p> <p> <ul id="CD014592-list-0010"> <li> <p>MEDLINE on OvidSP (1 January 1946 to May Week 1 2022)</p> </li> <li> <p>Embase on OvidSP (1 January 1974 to 2022 Week 19)</p> </li> </ul> </p> <p>The date of the most recent search was 16 May 2022.</p> <p><a href="./appendices#CD014592-sec-0132">Appendix 4</a> provides details of the searches. </p> </section> </section> <section id="CD014592-sec-0030"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of all relevant reviews and included trial reports to identify further relevant studies. </p> </section> </section> <section id="CD014592-sec-0031"> <h3 class="title" id="CD014592-sec-0031">Data collection and analysis</h3> <p>We conducted data collection and analysis in accordance with methods specified in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014592-bbs2-0061" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook/archive/v6.2.">Higgins 2022a</a>). </p> <section id="CD014592-sec-0032"> <h4 class="title">Selection of studies</h4> <p>Two review authors (AT and EJ) independently screened titles and abstracts of all the results returned by the search, then assessed the eligibility of the retrieved full‐text articles. We resolved any disagreements by discussion or by consulting a third review author. </p> </section> <section id="CD014592-sec-0033"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (AT and EJ) independently extracted data from the included studies using a piloted data extraction form. We compared the completed data extraction forms for disagreements, which we resolved by consensus. We entered all outcome data into Review Manager 5 (<a href="./references#CD014592-bbs2-0085" title="Review Manager 5 (RevMan 5). Version 5.4.1. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> </section> <section id="CD014592-sec-0034"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (AT and EJ) independently assessed the risk of bias for each included study using Cochrane's risk of bias tool (RoB 1), which covers the following domains (<a href="./references#CD014592-bbs2-0060" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). </p> <p> <ul id="CD014592-list-0011"> <li> <p>Random sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding of participants and personnel</p> </li> <li> <p>Blinding of outcome assessment</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective outcome reporting</p> </li> <li> <p>Other bias</p> </li> </ul> </p> <p>We assessed each source of bias as either high, low, or unclear and provide a justification for our judgement in the risk of bias tables. We resolved any disagreements by discussion. </p> </section> <section id="CD014592-sec-0035"> <h4 class="title">Measures of treatment effect</h4> <p>We based our analyses on available data from all included trials relevant to the comparisons and outcomes of interest. We summarised effect estimates for dichotomous outcomes using risk ratios (RRs) and corresponding 95% confidence intervals (CIs). For continuous outcomes, we used the mean difference (MD) or standardised mean difference (SMD) and corresponding 95% CI. We used final scores for continuous outcomes where change from baseline data were unavailable. </p> </section> <section id="CD014592-sec-0036"> <h4 class="title">Unit of analysis issues</h4> <p>We had planned to incorporate cross‐over trial data using the methods described in Chapter 23 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014592-bbs2-0062" title="HigginsJP , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Higgins 2022b</a>). We had planned to analyse multi‐arm studies that compared two interventions arms with one control group using the methods described in Chapter 23 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014592-bbs2-0062" title="HigginsJP , EldridgeS , LiT , editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Higgins 2022b</a>). We would have prevented double‐counting of individuals by analysing each treatment arm separately against the common control group and dividing the sample size of the common control group proportionately across each intervention comparison. </p> </section> <section id="CD014592-sec-0037"> <h4 class="title">Dealing with missing data</h4> <p>We contacted study authors to request missing data, where possible, and documented all attempts to contact authors for missing data or information in the <a href="./references#CD014592-sec-0142" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD014592-sec-0038"> <h4 class="title">Assessment of heterogeneity</h4> <p>We performed a qualitative assessment of clinical heterogeneity among studies (i.e. differences in study populations, interventions, and outcomes). Where studies were sufficiently similar to be included in a meta‐analysis, we assessed statistical heterogeneity by visually inspecting the forest plots, performing the Chi<sup>2</sup> test (P ≤ 0.10), and calculating the I<sup>2</sup> statistic (<a href="./references#CD014592-bbs2-0044" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Deeks 2022</a>). We planned to interpret I<sup>2</sup> values as follows. </p> <p> <ul id="CD014592-list-0012"> <li> <p>0% to 40%: represents low heterogeneity</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity</p> </li> <li> <p>75% to 100%: represents considerable heterogeneity</p> </li> </ul> </p> <p>We investigated possible causes of statistical heterogeneity, such as differing populations or interventions. We had intended to explore heterogeneity further through subgroup and sensitivity analyses. </p> </section> <section id="CD014592-sec-0039"> <h4 class="title">Assessment of reporting biases</h4> <p>We searched registries of prospectively registered trials to identify completed but unpublished trials. Had we included 10 or more trials in any meta‐analysis, we would have investigated potential reporting bias by generating funnel plots (<a href="./references#CD014592-bbs2-0049" title="EggerM , SmithGD , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34.">Egger 1997</a>; <a href="./references#CD014592-bbs2-0090" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ2011;343:d4002.">Sterne 2011</a>). </p> </section> <section id="CD014592-sec-0040"> <h4 class="title">Data synthesis</h4> <p>We combined outcome data from the individual trials in meta‐analyses using Review Manager 5 (<a href="./references#CD014592-bbs2-0085" title="Review Manager 5 (RevMan 5). Version 5.4.1. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> <p>Where appropriate, we pooled effect estimates across similar studies using fixed‐effect or random‐effects meta‐analysis techniques. We intended to use the random‐effects model where studies showed heterogeneity, defined as an I<sup>2</sup> statistic over 50%. Otherwise, we intended to use a fixed‐effect model to pool the data, using the Mantel‐Haenszel method for dichotomous data and the inverse variance method for continuous data (<a href="./references#CD014592-bbs2-0075" title="MantelN , HaenszelW . Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute1959;22(4):719-48.">Mantel 1959</a>). Had data allowed, we would have used change from baseline data for continuous outcomes; instead, we used raw outcome data. Where a study collected data for a single outcome using multiple tools, we used data from the tool with the highest validity according to Cronbach's alpha. Additionally, where data were available for multiple types of adverse event, we used the outcome with the most events to avoid double‐counting. </p> <p>Where outcome data from individual trials were not sufficiently similar to be combined quantitatively, we provided a narrative description of results from clinically comparable trials using the synthesis without meta‐analysis (SWiM) approach (<a href="./references#CD014592-bbs2-0040" title="CampbellM , McKenzieJE , SowdenA , KatikireddiSV , BrennanSE , EllisS , et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ2020;368:l6890. [DOI: 10.1136/bmj.l6890]">Campbell 2020</a>). </p> </section> <section id="CD014592-sec-0041"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Had data allowed, we would have performed the following subgroup analyses.</p> <p> <ul id="CD014592-list-0013"> <li> <p>Systemic versus topical oestrogen</p> </li> <li> <p>Parous versus nulliparous women</p> </li> <li> <p>Women with versus without a uterus</p> </li> </ul> </p> </section> <section id="CD014592-sec-0042"> <h4 class="title">Sensitivity analysis</h4> <p>Had data allowed, we would have excluded studies with a high risk of bias from our meta‐analyses for the primary outcomes to assess the robustness of our conclusions. </p> </section> <section id="CD014592-sec-0043"> <h4 class="title">Incorporating economic evidence</h4> <p>Following the search outlined in the <a href="#CD014592-sec-0026">Search methods for identification of studies</a>, we developed a BEC to summarise the availability and principal findings of the full economic evaluations that assess oestrogen therapy for treating POP in postmenopausal women (<a href="./references#CD014592-bbs2-0030" title="AlukoP , GraybillE , CraigD , HendersonC , DrummondM , WilsonEC , et al, on behalf of the Campbell and Cochrane Economics Methods Group. Chapter 20: Economic evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.">Aluko 2022</a>). This BEC encompassed full economic evaluations (i.e. cost‐effectiveness analyses, cost‐utility analyses, and cost‐benefit analyses) conducted as part of a single empirical study, such as an RCT, a model based on such as study, or a model based on several such studies. </p> </section> <section id="CD014592-sec-0044"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We prepared summary of findings tables for the four main comparisons listed in <a href="#CD014592-sec-0019">Types of interventions</a>. We planned to use the GRADE approach to assess the certainty of evidence related to the primary and secondary outcomes for the comparisons presented in the summary of findings tables (<a href="./references#CD014592-bbs2-0087" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Schünemann 2021</a>). The GRADE approach considers five domains (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of the body of evidence for each outcome. Had we included any data in our summary of findings tables, we would have justified all decisions to downgrade the certainty of evidence in footnotes. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD014592-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD014592-sec-0045"></div> <section id="CD014592-sec-0046"> <h3 class="title">Description of studies</h3> <section id="CD014592-sec-0047"> <h4 class="title">Results of the search</h4> <section id="CD014592-sec-0048"> <h5 class="title">Search for clinical effectiveness studies</h5> <p>The literature search produced 239 records. After the title and abstract screen, we retrieved the full‐text articles of 74 potentially eligible records, and after reading these articles, we included 14 studies (47 reports) in the review. We excluded nine studies (14 reports), providing reasons for exclusion in the <a href="./references#CD014592-sec-0143" title="">Characteristics of excluded studies</a> table. Additionally, we identified seven reports of four ongoing studies (see <a href="./references#CD014592-sec-0145" title="">Characteristics of ongoing studies</a> table) and six reports of three studies still awaiting classification (see <a href="./references#CD014592-bbs1-0003" title="">Studies awaiting classification</a>). <a href="#CD014592-fig-0001">Figure 1</a> shows the flow of literature through the study selection process. </p> <div class="figure" id="CD014592-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA diagram – clinical effectiveness searches." data-id="CD014592-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA diagram – clinical effectiveness searches.</p> </div> </div> </div> </section> <section id="CD014592-sec-0049"> <h5 class="title">Search for economic evaluations</h5> <p>The literature search returned 212 records. After screening, we retrieved the full‐text article of only one record. This was an ongoing study and was not included in the BEC for this version of the review. <a href="#CD014592-fig-0002">Figure 2</a> shows the flow of literature through the study selection process. </p> <div class="figure" id="CD014592-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="PRISMA diagram – cost effectiveness searches." data-id="CD014592-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA diagram – cost effectiveness searches.</p> </div> </div> </div> </section> </section> <section id="CD014592-sec-0050"> <h4 class="title">Included studies</h4> <p>We included 14 studies (<a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a>; <a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>; <a href="./references#CD014592-bbs2-0003" title="ChiengthongK , RuanphooP , ChatsuwanT , BunyavejchevinS . Effect of vaginal estrogen in postmenopausal women using vaginal pessary for pelvic organ prolapse treatment: a randomized controlled trial. International Urogynecology Journal2022;33(7):1833-8. [DOI: 10.1007/s00192-021-04821-y]TCTR20180329001. Effect of vaginal estriol 0.03 mg with Lactobacillus acidophilus on incidence of bacterial vaginosis in patient using pessary for treatment of pelvic organ prolapse. thaiclinicaltrials.org/show/TCTR20180329001 (first received 29 March 2018). ">Chiengthong 2022</a>; <a href="./references#CD014592-bbs2-0004" title="CoelhoSC , GiraldoPC , BritoLG , Teatin JuliatoCR . Estrogen use on complications for women treating pelvic organ prolapse with vaginal pessaries (ESTRO-PESS)-a randomized clinical trial (Abstract 007). International Urogynecology Journal2020;31(Suppl 1):S4. [DOI: 10.1007/s00192-020-04555-3]RBR-23sqxz. Impact of cream vaginal use on complications in women using vaginal ring in treatment of genital prolapse: a randomized clinical trial [Impacto do uso do creme vaginal nas complicações em mulheres usuárias de anel vaginais no tratamento do prolapso genital: ensaio clínico randomizado] [Impact of estrogen use on complications in women using vaginal pessaries with genital prolapse: a randomized clinical trial [Impacto do uso do estrogênio nas complicações em mulheres usuárias de pessários vaginais com prolapso genital: ensaio clínico randomizado]]. ensaiosclinicos.gov.br/rg/RBR-23sqxz (first received 24 August 2018). ">Coelho 2020</a>; <a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a>; <a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>; <a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>; <a href="./references#CD014592-bbs2-0008" title="NunesJC , FeldnerPC , CastroRA , NaderHB , SartoriMF , GirãoMB . Uterine prolapse: evaluation of glycosaminoglycans in postmenopausal women after estrogen therapy. Climacteric2011;14(1):121-5. ">Nunes 2011</a>; <a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a>; <a href="./references#CD014592-bbs2-0010" title="StipicI , PolasekO , VulicM , PundaH , GrandicL , StrinicT . Estrogen replacement therapy improves pulmonary function in postmenopausal women with genital prolapse. Rejuvenation Research2012;15(6):596-600. [DOI: 10.1089/rej.2012.1337]">Stipic 2012</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>; <a href="./references#CD014592-bbs2-0012" title="TontivuthikulP , SanmeeU , Wongtra-NganS , PongnarisornC . Effect of local estrogen cream on vaginal health after pessary use for prolapsed pelvic organ: a randomized controlled trial. Journal of the Medical Association of Thailand2016;99(7):757-63. ">Tontivuthikul 2016</a>; <a href="./references#CD014592-bbs2-0013" title="NCT00803335. The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse [The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse: a randomized control trial]. clinicaltrials.gov/ct2/show/NCT00803335 (first received 05 December 2008). VaccaroCM , CrispCC , EstanolMV , FellnerAN , MutemaGK , KleemanSD , et al. Administration of vaginal estrogen in women with vaginal atrophy prior to prolapse surgery: an assessment of quality of life outcomes and medication adherence (Abstract 286). International Urogynecology Journal2011;22(Suppl 3):S1839-40. [DOI: 10.1007/s00192-011-1521-1]VaccaroCM , CrispCC , FellnerAN , PaulsRN . Impact of preoperative vaginal estrogen on patient quality of life measures: a randomized controlled trial (Abstract 120). Female Pelvic Medicine and Reconstructive Surgery2012;18(8 Suppl 1):S151-2. [DOI: 10.1097/SPV.0b013e31826abf55]VaccaroCM , MutemaGK , FellnerAN , CrispCC , EstanolMV , KleemanSD , et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2013;19(1):34-9. [DOI: 10.1097/SPV.0b013e318278cc40]VaccaroCM , MutemaGK , FellnerAN , CrispCC , PaulsRN . The effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial (Abstract 02). Female Pelvic Medicine and Reconstructive Surgery2012;18(2 Suppl 1):S14. [DOI: 10.1097/SPV.0b013e31824bf52d]">Vaccaro 2013</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>). For further details, see the <a href="./references#CD014592-sec-0142" title="">Characteristics of included studies</a> table. We contacted the authors of two included studies for further details (<a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>), but only received a response regarding <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>. </p> <section id="CD014592-sec-0051"> <h5 class="title">Design</h5> <p>Thirteen studies were parallel‐arm RCTs (<a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a>; <a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>; <a href="./references#CD014592-bbs2-0003" title="ChiengthongK , RuanphooP , ChatsuwanT , BunyavejchevinS . Effect of vaginal estrogen in postmenopausal women using vaginal pessary for pelvic organ prolapse treatment: a randomized controlled trial. International Urogynecology Journal2022;33(7):1833-8. [DOI: 10.1007/s00192-021-04821-y]TCTR20180329001. Effect of vaginal estriol 0.03 mg with Lactobacillus acidophilus on incidence of bacterial vaginosis in patient using pessary for treatment of pelvic organ prolapse. thaiclinicaltrials.org/show/TCTR20180329001 (first received 29 March 2018). ">Chiengthong 2022</a>; <a href="./references#CD014592-bbs2-0004" title="CoelhoSC , GiraldoPC , BritoLG , Teatin JuliatoCR . Estrogen use on complications for women treating pelvic organ prolapse with vaginal pessaries (ESTRO-PESS)-a randomized clinical trial (Abstract 007). International Urogynecology Journal2020;31(Suppl 1):S4. [DOI: 10.1007/s00192-020-04555-3]RBR-23sqxz. Impact of cream vaginal use on complications in women using vaginal ring in treatment of genital prolapse: a randomized clinical trial [Impacto do uso do creme vaginal nas complicações em mulheres usuárias de anel vaginais no tratamento do prolapso genital: ensaio clínico randomizado] [Impact of estrogen use on complications in women using vaginal pessaries with genital prolapse: a randomized clinical trial [Impacto do uso do estrogênio nas complicações em mulheres usuárias de pessários vaginais com prolapso genital: ensaio clínico randomizado]]. ensaiosclinicos.gov.br/rg/RBR-23sqxz (first received 24 August 2018). ">Coelho 2020</a>; <a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a>; <a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>; <a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>; <a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a>; <a href="./references#CD014592-bbs2-0010" title="StipicI , PolasekO , VulicM , PundaH , GrandicL , StrinicT . Estrogen replacement therapy improves pulmonary function in postmenopausal women with genital prolapse. Rejuvenation Research2012;15(6):596-600. [DOI: 10.1089/rej.2012.1337]">Stipic 2012</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>; <a href="./references#CD014592-bbs2-0012" title="TontivuthikulP , SanmeeU , Wongtra-NganS , PongnarisornC . Effect of local estrogen cream on vaginal health after pessary use for prolapsed pelvic organ: a randomized controlled trial. Journal of the Medical Association of Thailand2016;99(7):757-63. ">Tontivuthikul 2016</a>; <a href="./references#CD014592-bbs2-0013" title="NCT00803335. The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse [The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse: a randomized control trial]. clinicaltrials.gov/ct2/show/NCT00803335 (first received 05 December 2008). VaccaroCM , CrispCC , EstanolMV , FellnerAN , MutemaGK , KleemanSD , et al. Administration of vaginal estrogen in women with vaginal atrophy prior to prolapse surgery: an assessment of quality of life outcomes and medication adherence (Abstract 286). International Urogynecology Journal2011;22(Suppl 3):S1839-40. [DOI: 10.1007/s00192-011-1521-1]VaccaroCM , CrispCC , FellnerAN , PaulsRN . Impact of preoperative vaginal estrogen on patient quality of life measures: a randomized controlled trial (Abstract 120). Female Pelvic Medicine and Reconstructive Surgery2012;18(8 Suppl 1):S151-2. [DOI: 10.1097/SPV.0b013e31826abf55]VaccaroCM , MutemaGK , FellnerAN , CrispCC , EstanolMV , KleemanSD , et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2013;19(1):34-9. [DOI: 10.1097/SPV.0b013e318278cc40]VaccaroCM , MutemaGK , FellnerAN , CrispCC , PaulsRN . The effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial (Abstract 02). Female Pelvic Medicine and Reconstructive Surgery2012;18(2 Suppl 1):S14. [DOI: 10.1097/SPV.0b013e31824bf52d]">Vaccaro 2013</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>). <a href="./references#CD014592-bbs2-0008" title="NunesJC , FeldnerPC , CastroRA , NaderHB , SartoriMF , GirãoMB . Uterine prolapse: evaluation of glycosaminoglycans in postmenopausal women after estrogen therapy. Climacteric2011;14(1):121-5. ">Nunes 2011</a> randomised two of its arms, but the third arm (no intervention) was not randomised, and the participants did not have POP. </p> <p><a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a> had three study arms, and <a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a> had four study arms. <a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a> initially randomised participants into two groups and then re‐randomised participants of the intervention group following surgery to either continue or cease the intervention. <a href="./references#CD014592-bbs2-0013" title="NCT00803335. The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse [The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse: a randomized control trial]. clinicaltrials.gov/ct2/show/NCT00803335 (first received 05 December 2008). VaccaroCM , CrispCC , EstanolMV , FellnerAN , MutemaGK , KleemanSD , et al. Administration of vaginal estrogen in women with vaginal atrophy prior to prolapse surgery: an assessment of quality of life outcomes and medication adherence (Abstract 286). International Urogynecology Journal2011;22(Suppl 3):S1839-40. [DOI: 10.1007/s00192-011-1521-1]VaccaroCM , CrispCC , FellnerAN , PaulsRN . Impact of preoperative vaginal estrogen on patient quality of life measures: a randomized controlled trial (Abstract 120). Female Pelvic Medicine and Reconstructive Surgery2012;18(8 Suppl 1):S151-2. [DOI: 10.1097/SPV.0b013e31826abf55]VaccaroCM , MutemaGK , FellnerAN , CrispCC , EstanolMV , KleemanSD , et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2013;19(1):34-9. [DOI: 10.1097/SPV.0b013e318278cc40]VaccaroCM , MutemaGK , FellnerAN , CrispCC , PaulsRN . The effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial (Abstract 02). Female Pelvic Medicine and Reconstructive Surgery2012;18(2 Suppl 1):S14. [DOI: 10.1097/SPV.0b013e31824bf52d]">Vaccaro 2013</a> was initially a three‐arm study, but the first group were excluded early in the trial, leaving only two arms. </p> </section> <section id="CD014592-sec-0052"> <h5 class="title">Sample size</h5> <p>The smallest study had eight participants (<a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a>), while the largest had 186 (<a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>). </p> </section> <section id="CD014592-sec-0053"> <h5 class="title">Setting</h5> <p>The included studies were set in Austria (<a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>), Brazil (<a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a>; <a href="./references#CD014592-bbs2-0004" title="CoelhoSC , GiraldoPC , BritoLG , Teatin JuliatoCR . Estrogen use on complications for women treating pelvic organ prolapse with vaginal pessaries (ESTRO-PESS)-a randomized clinical trial (Abstract 007). International Urogynecology Journal2020;31(Suppl 1):S4. [DOI: 10.1007/s00192-020-04555-3]RBR-23sqxz. Impact of cream vaginal use on complications in women using vaginal ring in treatment of genital prolapse: a randomized clinical trial [Impacto do uso do creme vaginal nas complicações em mulheres usuárias de anel vaginais no tratamento do prolapso genital: ensaio clínico randomizado] [Impact of estrogen use on complications in women using vaginal pessaries with genital prolapse: a randomized clinical trial [Impacto do uso do estrogênio nas complicações em mulheres usuárias de pessários vaginais com prolapso genital: ensaio clínico randomizado]]. ensaiosclinicos.gov.br/rg/RBR-23sqxz (first received 24 August 2018). ">Coelho 2020</a>; <a href="./references#CD014592-bbs2-0008" title="NunesJC , FeldnerPC , CastroRA , NaderHB , SartoriMF , GirãoMB . Uterine prolapse: evaluation of glycosaminoglycans in postmenopausal women after estrogen therapy. Climacteric2011;14(1):121-5. ">Nunes 2011</a>), China (<a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>), Croatia (<a href="./references#CD014592-bbs2-0010" title="StipicI , PolasekO , VulicM , PundaH , GrandicL , StrinicT . Estrogen replacement therapy improves pulmonary function in postmenopausal women with genital prolapse. Rejuvenation Research2012;15(6):596-600. [DOI: 10.1089/rej.2012.1337]">Stipic 2012</a>), Denmark (<a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a>), Italy (<a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>), Thailand (<a href="./references#CD014592-bbs2-0003" title="ChiengthongK , RuanphooP , ChatsuwanT , BunyavejchevinS . Effect of vaginal estrogen in postmenopausal women using vaginal pessary for pelvic organ prolapse treatment: a randomized controlled trial. International Urogynecology Journal2022;33(7):1833-8. [DOI: 10.1007/s00192-021-04821-y]TCTR20180329001. Effect of vaginal estriol 0.03 mg with Lactobacillus acidophilus on incidence of bacterial vaginosis in patient using pessary for treatment of pelvic organ prolapse. thaiclinicaltrials.org/show/TCTR20180329001 (first received 29 March 2018). ">Chiengthong 2022</a>; <a href="./references#CD014592-bbs2-0012" title="TontivuthikulP , SanmeeU , Wongtra-NganS , PongnarisornC . Effect of local estrogen cream on vaginal health after pessary use for prolapsed pelvic organ: a randomized controlled trial. Journal of the Medical Association of Thailand2016;99(7):757-63. ">Tontivuthikul 2016</a>), the UK (<a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>), and the USA (<a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>; <a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a>; <a href="./references#CD014592-bbs2-0013" title="NCT00803335. The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse [The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse: a randomized control trial]. clinicaltrials.gov/ct2/show/NCT00803335 (first received 05 December 2008). VaccaroCM , CrispCC , EstanolMV , FellnerAN , MutemaGK , KleemanSD , et al. Administration of vaginal estrogen in women with vaginal atrophy prior to prolapse surgery: an assessment of quality of life outcomes and medication adherence (Abstract 286). International Urogynecology Journal2011;22(Suppl 3):S1839-40. [DOI: 10.1007/s00192-011-1521-1]VaccaroCM , CrispCC , FellnerAN , PaulsRN . Impact of preoperative vaginal estrogen on patient quality of life measures: a randomized controlled trial (Abstract 120). Female Pelvic Medicine and Reconstructive Surgery2012;18(8 Suppl 1):S151-2. [DOI: 10.1097/SPV.0b013e31826abf55]VaccaroCM , MutemaGK , FellnerAN , CrispCC , EstanolMV , KleemanSD , et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2013;19(1):34-9. [DOI: 10.1097/SPV.0b013e318278cc40]VaccaroCM , MutemaGK , FellnerAN , CrispCC , PaulsRN . The effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial (Abstract 02). Female Pelvic Medicine and Reconstructive Surgery2012;18(2 Suppl 1):S14. [DOI: 10.1097/SPV.0b013e31824bf52d]">Vaccaro 2013</a>). </p> <p>Nine studies were conducted in a single centre (<a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a>; <a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>; <a href="./references#CD014592-bbs2-0003" title="ChiengthongK , RuanphooP , ChatsuwanT , BunyavejchevinS . Effect of vaginal estrogen in postmenopausal women using vaginal pessary for pelvic organ prolapse treatment: a randomized controlled trial. International Urogynecology Journal2022;33(7):1833-8. [DOI: 10.1007/s00192-021-04821-y]TCTR20180329001. Effect of vaginal estriol 0.03 mg with Lactobacillus acidophilus on incidence of bacterial vaginosis in patient using pessary for treatment of pelvic organ prolapse. thaiclinicaltrials.org/show/TCTR20180329001 (first received 29 March 2018). ">Chiengthong 2022</a>; <a href="./references#CD014592-bbs2-0004" title="CoelhoSC , GiraldoPC , BritoLG , Teatin JuliatoCR . Estrogen use on complications for women treating pelvic organ prolapse with vaginal pessaries (ESTRO-PESS)-a randomized clinical trial (Abstract 007). International Urogynecology Journal2020;31(Suppl 1):S4. [DOI: 10.1007/s00192-020-04555-3]RBR-23sqxz. Impact of cream vaginal use on complications in women using vaginal ring in treatment of genital prolapse: a randomized clinical trial [Impacto do uso do creme vaginal nas complicações em mulheres usuárias de anel vaginais no tratamento do prolapso genital: ensaio clínico randomizado] [Impact of estrogen use on complications in women using vaginal pessaries with genital prolapse: a randomized clinical trial [Impacto do uso do estrogênio nas complicações em mulheres usuárias de pessários vaginais com prolapso genital: ensaio clínico randomizado]]. ensaiosclinicos.gov.br/rg/RBR-23sqxz (first received 24 August 2018). ">Coelho 2020</a>; <a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>; <a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a>; <a href="./references#CD014592-bbs2-0010" title="StipicI , PolasekO , VulicM , PundaH , GrandicL , StrinicT . Estrogen replacement therapy improves pulmonary function in postmenopausal women with genital prolapse. Rejuvenation Research2012;15(6):596-600. [DOI: 10.1089/rej.2012.1337]">Stipic 2012</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>; <a href="./references#CD014592-bbs2-0012" title="TontivuthikulP , SanmeeU , Wongtra-NganS , PongnarisornC . Effect of local estrogen cream on vaginal health after pessary use for prolapsed pelvic organ: a randomized controlled trial. Journal of the Medical Association of Thailand2016;99(7):757-63. ">Tontivuthikul 2016</a>), while four were multicentre studies (<a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a>; <a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>; <a href="./references#CD014592-bbs2-0013" title="NCT00803335. The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse [The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse: a randomized control trial]. clinicaltrials.gov/ct2/show/NCT00803335 (first received 05 December 2008). VaccaroCM , CrispCC , EstanolMV , FellnerAN , MutemaGK , KleemanSD , et al. Administration of vaginal estrogen in women with vaginal atrophy prior to prolapse surgery: an assessment of quality of life outcomes and medication adherence (Abstract 286). International Urogynecology Journal2011;22(Suppl 3):S1839-40. [DOI: 10.1007/s00192-011-1521-1]VaccaroCM , CrispCC , FellnerAN , PaulsRN . Impact of preoperative vaginal estrogen on patient quality of life measures: a randomized controlled trial (Abstract 120). Female Pelvic Medicine and Reconstructive Surgery2012;18(8 Suppl 1):S151-2. [DOI: 10.1097/SPV.0b013e31826abf55]VaccaroCM , MutemaGK , FellnerAN , CrispCC , EstanolMV , KleemanSD , et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2013;19(1):34-9. [DOI: 10.1097/SPV.0b013e318278cc40]VaccaroCM , MutemaGK , FellnerAN , CrispCC , PaulsRN . The effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial (Abstract 02). Female Pelvic Medicine and Reconstructive Surgery2012;18(2 Suppl 1):S14. [DOI: 10.1097/SPV.0b013e31824bf52d]">Vaccaro 2013</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>). <a href="./references#CD014592-bbs2-0008" title="NunesJC , FeldnerPC , CastroRA , NaderHB , SartoriMF , GirãoMB . Uterine prolapse: evaluation of glycosaminoglycans in postmenopausal women after estrogen therapy. Climacteric2011;14(1):121-5. ">Nunes 2011</a> did not report the number of participating sites. </p> </section> <section id="CD014592-sec-0054"> <h5 class="title">Participants</h5> <p>In terms of POP type and severity, 10 studies recruited women with varying degrees of POP severity (<a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>; <a href="./references#CD014592-bbs2-0003" title="ChiengthongK , RuanphooP , ChatsuwanT , BunyavejchevinS . Effect of vaginal estrogen in postmenopausal women using vaginal pessary for pelvic organ prolapse treatment: a randomized controlled trial. International Urogynecology Journal2022;33(7):1833-8. [DOI: 10.1007/s00192-021-04821-y]TCTR20180329001. Effect of vaginal estriol 0.03 mg with Lactobacillus acidophilus on incidence of bacterial vaginosis in patient using pessary for treatment of pelvic organ prolapse. thaiclinicaltrials.org/show/TCTR20180329001 (first received 29 March 2018). ">Chiengthong 2022</a>; <a href="./references#CD014592-bbs2-0004" title="CoelhoSC , GiraldoPC , BritoLG , Teatin JuliatoCR . Estrogen use on complications for women treating pelvic organ prolapse with vaginal pessaries (ESTRO-PESS)-a randomized clinical trial (Abstract 007). International Urogynecology Journal2020;31(Suppl 1):S4. [DOI: 10.1007/s00192-020-04555-3]RBR-23sqxz. Impact of cream vaginal use on complications in women using vaginal ring in treatment of genital prolapse: a randomized clinical trial [Impacto do uso do creme vaginal nas complicações em mulheres usuárias de anel vaginais no tratamento do prolapso genital: ensaio clínico randomizado] [Impact of estrogen use on complications in women using vaginal pessaries with genital prolapse: a randomized clinical trial [Impacto do uso do estrogênio nas complicações em mulheres usuárias de pessários vaginais com prolapso genital: ensaio clínico randomizado]]. ensaiosclinicos.gov.br/rg/RBR-23sqxz (first received 24 August 2018). ">Coelho 2020</a>; <a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>; <a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>; <a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>; <a href="./references#CD014592-bbs2-0012" title="TontivuthikulP , SanmeeU , Wongtra-NganS , PongnarisornC . Effect of local estrogen cream on vaginal health after pessary use for prolapsed pelvic organ: a randomized controlled trial. Journal of the Medical Association of Thailand2016;99(7):757-63. ">Tontivuthikul 2016</a>; <a href="./references#CD014592-bbs2-0013" title="NCT00803335. The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse [The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse: a randomized control trial]. clinicaltrials.gov/ct2/show/NCT00803335 (first received 05 December 2008). VaccaroCM , CrispCC , EstanolMV , FellnerAN , MutemaGK , KleemanSD , et al. Administration of vaginal estrogen in women with vaginal atrophy prior to prolapse surgery: an assessment of quality of life outcomes and medication adherence (Abstract 286). International Urogynecology Journal2011;22(Suppl 3):S1839-40. [DOI: 10.1007/s00192-011-1521-1]VaccaroCM , CrispCC , FellnerAN , PaulsRN . Impact of preoperative vaginal estrogen on patient quality of life measures: a randomized controlled trial (Abstract 120). Female Pelvic Medicine and Reconstructive Surgery2012;18(8 Suppl 1):S151-2. [DOI: 10.1097/SPV.0b013e31826abf55]VaccaroCM , MutemaGK , FellnerAN , CrispCC , EstanolMV , KleemanSD , et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2013;19(1):34-9. [DOI: 10.1097/SPV.0b013e318278cc40]VaccaroCM , MutemaGK , FellnerAN , CrispCC , PaulsRN . The effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial (Abstract 02). Female Pelvic Medicine and Reconstructive Surgery2012;18(2 Suppl 1):S14. [DOI: 10.1097/SPV.0b013e31824bf52d]">Vaccaro 2013</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>). Three recruited women with central compartment (uterine) POP (<a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a>; <a href="./references#CD014592-bbs2-0008" title="NunesJC , FeldnerPC , CastroRA , NaderHB , SartoriMF , GirãoMB . Uterine prolapse: evaluation of glycosaminoglycans in postmenopausal women after estrogen therapy. Climacteric2011;14(1):121-5. ">Nunes 2011</a>; <a href="./references#CD014592-bbs2-0010" title="StipicI , PolasekO , VulicM , PundaH , GrandicL , StrinicT . Estrogen replacement therapy improves pulmonary function in postmenopausal women with genital prolapse. Rejuvenation Research2012;15(6):596-600. [DOI: 10.1089/rej.2012.1337]">Stipic 2012</a>), while one recruited women with anterior compartment or central compartment (uterine) POP (<a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>). In two studies, participants had anterior, central (apical), or posterior prolapse, or more than one of those types (<a href="./references#CD014592-bbs2-0004" title="CoelhoSC , GiraldoPC , BritoLG , Teatin JuliatoCR . Estrogen use on complications for women treating pelvic organ prolapse with vaginal pessaries (ESTRO-PESS)-a randomized clinical trial (Abstract 007). International Urogynecology Journal2020;31(Suppl 1):S4. [DOI: 10.1007/s00192-020-04555-3]RBR-23sqxz. Impact of cream vaginal use on complications in women using vaginal ring in treatment of genital prolapse: a randomized clinical trial [Impacto do uso do creme vaginal nas complicações em mulheres usuárias de anel vaginais no tratamento do prolapso genital: ensaio clínico randomizado] [Impact of estrogen use on complications in women using vaginal pessaries with genital prolapse: a randomized clinical trial [Impacto do uso do estrogênio nas complicações em mulheres usuárias de pessários vaginais com prolapso genital: ensaio clínico randomizado]]. ensaiosclinicos.gov.br/rg/RBR-23sqxz (first received 24 August 2018). ">Coelho 2020</a>; <a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>). In <a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a>, participants had uterine or anterior compartment POP, or both. The participants in <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a> had POP affecting either the anterior, apical, or posterior compartments. </p> <p>Four studies did not report POP severity (<a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a>; <a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a>; <a href="./references#CD014592-bbs2-0008" title="NunesJC , FeldnerPC , CastroRA , NaderHB , SartoriMF , GirãoMB . Uterine prolapse: evaluation of glycosaminoglycans in postmenopausal women after estrogen therapy. Climacteric2011;14(1):121-5. ">Nunes 2011</a>; <a href="./references#CD014592-bbs2-0010" title="StipicI , PolasekO , VulicM , PundaH , GrandicL , StrinicT . Estrogen replacement therapy improves pulmonary function in postmenopausal women with genital prolapse. Rejuvenation Research2012;15(6):596-600. [DOI: 10.1089/rej.2012.1337]">Stipic 2012</a>), while six did not report the affected compartments (<a href="./references#CD014592-bbs2-0003" title="ChiengthongK , RuanphooP , ChatsuwanT , BunyavejchevinS . Effect of vaginal estrogen in postmenopausal women using vaginal pessary for pelvic organ prolapse treatment: a randomized controlled trial. International Urogynecology Journal2022;33(7):1833-8. [DOI: 10.1007/s00192-021-04821-y]TCTR20180329001. Effect of vaginal estriol 0.03 mg with Lactobacillus acidophilus on incidence of bacterial vaginosis in patient using pessary for treatment of pelvic organ prolapse. thaiclinicaltrials.org/show/TCTR20180329001 (first received 29 March 2018). ">Chiengthong 2022</a>; <a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a>; <a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>; <a href="./references#CD014592-bbs2-0012" title="TontivuthikulP , SanmeeU , Wongtra-NganS , PongnarisornC . Effect of local estrogen cream on vaginal health after pessary use for prolapsed pelvic organ: a randomized controlled trial. Journal of the Medical Association of Thailand2016;99(7):757-63. ">Tontivuthikul 2016</a>; <a href="./references#CD014592-bbs2-0013" title="NCT00803335. The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse [The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse: a randomized control trial]. clinicaltrials.gov/ct2/show/NCT00803335 (first received 05 December 2008). VaccaroCM , CrispCC , EstanolMV , FellnerAN , MutemaGK , KleemanSD , et al. Administration of vaginal estrogen in women with vaginal atrophy prior to prolapse surgery: an assessment of quality of life outcomes and medication adherence (Abstract 286). International Urogynecology Journal2011;22(Suppl 3):S1839-40. [DOI: 10.1007/s00192-011-1521-1]VaccaroCM , CrispCC , FellnerAN , PaulsRN . Impact of preoperative vaginal estrogen on patient quality of life measures: a randomized controlled trial (Abstract 120). Female Pelvic Medicine and Reconstructive Surgery2012;18(8 Suppl 1):S151-2. [DOI: 10.1097/SPV.0b013e31826abf55]VaccaroCM , MutemaGK , FellnerAN , CrispCC , EstanolMV , KleemanSD , et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2013;19(1):34-9. [DOI: 10.1097/SPV.0b013e318278cc40]VaccaroCM , MutemaGK , FellnerAN , CrispCC , PaulsRN . The effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial (Abstract 02). Female Pelvic Medicine and Reconstructive Surgery2012;18(2 Suppl 1):S14. [DOI: 10.1097/SPV.0b013e31824bf52d]">Vaccaro 2013</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>). </p> <p>In <a href="./references#CD014592-bbs2-0003" title="ChiengthongK , RuanphooP , ChatsuwanT , BunyavejchevinS . Effect of vaginal estrogen in postmenopausal women using vaginal pessary for pelvic organ prolapse treatment: a randomized controlled trial. International Urogynecology Journal2022;33(7):1833-8. [DOI: 10.1007/s00192-021-04821-y]TCTR20180329001. Effect of vaginal estriol 0.03 mg with Lactobacillus acidophilus on incidence of bacterial vaginosis in patient using pessary for treatment of pelvic organ prolapse. thaiclinicaltrials.org/show/TCTR20180329001 (first received 29 March 2018). ">Chiengthong 2022</a>, 100% of women in the intervention group and 84.6% in the non‐intervention group had one or more children, while in nine studies, most participants had two or more children (<a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>; <a href="./references#CD014592-bbs2-0004" title="CoelhoSC , GiraldoPC , BritoLG , Teatin JuliatoCR . Estrogen use on complications for women treating pelvic organ prolapse with vaginal pessaries (ESTRO-PESS)-a randomized clinical trial (Abstract 007). International Urogynecology Journal2020;31(Suppl 1):S4. [DOI: 10.1007/s00192-020-04555-3]RBR-23sqxz. Impact of cream vaginal use on complications in women using vaginal ring in treatment of genital prolapse: a randomized clinical trial [Impacto do uso do creme vaginal nas complicações em mulheres usuárias de anel vaginais no tratamento do prolapso genital: ensaio clínico randomizado] [Impact of estrogen use on complications in women using vaginal pessaries with genital prolapse: a randomized clinical trial [Impacto do uso do estrogênio nas complicações em mulheres usuárias de pessários vaginais com prolapso genital: ensaio clínico randomizado]]. ensaiosclinicos.gov.br/rg/RBR-23sqxz (first received 24 August 2018). ">Coelho 2020</a>; <a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>; <a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>; <a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a>; <a href="./references#CD014592-bbs2-0010" title="StipicI , PolasekO , VulicM , PundaH , GrandicL , StrinicT . Estrogen replacement therapy improves pulmonary function in postmenopausal women with genital prolapse. Rejuvenation Research2012;15(6):596-600. [DOI: 10.1089/rej.2012.1337]">Stipic 2012</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>; <a href="./references#CD014592-bbs2-0012" title="TontivuthikulP , SanmeeU , Wongtra-NganS , PongnarisornC . Effect of local estrogen cream on vaginal health after pessary use for prolapsed pelvic organ: a randomized controlled trial. Journal of the Medical Association of Thailand2016;99(7):757-63. ">Tontivuthikul 2016</a>; <a href="./references#CD014592-bbs2-0013" title="NCT00803335. The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse [The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse: a randomized control trial]. clinicaltrials.gov/ct2/show/NCT00803335 (first received 05 December 2008). VaccaroCM , CrispCC , EstanolMV , FellnerAN , MutemaGK , KleemanSD , et al. Administration of vaginal estrogen in women with vaginal atrophy prior to prolapse surgery: an assessment of quality of life outcomes and medication adherence (Abstract 286). International Urogynecology Journal2011;22(Suppl 3):S1839-40. [DOI: 10.1007/s00192-011-1521-1]VaccaroCM , CrispCC , FellnerAN , PaulsRN . Impact of preoperative vaginal estrogen on patient quality of life measures: a randomized controlled trial (Abstract 120). Female Pelvic Medicine and Reconstructive Surgery2012;18(8 Suppl 1):S151-2. [DOI: 10.1097/SPV.0b013e31826abf55]VaccaroCM , MutemaGK , FellnerAN , CrispCC , EstanolMV , KleemanSD , et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2013;19(1):34-9. [DOI: 10.1097/SPV.0b013e318278cc40]VaccaroCM , MutemaGK , FellnerAN , CrispCC , PaulsRN . The effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial (Abstract 02). Female Pelvic Medicine and Reconstructive Surgery2012;18(2 Suppl 1):S14. [DOI: 10.1097/SPV.0b013e31824bf52d]">Vaccaro 2013</a>). In <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>, participants were roughly balanced in terms of whether they had two or fewer children (53%) or more than two children (47%). In <a href="./references#CD014592-bbs2-0008" title="NunesJC , FeldnerPC , CastroRA , NaderHB , SartoriMF , GirãoMB . Uterine prolapse: evaluation of glycosaminoglycans in postmenopausal women after estrogen therapy. Climacteric2011;14(1):121-5. ">Nunes 2011</a>, average parity across the groups was at least four births. Two studies did not report parity (<a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a>; <a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a>). </p> <p>In three studies, none of the women had undergone a hysterectomy (<a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>; <a href="./references#CD014592-bbs2-0008" title="NunesJC , FeldnerPC , CastroRA , NaderHB , SartoriMF , GirãoMB . Uterine prolapse: evaluation of glycosaminoglycans in postmenopausal women after estrogen therapy. Climacteric2011;14(1):121-5. ">Nunes 2011</a>; <a href="./references#CD014592-bbs2-0010" title="StipicI , PolasekO , VulicM , PundaH , GrandicL , StrinicT . Estrogen replacement therapy improves pulmonary function in postmenopausal women with genital prolapse. Rejuvenation Research2012;15(6):596-600. [DOI: 10.1089/rej.2012.1337]">Stipic 2012</a>). In <a href="./references#CD014592-bbs2-0003" title="ChiengthongK , RuanphooP , ChatsuwanT , BunyavejchevinS . Effect of vaginal estrogen in postmenopausal women using vaginal pessary for pelvic organ prolapse treatment: a randomized controlled trial. International Urogynecology Journal2022;33(7):1833-8. [DOI: 10.1007/s00192-021-04821-y]TCTR20180329001. Effect of vaginal estriol 0.03 mg with Lactobacillus acidophilus on incidence of bacterial vaginosis in patient using pessary for treatment of pelvic organ prolapse. thaiclinicaltrials.org/show/TCTR20180329001 (first received 29 March 2018). ">Chiengthong 2022</a>, under 20% of women had had a hysterectomy, while in <a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>, the proportion of women with previous hysterectomy ranged from 27% to 33% between groups. In <a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>, prior rates of hysterectomy ranged from 10% in the control group to 28% in the intervention group. In <a href="./references#CD014592-bbs2-0012" title="TontivuthikulP , SanmeeU , Wongtra-NganS , PongnarisornC . Effect of local estrogen cream on vaginal health after pessary use for prolapsed pelvic organ: a randomized controlled trial. Journal of the Medical Association of Thailand2016;99(7):757-63. ">Tontivuthikul 2016</a>, 25% of women in the intervention group had undergone hysterectomy, compared to 20% in the control group. Hysterectomy rates across groups in <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a> ranged from 16% to 24%. All participants in <a href="./references#CD014592-bbs2-0013" title="NCT00803335. The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse [The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse: a randomized control trial]. clinicaltrials.gov/ct2/show/NCT00803335 (first received 05 December 2008). VaccaroCM , CrispCC , EstanolMV , FellnerAN , MutemaGK , KleemanSD , et al. Administration of vaginal estrogen in women with vaginal atrophy prior to prolapse surgery: an assessment of quality of life outcomes and medication adherence (Abstract 286). International Urogynecology Journal2011;22(Suppl 3):S1839-40. [DOI: 10.1007/s00192-011-1521-1]VaccaroCM , CrispCC , FellnerAN , PaulsRN . Impact of preoperative vaginal estrogen on patient quality of life measures: a randomized controlled trial (Abstract 120). Female Pelvic Medicine and Reconstructive Surgery2012;18(8 Suppl 1):S151-2. [DOI: 10.1097/SPV.0b013e31826abf55]VaccaroCM , MutemaGK , FellnerAN , CrispCC , EstanolMV , KleemanSD , et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2013;19(1):34-9. [DOI: 10.1097/SPV.0b013e318278cc40]VaccaroCM , MutemaGK , FellnerAN , CrispCC , PaulsRN . The effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial (Abstract 02). Female Pelvic Medicine and Reconstructive Surgery2012;18(2 Suppl 1):S14. [DOI: 10.1097/SPV.0b013e31824bf52d]">Vaccaro 2013</a> had previously undergone hysterectomy. Five studies did not report previous hysterectomy (<a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a>; <a href="./references#CD014592-bbs2-0004" title="CoelhoSC , GiraldoPC , BritoLG , Teatin JuliatoCR . Estrogen use on complications for women treating pelvic organ prolapse with vaginal pessaries (ESTRO-PESS)-a randomized clinical trial (Abstract 007). International Urogynecology Journal2020;31(Suppl 1):S4. [DOI: 10.1007/s00192-020-04555-3]RBR-23sqxz. Impact of cream vaginal use on complications in women using vaginal ring in treatment of genital prolapse: a randomized clinical trial [Impacto do uso do creme vaginal nas complicações em mulheres usuárias de anel vaginais no tratamento do prolapso genital: ensaio clínico randomizado] [Impact of estrogen use on complications in women using vaginal pessaries with genital prolapse: a randomized clinical trial [Impacto do uso do estrogênio nas complicações em mulheres usuárias de pessários vaginais com prolapso genital: ensaio clínico randomizado]]. ensaiosclinicos.gov.br/rg/RBR-23sqxz (first received 24 August 2018). ">Coelho 2020</a>; <a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a>; <a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>). </p> <p>The average age of participants was under 65 years in seven studies (<a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a>; <a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>; <a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a>; <a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>; <a href="./references#CD014592-bbs2-0008" title="NunesJC , FeldnerPC , CastroRA , NaderHB , SartoriMF , GirãoMB . Uterine prolapse: evaluation of glycosaminoglycans in postmenopausal women after estrogen therapy. Climacteric2011;14(1):121-5. ">Nunes 2011</a>; <a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a>; <a href="./references#CD014592-bbs2-0010" title="StipicI , PolasekO , VulicM , PundaH , GrandicL , StrinicT . Estrogen replacement therapy improves pulmonary function in postmenopausal women with genital prolapse. Rejuvenation Research2012;15(6):596-600. [DOI: 10.1089/rej.2012.1337]">Stipic 2012</a>), and 65 years or over in five studies (<a href="./references#CD014592-bbs2-0003" title="ChiengthongK , RuanphooP , ChatsuwanT , BunyavejchevinS . Effect of vaginal estrogen in postmenopausal women using vaginal pessary for pelvic organ prolapse treatment: a randomized controlled trial. International Urogynecology Journal2022;33(7):1833-8. [DOI: 10.1007/s00192-021-04821-y]TCTR20180329001. Effect of vaginal estriol 0.03 mg with Lactobacillus acidophilus on incidence of bacterial vaginosis in patient using pessary for treatment of pelvic organ prolapse. thaiclinicaltrials.org/show/TCTR20180329001 (first received 29 March 2018). ">Chiengthong 2022</a>; <a href="./references#CD014592-bbs2-0004" title="CoelhoSC , GiraldoPC , BritoLG , Teatin JuliatoCR . Estrogen use on complications for women treating pelvic organ prolapse with vaginal pessaries (ESTRO-PESS)-a randomized clinical trial (Abstract 007). International Urogynecology Journal2020;31(Suppl 1):S4. [DOI: 10.1007/s00192-020-04555-3]RBR-23sqxz. Impact of cream vaginal use on complications in women using vaginal ring in treatment of genital prolapse: a randomized clinical trial [Impacto do uso do creme vaginal nas complicações em mulheres usuárias de anel vaginais no tratamento do prolapso genital: ensaio clínico randomizado] [Impact of estrogen use on complications in women using vaginal pessaries with genital prolapse: a randomized clinical trial [Impacto do uso do estrogênio nas complicações em mulheres usuárias de pessários vaginais com prolapso genital: ensaio clínico randomizado]]. ensaiosclinicos.gov.br/rg/RBR-23sqxz (first received 24 August 2018). ">Coelho 2020</a>; <a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>; <a href="./references#CD014592-bbs2-0012" title="TontivuthikulP , SanmeeU , Wongtra-NganS , PongnarisornC . Effect of local estrogen cream on vaginal health after pessary use for prolapsed pelvic organ: a randomized controlled trial. Journal of the Medical Association of Thailand2016;99(7):757-63. ">Tontivuthikul 2016</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>). In <a href="./references#CD014592-bbs2-0013" title="NCT00803335. The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse [The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse: a randomized control trial]. clinicaltrials.gov/ct2/show/NCT00803335 (first received 05 December 2008). VaccaroCM , CrispCC , EstanolMV , FellnerAN , MutemaGK , KleemanSD , et al. Administration of vaginal estrogen in women with vaginal atrophy prior to prolapse surgery: an assessment of quality of life outcomes and medication adherence (Abstract 286). International Urogynecology Journal2011;22(Suppl 3):S1839-40. [DOI: 10.1007/s00192-011-1521-1]VaccaroCM , CrispCC , FellnerAN , PaulsRN . Impact of preoperative vaginal estrogen on patient quality of life measures: a randomized controlled trial (Abstract 120). Female Pelvic Medicine and Reconstructive Surgery2012;18(8 Suppl 1):S151-2. [DOI: 10.1097/SPV.0b013e31826abf55]VaccaroCM , MutemaGK , FellnerAN , CrispCC , EstanolMV , KleemanSD , et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2013;19(1):34-9. [DOI: 10.1097/SPV.0b013e318278cc40]VaccaroCM , MutemaGK , FellnerAN , CrispCC , PaulsRN . The effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial (Abstract 02). Female Pelvic Medicine and Reconstructive Surgery2012;18(2 Suppl 1):S14. [DOI: 10.1097/SPV.0b013e31824bf52d]">Vaccaro 2013</a>, the average age of participants was under 65 years in the intervention group and over 65 years in the control group. <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a> reported the median age of participants at diagnosis of POP, which was 66 years in the intervention group and 65 years in the control group. </p> <p>Average BMI of the women was greater than 25 kg/m<sup>2</sup> in nine studies (<a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>; <a href="./references#CD014592-bbs2-0004" title="CoelhoSC , GiraldoPC , BritoLG , Teatin JuliatoCR . Estrogen use on complications for women treating pelvic organ prolapse with vaginal pessaries (ESTRO-PESS)-a randomized clinical trial (Abstract 007). International Urogynecology Journal2020;31(Suppl 1):S4. [DOI: 10.1007/s00192-020-04555-3]RBR-23sqxz. Impact of cream vaginal use on complications in women using vaginal ring in treatment of genital prolapse: a randomized clinical trial [Impacto do uso do creme vaginal nas complicações em mulheres usuárias de anel vaginais no tratamento do prolapso genital: ensaio clínico randomizado] [Impact of estrogen use on complications in women using vaginal pessaries with genital prolapse: a randomized clinical trial [Impacto do uso do estrogênio nas complicações em mulheres usuárias de pessários vaginais com prolapso genital: ensaio clínico randomizado]]. ensaiosclinicos.gov.br/rg/RBR-23sqxz (first received 24 August 2018). ">Coelho 2020</a>; <a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>; <a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>; <a href="./references#CD014592-bbs2-0008" title="NunesJC , FeldnerPC , CastroRA , NaderHB , SartoriMF , GirãoMB . Uterine prolapse: evaluation of glycosaminoglycans in postmenopausal women after estrogen therapy. Climacteric2011;14(1):121-5. ">Nunes 2011</a>; <a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a>; <a href="./references#CD014592-bbs2-0010" title="StipicI , PolasekO , VulicM , PundaH , GrandicL , StrinicT . Estrogen replacement therapy improves pulmonary function in postmenopausal women with genital prolapse. Rejuvenation Research2012;15(6):596-600. [DOI: 10.1089/rej.2012.1337]">Stipic 2012</a>; <a href="./references#CD014592-bbs2-0013" title="NCT00803335. The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse [The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse: a randomized control trial]. clinicaltrials.gov/ct2/show/NCT00803335 (first received 05 December 2008). VaccaroCM , CrispCC , EstanolMV , FellnerAN , MutemaGK , KleemanSD , et al. Administration of vaginal estrogen in women with vaginal atrophy prior to prolapse surgery: an assessment of quality of life outcomes and medication adherence (Abstract 286). International Urogynecology Journal2011;22(Suppl 3):S1839-40. [DOI: 10.1007/s00192-011-1521-1]VaccaroCM , CrispCC , FellnerAN , PaulsRN . Impact of preoperative vaginal estrogen on patient quality of life measures: a randomized controlled trial (Abstract 120). Female Pelvic Medicine and Reconstructive Surgery2012;18(8 Suppl 1):S151-2. [DOI: 10.1097/SPV.0b013e31826abf55]VaccaroCM , MutemaGK , FellnerAN , CrispCC , EstanolMV , KleemanSD , et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2013;19(1):34-9. [DOI: 10.1097/SPV.0b013e318278cc40]VaccaroCM , MutemaGK , FellnerAN , CrispCC , PaulsRN . The effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial (Abstract 02). Female Pelvic Medicine and Reconstructive Surgery2012;18(2 Suppl 1):S14. [DOI: 10.1097/SPV.0b013e31824bf52d]">Vaccaro 2013</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>), and under 25 kg/m<b><sup>2</sup> </b> in three studies (<a href="./references#CD014592-bbs2-0003" title="ChiengthongK , RuanphooP , ChatsuwanT , BunyavejchevinS . Effect of vaginal estrogen in postmenopausal women using vaginal pessary for pelvic organ prolapse treatment: a randomized controlled trial. International Urogynecology Journal2022;33(7):1833-8. [DOI: 10.1007/s00192-021-04821-y]TCTR20180329001. Effect of vaginal estriol 0.03 mg with Lactobacillus acidophilus on incidence of bacterial vaginosis in patient using pessary for treatment of pelvic organ prolapse. thaiclinicaltrials.org/show/TCTR20180329001 (first received 29 March 2018). ">Chiengthong 2022</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>; <a href="./references#CD014592-bbs2-0012" title="TontivuthikulP , SanmeeU , Wongtra-NganS , PongnarisornC . Effect of local estrogen cream on vaginal health after pessary use for prolapsed pelvic organ: a randomized controlled trial. Journal of the Medical Association of Thailand2016;99(7):757-63. ">Tontivuthikul 2016</a>). Two studies did not report BMI (<a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a>; <a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a>). </p> </section> <section id="CD014592-sec-0055"> <h5 class="title">Interventions</h5> <section id="CD014592-sec-0056"> <h6 class="title">Oestrogen therapy plus surgery versus surgery alone</h6> <p>Eleven studies evaluated oestrogen therapy plus surgery versus surgery alone (<a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a>; <a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>; <a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>; <a href="./references#CD014592-bbs2-0008" title="NunesJC , FeldnerPC , CastroRA , NaderHB , SartoriMF , GirãoMB . Uterine prolapse: evaluation of glycosaminoglycans in postmenopausal women after estrogen therapy. Climacteric2011;14(1):121-5. ">Nunes 2011</a>; <a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a>; <a href="./references#CD014592-bbs2-0010" title="StipicI , PolasekO , VulicM , PundaH , GrandicL , StrinicT . Estrogen replacement therapy improves pulmonary function in postmenopausal women with genital prolapse. Rejuvenation Research2012;15(6):596-600. [DOI: 10.1089/rej.2012.1337]">Stipic 2012</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>; <a href="./references#CD014592-bbs2-0013" title="NCT00803335. The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse [The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse: a randomized control trial]. clinicaltrials.gov/ct2/show/NCT00803335 (first received 05 December 2008). VaccaroCM , CrispCC , EstanolMV , FellnerAN , MutemaGK , KleemanSD , et al. Administration of vaginal estrogen in women with vaginal atrophy prior to prolapse surgery: an assessment of quality of life outcomes and medication adherence (Abstract 286). International Urogynecology Journal2011;22(Suppl 3):S1839-40. [DOI: 10.1007/s00192-011-1521-1]VaccaroCM , CrispCC , FellnerAN , PaulsRN . Impact of preoperative vaginal estrogen on patient quality of life measures: a randomized controlled trial (Abstract 120). Female Pelvic Medicine and Reconstructive Surgery2012;18(8 Suppl 1):S151-2. [DOI: 10.1097/SPV.0b013e31826abf55]VaccaroCM , MutemaGK , FellnerAN , CrispCC , EstanolMV , KleemanSD , et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2013;19(1):34-9. [DOI: 10.1097/SPV.0b013e318278cc40]VaccaroCM , MutemaGK , FellnerAN , CrispCC , PaulsRN . The effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial (Abstract 02). Female Pelvic Medicine and Reconstructive Surgery2012;18(2 Suppl 1):S14. [DOI: 10.1097/SPV.0b013e31824bf52d]">Vaccaro 2013</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>; <a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a>; <a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>). </p> <p>The types and doses of included topical oestrogens were as follows.</p> <p> <ul id="CD014592-list-0014"> <li> <p>Oestriol 50 μg vaginal gel (<a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>) </p> </li> <li> <p>Oestradiol hemihydrate 1 g (<a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>; <a href="./references#CD014592-bbs2-0010" title="StipicI , PolasekO , VulicM , PundaH , GrandicL , StrinicT . Estrogen replacement therapy improves pulmonary function in postmenopausal women with genital prolapse. Rejuvenation Research2012;15(6):596-600. [DOI: 10.1089/rej.2012.1337]">Stipic 2012</a>) </p> </li> <li> <p>Promestriene 0.5 g cream (<a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>) </p> </li> <li> <p>Conjugated equine oestrogen vaginal cream (Premarin) 1.0 g (<a href="./references#CD014592-bbs2-0013" title="NCT00803335. The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse [The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse: a randomized control trial]. clinicaltrials.gov/ct2/show/NCT00803335 (first received 05 December 2008). VaccaroCM , CrispCC , EstanolMV , FellnerAN , MutemaGK , KleemanSD , et al. Administration of vaginal estrogen in women with vaginal atrophy prior to prolapse surgery: an assessment of quality of life outcomes and medication adherence (Abstract 286). International Urogynecology Journal2011;22(Suppl 3):S1839-40. [DOI: 10.1007/s00192-011-1521-1]VaccaroCM , CrispCC , FellnerAN , PaulsRN . Impact of preoperative vaginal estrogen on patient quality of life measures: a randomized controlled trial (Abstract 120). Female Pelvic Medicine and Reconstructive Surgery2012;18(8 Suppl 1):S151-2. [DOI: 10.1097/SPV.0b013e31826abf55]VaccaroCM , MutemaGK , FellnerAN , CrispCC , EstanolMV , KleemanSD , et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2013;19(1):34-9. [DOI: 10.1097/SPV.0b013e318278cc40]VaccaroCM , MutemaGK , FellnerAN , CrispCC , PaulsRN . The effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial (Abstract 02). Female Pelvic Medicine and Reconstructive Surgery2012;18(2 Suppl 1):S14. [DOI: 10.1097/SPV.0b013e31824bf52d]">Vaccaro 2013</a>) </p> </li> <li> <p>Oestradiol hemihydrate (Vagifem) 10 μg (<a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>, <a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a>) </p> </li> <li> <p>Oestradiol vaginal ring (Estring; <a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>) </p> </li> </ul> </p> <p>The types and doses of included systemic oestrogens were as follows.</p> <p> <ul id="CD014592-list-0015"> <li> <p>Conjugated equine oestrogen (Premarin) 0.625 mg/g (<a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a>; <a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a>) </p> </li> <li> <p>Conjugated equine oestrogen (Premarin) 1.26 mg (<a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a>) </p> </li> <li> <p>17‐beta‐oestradiol 50 g transdermal (<a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a>) </p> </li> <li> <p>"oral oestrogen" (no other details; <a href="./references#CD014592-bbs2-0008" title="NunesJC , FeldnerPC , CastroRA , NaderHB , SartoriMF , GirãoMB . Uterine prolapse: evaluation of glycosaminoglycans in postmenopausal women after estrogen therapy. Climacteric2011;14(1):121-5. ">Nunes 2011</a>) </p> </li> </ul> </p> <p>The types of surgery were as follows.</p> <p> <ul id="CD014592-list-0016"> <li> <p>Hysterectomy (<a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a>; <a href="./references#CD014592-bbs2-0008" title="NunesJC , FeldnerPC , CastroRA , NaderHB , SartoriMF , GirãoMB . Uterine prolapse: evaluation of glycosaminoglycans in postmenopausal women after estrogen therapy. Climacteric2011;14(1):121-5. ">Nunes 2011</a>; <a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a>) </p> </li> <li> <p>Hysterectomy and anterior colporrhaphy (<a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>) </p> </li> <li> <p>Hysterectomy with or without salpingo‐oophorectomy, anterior repair, posterior repair, or sacrospinous fixation (<a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>) </p> </li> <li> <p>Hysterectomy, anterior and posterior colporrhaphy, Manchester‐Fothergill operation, or a combination of these (<a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a>). These participants were also offered PFME. </p> </li> <li> <p>Reconstructive surgery, including hysterectomy and "kit" procedures (<a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>) </p> </li> <li> <p>Pelvic reconstructive surgery using mesh (<a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>) </p> </li> </ul> </p> <p><a href="./references#CD014592-bbs2-0013" title="NCT00803335. The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse [The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse: a randomized control trial]. clinicaltrials.gov/ct2/show/NCT00803335 (first received 05 December 2008). VaccaroCM , CrispCC , EstanolMV , FellnerAN , MutemaGK , KleemanSD , et al. Administration of vaginal estrogen in women with vaginal atrophy prior to prolapse surgery: an assessment of quality of life outcomes and medication adherence (Abstract 286). International Urogynecology Journal2011;22(Suppl 3):S1839-40. [DOI: 10.1007/s00192-011-1521-1]VaccaroCM , CrispCC , FellnerAN , PaulsRN . Impact of preoperative vaginal estrogen on patient quality of life measures: a randomized controlled trial (Abstract 120). Female Pelvic Medicine and Reconstructive Surgery2012;18(8 Suppl 1):S151-2. [DOI: 10.1097/SPV.0b013e31826abf55]VaccaroCM , MutemaGK , FellnerAN , CrispCC , EstanolMV , KleemanSD , et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2013;19(1):34-9. [DOI: 10.1097/SPV.0b013e318278cc40]VaccaroCM , MutemaGK , FellnerAN , CrispCC , PaulsRN . The effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial (Abstract 02). Female Pelvic Medicine and Reconstructive Surgery2012;18(2 Suppl 1):S14. [DOI: 10.1097/SPV.0b013e31824bf52d]">Vaccaro 2013</a> described the surgery as either vaginal, robotic, or abdominal with no further details. Two studies did not describe the surgical procedures (<a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>; <a href="./references#CD014592-bbs2-0010" title="StipicI , PolasekO , VulicM , PundaH , GrandicL , StrinicT . Estrogen replacement therapy improves pulmonary function in postmenopausal women with genital prolapse. Rejuvenation Research2012;15(6):596-600. [DOI: 10.1089/rej.2012.1337]">Stipic 2012</a>). </p> </section> <section id="CD014592-sec-0057"> <h6 class="title">Topical oestrogen therapy plus pessary versus pessary alone</h6> <p>Three studies evaluated topical oestrogen therapy plus pessary versus pessary alone (<a href="./references#CD014592-bbs2-0003" title="ChiengthongK , RuanphooP , ChatsuwanT , BunyavejchevinS . Effect of vaginal estrogen in postmenopausal women using vaginal pessary for pelvic organ prolapse treatment: a randomized controlled trial. International Urogynecology Journal2022;33(7):1833-8. [DOI: 10.1007/s00192-021-04821-y]TCTR20180329001. Effect of vaginal estriol 0.03 mg with Lactobacillus acidophilus on incidence of bacterial vaginosis in patient using pessary for treatment of pelvic organ prolapse. thaiclinicaltrials.org/show/TCTR20180329001 (first received 29 March 2018). ">Chiengthong 2022</a>; <a href="./references#CD014592-bbs2-0004" title="CoelhoSC , GiraldoPC , BritoLG , Teatin JuliatoCR . Estrogen use on complications for women treating pelvic organ prolapse with vaginal pessaries (ESTRO-PESS)-a randomized clinical trial (Abstract 007). International Urogynecology Journal2020;31(Suppl 1):S4. [DOI: 10.1007/s00192-020-04555-3]RBR-23sqxz. Impact of cream vaginal use on complications in women using vaginal ring in treatment of genital prolapse: a randomized clinical trial [Impacto do uso do creme vaginal nas complicações em mulheres usuárias de anel vaginais no tratamento do prolapso genital: ensaio clínico randomizado] [Impact of estrogen use on complications in women using vaginal pessaries with genital prolapse: a randomized clinical trial [Impacto do uso do estrogênio nas complicações em mulheres usuárias de pessários vaginais com prolapso genital: ensaio clínico randomizado]]. ensaiosclinicos.gov.br/rg/RBR-23sqxz (first received 24 August 2018). ">Coelho 2020</a>; <a href="./references#CD014592-bbs2-0012" title="TontivuthikulP , SanmeeU , Wongtra-NganS , PongnarisornC . Effect of local estrogen cream on vaginal health after pessary use for prolapsed pelvic organ: a randomized controlled trial. Journal of the Medical Association of Thailand2016;99(7):757-63. ">Tontivuthikul 2016</a>). All three studies recruited women who were already using a pessary. <a href="./references#CD014592-bbs2-0012" title="TontivuthikulP , SanmeeU , Wongtra-NganS , PongnarisornC . Effect of local estrogen cream on vaginal health after pessary use for prolapsed pelvic organ: a randomized controlled trial. Journal of the Medical Association of Thailand2016;99(7):757-63. ">Tontivuthikul 2016</a> also included pretreatment with oestrogen cream for all participants. </p> </section> </section> <section id="CD014592-sec-0058"> <h5 class="title">Outcomes</h5> <p>Two studies reported usable data for our primary outcome of participant‐reported subjective cure of POP (<a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>). </p> <p>There was usable data for the following secondary outcomes.</p> <p> <ul id="CD014592-list-0017"> <li> <p>Improvement or cure of associated urinary symptoms (<a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>) </p> </li> <li> <p>Improvement or cure of associated bowel symptoms (<a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>) </p> </li> <li> <p>Improvement or cure of associated sexual symptoms (<a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>) </p> </li> <li> <p>Objective improvement or cure of POP symptoms (<a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>) </p> </li> <li> <p>Condition‐specific quality of life (<a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>) </p> </li> <li> <p>Generic quality of life or health status (<a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>) </p> </li> <li> <p>Participant adherence to the intervention (<a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a>; <a href="./references#CD014592-bbs2-0013" title="NCT00803335. The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse [The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse: a randomized control trial]. clinicaltrials.gov/ct2/show/NCT00803335 (first received 05 December 2008). VaccaroCM , CrispCC , EstanolMV , FellnerAN , MutemaGK , KleemanSD , et al. Administration of vaginal estrogen in women with vaginal atrophy prior to prolapse surgery: an assessment of quality of life outcomes and medication adherence (Abstract 286). International Urogynecology Journal2011;22(Suppl 3):S1839-40. [DOI: 10.1007/s00192-011-1521-1]VaccaroCM , CrispCC , FellnerAN , PaulsRN . Impact of preoperative vaginal estrogen on patient quality of life measures: a randomized controlled trial (Abstract 120). Female Pelvic Medicine and Reconstructive Surgery2012;18(8 Suppl 1):S151-2. [DOI: 10.1097/SPV.0b013e31826abf55]VaccaroCM , MutemaGK , FellnerAN , CrispCC , EstanolMV , KleemanSD , et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2013;19(1):34-9. [DOI: 10.1097/SPV.0b013e318278cc40]VaccaroCM , MutemaGK , FellnerAN , CrispCC , PaulsRN . The effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial (Abstract 02). Female Pelvic Medicine and Reconstructive Surgery2012;18(2 Suppl 1):S14. [DOI: 10.1097/SPV.0b013e31824bf52d]">Vaccaro 2013</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>) </p> </li> <li> <p>Adverse events (<a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>; <a href="./references#CD014592-bbs2-0003" title="ChiengthongK , RuanphooP , ChatsuwanT , BunyavejchevinS . Effect of vaginal estrogen in postmenopausal women using vaginal pessary for pelvic organ prolapse treatment: a randomized controlled trial. International Urogynecology Journal2022;33(7):1833-8. [DOI: 10.1007/s00192-021-04821-y]TCTR20180329001. Effect of vaginal estriol 0.03 mg with Lactobacillus acidophilus on incidence of bacterial vaginosis in patient using pessary for treatment of pelvic organ prolapse. thaiclinicaltrials.org/show/TCTR20180329001 (first received 29 March 2018). ">Chiengthong 2022</a>; <a href="./references#CD014592-bbs2-0004" title="CoelhoSC , GiraldoPC , BritoLG , Teatin JuliatoCR . Estrogen use on complications for women treating pelvic organ prolapse with vaginal pessaries (ESTRO-PESS)-a randomized clinical trial (Abstract 007). International Urogynecology Journal2020;31(Suppl 1):S4. [DOI: 10.1007/s00192-020-04555-3]RBR-23sqxz. Impact of cream vaginal use on complications in women using vaginal ring in treatment of genital prolapse: a randomized clinical trial [Impacto do uso do creme vaginal nas complicações em mulheres usuárias de anel vaginais no tratamento do prolapso genital: ensaio clínico randomizado] [Impact of estrogen use on complications in women using vaginal pessaries with genital prolapse: a randomized clinical trial [Impacto do uso do estrogênio nas complicações em mulheres usuárias de pessários vaginais com prolapso genital: ensaio clínico randomizado]]. ensaiosclinicos.gov.br/rg/RBR-23sqxz (first received 24 August 2018). ">Coelho 2020</a>; <a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a>; <a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>; <a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>; <a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>; <a href="./references#CD014592-bbs2-0012" title="TontivuthikulP , SanmeeU , Wongtra-NganS , PongnarisornC . Effect of local estrogen cream on vaginal health after pessary use for prolapsed pelvic organ: a randomized controlled trial. Journal of the Medical Association of Thailand2016;99(7):757-63. ">Tontivuthikul 2016</a>; <a href="./references#CD014592-bbs2-0013" title="NCT00803335. The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse [The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse: a randomized control trial]. clinicaltrials.gov/ct2/show/NCT00803335 (first received 05 December 2008). VaccaroCM , CrispCC , EstanolMV , FellnerAN , MutemaGK , KleemanSD , et al. Administration of vaginal estrogen in women with vaginal atrophy prior to prolapse surgery: an assessment of quality of life outcomes and medication adherence (Abstract 286). International Urogynecology Journal2011;22(Suppl 3):S1839-40. [DOI: 10.1007/s00192-011-1521-1]VaccaroCM , CrispCC , FellnerAN , PaulsRN . Impact of preoperative vaginal estrogen on patient quality of life measures: a randomized controlled trial (Abstract 120). Female Pelvic Medicine and Reconstructive Surgery2012;18(8 Suppl 1):S151-2. [DOI: 10.1097/SPV.0b013e31826abf55]VaccaroCM , MutemaGK , FellnerAN , CrispCC , EstanolMV , KleemanSD , et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2013;19(1):34-9. [DOI: 10.1097/SPV.0b013e318278cc40]VaccaroCM , MutemaGK , FellnerAN , CrispCC , PaulsRN . The effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial (Abstract 02). Female Pelvic Medicine and Reconstructive Surgery2012;18(2 Suppl 1):S14. [DOI: 10.1097/SPV.0b013e31824bf52d]">Vaccaro 2013</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>) </p> </li> <li> <p>Surgical outcomes (<a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>; <a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>; <a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>) </p> </li> </ul> </p> <p>No study reported psychological or emotional well‐being. Three studies provided no usable data for our outcomes of interest (<a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a>; <a href="./references#CD014592-bbs2-0008" title="NunesJC , FeldnerPC , CastroRA , NaderHB , SartoriMF , GirãoMB . Uterine prolapse: evaluation of glycosaminoglycans in postmenopausal women after estrogen therapy. Climacteric2011;14(1):121-5. ">Nunes 2011</a>; <a href="./references#CD014592-bbs2-0010" title="StipicI , PolasekO , VulicM , PundaH , GrandicL , StrinicT . Estrogen replacement therapy improves pulmonary function in postmenopausal women with genital prolapse. Rejuvenation Research2012;15(6):596-600. [DOI: 10.1089/rej.2012.1337]">Stipic 2012</a>). </p> <p>The <a href="./references#CD014592-sec-0142" title="">Characteristics of included studies</a> table presents details of the tools used to measure outcomes. </p> </section> </section> <section id="CD014592-sec-0059"> <h4 class="title">Excluded studies</h4> <p>We excluded eight studies: five had an ineligible population (<a href="./references#CD014592-bbs2-0016" title="ChinthakananO , WattanayingcharoenchaiR , AimjirakulK , Sarit-ApirakS , ManonaiJ . Comparison of vaginal moisturizers with ultralow dose estriol &amp; lactobacilluls acidophilus vaginaltablets in pelvic organ prolapse women who were treated with vaginal pessary: a randomized controlled trial (Abstract 144). International Urogynecology Journal2019;30(Suppl 1):S168. [DOI: 10.1007/s00192-019-04125-2]ChinthakananO , WattanayingcharoenchaiR , AimjirakulK , Sarit-apirakS , ManonaiJ . Comparison of vaginal moisturizers with ultra-low dose estriol &amp; lactobacilluls acidophilus vaginal tablets in pelvic organ prolapse women whowere treated with vaginal pessary: a randomized controlled trial (Scientific Salon 144). Female Pelvic Medicine and Reconstructive Surgery2019;25(5 Suppl 1):S142. [DOI: 10.1097/SPV.0000000000000767]ChinthakananO , TCTR20160621001. Comparison of vaginal moisturizers with ultra-low dose estriol &amp; Lactobacillus acidophilus vaginal tablets in pelvic organ prolapse women who were treated with vaginal pessary: a randomized controlled trial. thaiclinicaltrials.org/show/TCTR20160621001 (first received 20 June 2016). ">Chinthakanan 2019</a>; <a href="./references#CD014592-bbs2-0017" title="NCT01843166. Vaginal estrogen with pessary treatment [Use of vaginal estrogen with pessary treatment of pelvic organ prolapse and urinary incontinence]. clinicaltrials.gov/show/NCT01843166 (first received 30 April 2013). ">Chou 2013</a>; <a href="./references#CD014592-bbs2-0020" title="NCT01648751. Vaginal estrogen and pelvic floor physical therapy in women with symptomatic mild prolapse [Impact of vaginal estrogen in the treatment of symptomatic mild pelvic organ prolapse with pelvic floor physical therapy]. clinicaltrials.gov/show/NCT01648751 (first received 24 July 2012). ">Moalli 2012</a>; <a href="./references#CD014592-bbs2-0019" title="NCT02316249. Vaginal creams to reduce vaginal erosion in pessary users [Vaginal creams for reduction of vaginal discharge and erosion in patients using ring with support or gellhorn pessaries to reduce pelvic organ prolapse]. clinicaltrials.gov/show/NCT02316249 (first received 12 December 2014). ">Lind 2014</a>; <a href="./references#CD014592-bbs2-0021" title="NCT02691936. Comparison of vaginal laser therapy to vaginal estrogen therapy (VeLVET) [A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause]. clinicaltrials.gov/ct2/show/NCT02691936 (first received 25 February 2016). ParaisoMF , FerrandoCA , KarramMM , SokolER , RardinCR , MatthewsCA , et al. Comparison of vaginal laser therapy to vaginal estrogen therapy (VELVET) for women with genitourinary syndrome of menopause (GSM) (Abstract 62). Female Pelvic Medicine and Reconstructive Surgery2018;24(5 Suppl 1):S45-6. [DOI: 10.1097/SPV.0000000000000617]ParaisoMF , FerrandoCA , SokolER , RardinCR , MatthewsCA , KarramMM , et al. A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: the VeLVET Trial. Menopause2020;27(1):50-6. [DOI: 10.1097/GME.0000000000001416]">Paraiso 2020</a>), and three evaluated an ineligible intervention (<a href="./references#CD014592-bbs2-0015" title="BarberMD , ViscoAG , WymanJF , FantlJA , BumpRC , on behalf of the Continence Program for Women Research Group. Sexual function in women with urinary incontinence and pelvic organ prolapse. Obstetrics and Gynecology2002;99(2):281-9. ">Barber 2002</a>; <a href="./references#CD014592-bbs2-0018" title="JiangG , ZhuT , ZhouY , MaQ . Effect of puerarin on vaginal connective tissue in patients with pelvic organ prolapse. International Journal of Clinical and Experimental Medicine2017;10(1):732-8. ">Jiang 2017</a>; <a href="./references#CD014592-bbs2-0022" title="ValenteM , DettoriC , FeraudoE , ReME . Pelvic-floor: new therapeutic approach (Abstract IDP66). International Urogynecological Journal2000;11(Suppl 1):S97. ">Valente 2000</a>). For further information, see the <a href="./references#CD014592-sec-0143" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD014592-sec-0060"> <h4 class="title">Studies awaiting classification</h4> <p>For three studies, we have requested information from the study authors to clarify eligibility but have yet to receive a response (<a href="./references#CD014592-bbs2-0023" title="NCT03032848. Vaginal estrogens comparative trial on pelvic organ prolapse patients [Randomized, blinded trial comparing vaginal estrogens on pelvic organ prolapse patients]. clinicaltrials.gov/show/NCT03032848 (first received 26 January 2017). PinhatE . RE: Study query: Vaginal Estrogens Comparative Trial on Pelvic Organ Prolapse Patients. Email to: E Johnson 18 January 2022. PinhatEC . Estudo Comparativo De Cremes Estrogênicos Em Pacientes Com Prolapso Genital [Masters thesis] [Comparative Study of Estrogen Cream in Patients with Genital Prolapse. For information only, English title translated via Google Translate™]. Curitiba (Brazil): Universidade Federal do Paraná, 2017. ">Pinhat 2013</a>; <a href="./references#CD014592-bbs2-0024" title="VardyMD , LindsayR , ScottiRJ , MikhailM , RichartRM , NievesJ , et al. Short-term urogenital effects of raloxifene, tamoxifen, and estrogen. American Journal of Obstetrics and Gynecology2003;189(1):81-8. VardyMD , ScottiRJ , LindsayR , RichartRM , CruzJ , NievesJ , et al. Short term urogenital effects of raloxifene, tamoxifen, and estrogen (Abstract 15). International Urogynecology Journal2001;12(Suppl 1):S33. ">Vardy 2003</a>; <a href="./references#CD014592-bbs2-0025" title="ZhuL , SunZ , LangJ . Could vaginal estrogen application prior to surgery reduce mesh exposure in transvaginal pelvic floor reconstruction with mesh? A 2-year randomized controlled trial (Abstract 156). Journal of Minimally Invasive Gynecology2014;21(Suppl 6):S47. [DOI: doi.org/10.1016/j.jmig.2014.08.170]ZhuL , SunZ . Could vaginal estrogen application prior to surgery reduce mesh exposure in transvaginal pelvic floor reconstruction with mesh? A 2-year randomized controlled trial (Abstract PP 46). International Urogynecology Journal2014;25(Suppl 1):S52. [DOI: 10.1007/s00192-014-2429-3]">Zhu 2014</a>). The <a href="./references#CD014592-bbs1-0003" title="">Studies awaiting classification</a> table provides further information. </p> </section> <section id="CD014592-sec-0061"> <h4 class="title">Ongoing studies</h4> <p>We identified four ongoing studies (<a href="./references#CD014592-bbs2-0026" title="NCT02431897. Investigation to minimize prolapse recurrence of the vagina using estrogen (IMPROVE) [Investigation to minimize prolapse recurrence of the vagina using estrogen]. clinicaltrials.gov/show/NCT02431897 (first received 01 May 2015). RahnDD , RichterHE , SungVW , LarsenWI , HynanLS . Design of a randomized clinical trial of perioperative vaginal estrogen versus placebo with transvaginal native tissue apical prolapse repair (investigation to minimize prolapse repair of the vagina using estrogen: IMPROVE). Female Pelvic Medicine and Reconstructive Surgery2021;27(1):e227-33. [DOI: 10.1097/SPV.0000000000000899]">Rahn 2021</a>; <a href="./references#CD014592-bbs2-0027" title="EUCTR2017-003144-21-NL. Research into effectiveness and costs concerning the use of (vaginally administered) oestrogen before and after vaginal prolapse surgery, in women after menopause [Onderzoek naar de effectiviteit en kosten van vaginale oestrogeencrème bij vrouwen na de menopauze die een verzakkingsoperatie ondergaan] [Cost-effectiveness of perioperative vaginally administered oestrogen in postmenopausal women undergoing prolapse surgery [Kosteneffectiviteit van perioperatief gebruik van topicale oestrogenen bij postmenopauzale vrouwen die vaginale prolapsoperatie ondergaan]]. www.clinicaltrialsregister.eu/ctr-search/trial/2017-003144-21/NL (first received 28 February 2018). NL6853, NTR7031. Research into effectiveness and costs concerning the use of oestrogen before and after vaginal prolapse surgery in women after menopause [Cost-effectiveness of perioperative vaginally administered oestrogen in postmenopausal women undergonig prolapse surgery]. trialregister.nl/trial/6853 [Dutch Trial Register (NTR) is undergoing redevelopment, information available via trialsearch.who.int/Trial2.aspx?TrialID=NTR7031] (first received 19 February 2018). ">Roovers 2018</a>; <a href="./references#CD014592-bbs2-0028" title="NCT01886794. Hormonal status on blood flow and tissue in pelvic organ prolapse [Role of hormonal status on vascularization and vaginal tissue in women with pelvic organ prolapse]. clinicaltrials.gov/show/NCT01886794 (first received 26 June 2013). ">Vincent 2013</a>; <a href="./references#CD014592-bbs2-0029" title="ChiCTR2000032753. The effect of intravaginal conjugated estrogen on ring pessary use for pelvic organ prolapse: a multicenter randomized, double- blind, placebo controlled, clinical trial [国产环型带膜子宫托联合使用阴道结合雌激素乳膏治疗女性症状性盆腔脏器脱垂的多中心的随机安慰剂对照双盲临床研究]. chictr.org.cn/hvshowproject.aspx?id=32555 (first received 24 March 2020). NCT04393194. The effect of intra-vaginal conjugated estrogen cream on ring pessary use for pelvic organ prolapse [The effect of intravaginal conjugated estrogen on ring pessary use for pelvic organ prolapse: a multicenter randomized, double- blind, placebo controlled, clinical trial]. clinicaltrials.gov/show/NCT04393194 (first received 19 May 2020). ">Zhu 2020</a>). The <a href="./references#CD014592-sec-0145" title="">Characteristics of ongoing studies</a> table provides further information. </p> </section> </section> <section id="CD014592-sec-0062"> <h3 class="title">Risk of bias in included studies</h3> <p>The <a href="./references#CD014592-sec-0142" title="">Characteristics of included studies</a> table provides further information on risk of bias assessments. For a graphical summary of risk of bias judgements, see <a href="#CD014592-fig-0003">Figure 3</a> and <a href="#CD014592-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD014592-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD014592-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD014592-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD014592-fig-0004" src="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD014592-sec-0063"> <h4 class="title">Allocation</h4> <section id="CD014592-sec-0064"> <h5 class="title">Random sequence generation</h5> <p>Eight studies adequately reported the method of randomisation, leading to a low risk of bias judgement for this domain (<a href="./references#CD014592-bbs2-0003" title="ChiengthongK , RuanphooP , ChatsuwanT , BunyavejchevinS . Effect of vaginal estrogen in postmenopausal women using vaginal pessary for pelvic organ prolapse treatment: a randomized controlled trial. International Urogynecology Journal2022;33(7):1833-8. [DOI: 10.1007/s00192-021-04821-y]TCTR20180329001. Effect of vaginal estriol 0.03 mg with Lactobacillus acidophilus on incidence of bacterial vaginosis in patient using pessary for treatment of pelvic organ prolapse. thaiclinicaltrials.org/show/TCTR20180329001 (first received 29 March 2018). ">Chiengthong 2022</a>; <a href="./references#CD014592-bbs2-0004" title="CoelhoSC , GiraldoPC , BritoLG , Teatin JuliatoCR . Estrogen use on complications for women treating pelvic organ prolapse with vaginal pessaries (ESTRO-PESS)-a randomized clinical trial (Abstract 007). International Urogynecology Journal2020;31(Suppl 1):S4. [DOI: 10.1007/s00192-020-04555-3]RBR-23sqxz. Impact of cream vaginal use on complications in women using vaginal ring in treatment of genital prolapse: a randomized clinical trial [Impacto do uso do creme vaginal nas complicações em mulheres usuárias de anel vaginais no tratamento do prolapso genital: ensaio clínico randomizado] [Impact of estrogen use on complications in women using vaginal pessaries with genital prolapse: a randomized clinical trial [Impacto do uso do estrogênio nas complicações em mulheres usuárias de pessários vaginais com prolapso genital: ensaio clínico randomizado]]. ensaiosclinicos.gov.br/rg/RBR-23sqxz (first received 24 August 2018). ">Coelho 2020</a>; <a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>; <a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>; <a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>; <a href="./references#CD014592-bbs2-0012" title="TontivuthikulP , SanmeeU , Wongtra-NganS , PongnarisornC . Effect of local estrogen cream on vaginal health after pessary use for prolapsed pelvic organ: a randomized controlled trial. Journal of the Medical Association of Thailand2016;99(7):757-63. ">Tontivuthikul 2016</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>). </p> <p>Four studies provided insufficient information for us to make a judgement, so we considered them at unclear risk of bias (<a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a>; <a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>; <a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a>; <a href="./references#CD014592-bbs2-0010" title="StipicI , PolasekO , VulicM , PundaH , GrandicL , StrinicT . Estrogen replacement therapy improves pulmonary function in postmenopausal women with genital prolapse. Rejuvenation Research2012;15(6):596-600. [DOI: 10.1089/rej.2012.1337]">Stipic 2012</a>). We also judged <a href="./references#CD014592-bbs2-0013" title="NCT00803335. The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse [The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse: a randomized control trial]. clinicaltrials.gov/ct2/show/NCT00803335 (first received 05 December 2008). VaccaroCM , CrispCC , EstanolMV , FellnerAN , MutemaGK , KleemanSD , et al. Administration of vaginal estrogen in women with vaginal atrophy prior to prolapse surgery: an assessment of quality of life outcomes and medication adherence (Abstract 286). International Urogynecology Journal2011;22(Suppl 3):S1839-40. [DOI: 10.1007/s00192-011-1521-1]VaccaroCM , CrispCC , FellnerAN , PaulsRN . Impact of preoperative vaginal estrogen on patient quality of life measures: a randomized controlled trial (Abstract 120). Female Pelvic Medicine and Reconstructive Surgery2012;18(8 Suppl 1):S151-2. [DOI: 10.1097/SPV.0b013e31826abf55]VaccaroCM , MutemaGK , FellnerAN , CrispCC , EstanolMV , KleemanSD , et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2013;19(1):34-9. [DOI: 10.1097/SPV.0b013e318278cc40]VaccaroCM , MutemaGK , FellnerAN , CrispCC , PaulsRN . The effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial (Abstract 02). Female Pelvic Medicine and Reconstructive Surgery2012;18(2 Suppl 1):S14. [DOI: 10.1097/SPV.0b013e31824bf52d]">Vaccaro 2013</a> at unclear risk for this domain: although its initial randomisation procedure seemed adequate, one arm was subsequently excluded and the handling of these participants may have been open to bias. </p> <p>We judged <a href="./references#CD014592-bbs2-0008" title="NunesJC , FeldnerPC , CastroRA , NaderHB , SartoriMF , GirãoMB . Uterine prolapse: evaluation of glycosaminoglycans in postmenopausal women after estrogen therapy. Climacteric2011;14(1):121-5. ">Nunes 2011</a> at high risk of bias for this domain because it provided no details on the randomisation procedure for two arms, while the third arm included non‐randomised women without POP. </p> </section> <section id="CD014592-sec-0065"> <h5 class="title">Allocation concealment</h5> <p>Allocation concealment was adequate and clearly described in three studies, which we judged at low risk of bias (<a href="./references#CD014592-bbs2-0003" title="ChiengthongK , RuanphooP , ChatsuwanT , BunyavejchevinS . Effect of vaginal estrogen in postmenopausal women using vaginal pessary for pelvic organ prolapse treatment: a randomized controlled trial. International Urogynecology Journal2022;33(7):1833-8. [DOI: 10.1007/s00192-021-04821-y]TCTR20180329001. Effect of vaginal estriol 0.03 mg with Lactobacillus acidophilus on incidence of bacterial vaginosis in patient using pessary for treatment of pelvic organ prolapse. thaiclinicaltrials.org/show/TCTR20180329001 (first received 29 March 2018). ">Chiengthong 2022</a>; <a href="./references#CD014592-bbs2-0004" title="CoelhoSC , GiraldoPC , BritoLG , Teatin JuliatoCR . Estrogen use on complications for women treating pelvic organ prolapse with vaginal pessaries (ESTRO-PESS)-a randomized clinical trial (Abstract 007). International Urogynecology Journal2020;31(Suppl 1):S4. [DOI: 10.1007/s00192-020-04555-3]RBR-23sqxz. Impact of cream vaginal use on complications in women using vaginal ring in treatment of genital prolapse: a randomized clinical trial [Impacto do uso do creme vaginal nas complicações em mulheres usuárias de anel vaginais no tratamento do prolapso genital: ensaio clínico randomizado] [Impact of estrogen use on complications in women using vaginal pessaries with genital prolapse: a randomized clinical trial [Impacto do uso do estrogênio nas complicações em mulheres usuárias de pessários vaginais com prolapso genital: ensaio clínico randomizado]]. ensaiosclinicos.gov.br/rg/RBR-23sqxz (first received 24 August 2018). ">Coelho 2020</a>; <a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>). Ten studies provided insufficient information for us to make a judgement, so we judged them at unclear risk (<a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a>; <a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>; <a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a>; <a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>; <a href="./references#CD014592-bbs2-0008" title="NunesJC , FeldnerPC , CastroRA , NaderHB , SartoriMF , GirãoMB . Uterine prolapse: evaluation of glycosaminoglycans in postmenopausal women after estrogen therapy. Climacteric2011;14(1):121-5. ">Nunes 2011</a>; <a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a>; <a href="./references#CD014592-bbs2-0010" title="StipicI , PolasekO , VulicM , PundaH , GrandicL , StrinicT . Estrogen replacement therapy improves pulmonary function in postmenopausal women with genital prolapse. Rejuvenation Research2012;15(6):596-600. [DOI: 10.1089/rej.2012.1337]">Stipic 2012</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>; <a href="./references#CD014592-bbs2-0012" title="TontivuthikulP , SanmeeU , Wongtra-NganS , PongnarisornC . Effect of local estrogen cream on vaginal health after pessary use for prolapsed pelvic organ: a randomized controlled trial. Journal of the Medical Association of Thailand2016;99(7):757-63. ">Tontivuthikul 2016</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>). <a href="./references#CD014592-bbs2-0013" title="NCT00803335. The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse [The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse: a randomized control trial]. clinicaltrials.gov/ct2/show/NCT00803335 (first received 05 December 2008). VaccaroCM , CrispCC , EstanolMV , FellnerAN , MutemaGK , KleemanSD , et al. Administration of vaginal estrogen in women with vaginal atrophy prior to prolapse surgery: an assessment of quality of life outcomes and medication adherence (Abstract 286). International Urogynecology Journal2011;22(Suppl 3):S1839-40. [DOI: 10.1007/s00192-011-1521-1]VaccaroCM , CrispCC , FellnerAN , PaulsRN . Impact of preoperative vaginal estrogen on patient quality of life measures: a randomized controlled trial (Abstract 120). Female Pelvic Medicine and Reconstructive Surgery2012;18(8 Suppl 1):S151-2. [DOI: 10.1097/SPV.0b013e31826abf55]VaccaroCM , MutemaGK , FellnerAN , CrispCC , EstanolMV , KleemanSD , et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2013;19(1):34-9. [DOI: 10.1097/SPV.0b013e318278cc40]VaccaroCM , MutemaGK , FellnerAN , CrispCC , PaulsRN . The effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial (Abstract 02). Female Pelvic Medicine and Reconstructive Surgery2012;18(2 Suppl 1):S14. [DOI: 10.1097/SPV.0b013e31824bf52d]">Vaccaro 2013</a> noted that blinding was not possible during enrolment, so we judged it at high risk of bias. </p> </section> </section> <section id="CD014592-sec-0066"> <h4 class="title">Blinding</h4> <section id="CD014592-sec-0067"> <h5 class="title">Performance bias</h5> <p>Two studies adequately blinded participants and personnel to the allocated treatment, leading to a low risk judgement for performance bias (<a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>; <a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a>). In eight studies, participants would have been aware of their allocated group owing to the nature of the interventions, or it was stated that blinding did not occur; we rated these studies at high risk of performance bias (<a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>; <a href="./references#CD014592-bbs2-0003" title="ChiengthongK , RuanphooP , ChatsuwanT , BunyavejchevinS . Effect of vaginal estrogen in postmenopausal women using vaginal pessary for pelvic organ prolapse treatment: a randomized controlled trial. International Urogynecology Journal2022;33(7):1833-8. [DOI: 10.1007/s00192-021-04821-y]TCTR20180329001. Effect of vaginal estriol 0.03 mg with Lactobacillus acidophilus on incidence of bacterial vaginosis in patient using pessary for treatment of pelvic organ prolapse. thaiclinicaltrials.org/show/TCTR20180329001 (first received 29 March 2018). ">Chiengthong 2022</a>; <a href="./references#CD014592-bbs2-0004" title="CoelhoSC , GiraldoPC , BritoLG , Teatin JuliatoCR . Estrogen use on complications for women treating pelvic organ prolapse with vaginal pessaries (ESTRO-PESS)-a randomized clinical trial (Abstract 007). International Urogynecology Journal2020;31(Suppl 1):S4. [DOI: 10.1007/s00192-020-04555-3]RBR-23sqxz. Impact of cream vaginal use on complications in women using vaginal ring in treatment of genital prolapse: a randomized clinical trial [Impacto do uso do creme vaginal nas complicações em mulheres usuárias de anel vaginais no tratamento do prolapso genital: ensaio clínico randomizado] [Impact of estrogen use on complications in women using vaginal pessaries with genital prolapse: a randomized clinical trial [Impacto do uso do estrogênio nas complicações em mulheres usuárias de pessários vaginais com prolapso genital: ensaio clínico randomizado]]. ensaiosclinicos.gov.br/rg/RBR-23sqxz (first received 24 August 2018). ">Coelho 2020</a>; <a href="./references#CD014592-bbs2-0010" title="StipicI , PolasekO , VulicM , PundaH , GrandicL , StrinicT . Estrogen replacement therapy improves pulmonary function in postmenopausal women with genital prolapse. Rejuvenation Research2012;15(6):596-600. [DOI: 10.1089/rej.2012.1337]">Stipic 2012</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>; <a href="./references#CD014592-bbs2-0012" title="TontivuthikulP , SanmeeU , Wongtra-NganS , PongnarisornC . Effect of local estrogen cream on vaginal health after pessary use for prolapsed pelvic organ: a randomized controlled trial. Journal of the Medical Association of Thailand2016;99(7):757-63. ">Tontivuthikul 2016</a>; <a href="./references#CD014592-bbs2-0013" title="NCT00803335. The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse [The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse: a randomized control trial]. clinicaltrials.gov/ct2/show/NCT00803335 (first received 05 December 2008). VaccaroCM , CrispCC , EstanolMV , FellnerAN , MutemaGK , KleemanSD , et al. Administration of vaginal estrogen in women with vaginal atrophy prior to prolapse surgery: an assessment of quality of life outcomes and medication adherence (Abstract 286). International Urogynecology Journal2011;22(Suppl 3):S1839-40. [DOI: 10.1007/s00192-011-1521-1]VaccaroCM , CrispCC , FellnerAN , PaulsRN . Impact of preoperative vaginal estrogen on patient quality of life measures: a randomized controlled trial (Abstract 120). Female Pelvic Medicine and Reconstructive Surgery2012;18(8 Suppl 1):S151-2. [DOI: 10.1097/SPV.0b013e31826abf55]VaccaroCM , MutemaGK , FellnerAN , CrispCC , EstanolMV , KleemanSD , et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2013;19(1):34-9. [DOI: 10.1097/SPV.0b013e318278cc40]VaccaroCM , MutemaGK , FellnerAN , CrispCC , PaulsRN . The effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial (Abstract 02). Female Pelvic Medicine and Reconstructive Surgery2012;18(2 Suppl 1):S14. [DOI: 10.1097/SPV.0b013e31824bf52d]">Vaccaro 2013</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>). Four studies provided insufficient information to permit judgement so were at unclear risk of performance bias (<a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a>; <a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a>; <a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>; <a href="./references#CD014592-bbs2-0008" title="NunesJC , FeldnerPC , CastroRA , NaderHB , SartoriMF , GirãoMB . Uterine prolapse: evaluation of glycosaminoglycans in postmenopausal women after estrogen therapy. Climacteric2011;14(1):121-5. ">Nunes 2011</a>). </p> </section> <section id="CD014592-sec-0068"> <h5 class="title">Detection bias</h5> <p>We judged six studies at low risk of detection bias as outcome assessment was adequately blinded (<a href="./references#CD014592-bbs2-0004" title="CoelhoSC , GiraldoPC , BritoLG , Teatin JuliatoCR . Estrogen use on complications for women treating pelvic organ prolapse with vaginal pessaries (ESTRO-PESS)-a randomized clinical trial (Abstract 007). International Urogynecology Journal2020;31(Suppl 1):S4. [DOI: 10.1007/s00192-020-04555-3]RBR-23sqxz. Impact of cream vaginal use on complications in women using vaginal ring in treatment of genital prolapse: a randomized clinical trial [Impacto do uso do creme vaginal nas complicações em mulheres usuárias de anel vaginais no tratamento do prolapso genital: ensaio clínico randomizado] [Impact of estrogen use on complications in women using vaginal pessaries with genital prolapse: a randomized clinical trial [Impacto do uso do estrogênio nas complicações em mulheres usuárias de pessários vaginais com prolapso genital: ensaio clínico randomizado]]. ensaiosclinicos.gov.br/rg/RBR-23sqxz (first received 24 August 2018). ">Coelho 2020</a>; <a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a>; <a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>; <a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a>; <a href="./references#CD014592-bbs2-0010" title="StipicI , PolasekO , VulicM , PundaH , GrandicL , StrinicT . Estrogen replacement therapy improves pulmonary function in postmenopausal women with genital prolapse. Rejuvenation Research2012;15(6):596-600. [DOI: 10.1089/rej.2012.1337]">Stipic 2012</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>). Seven studies provided insufficient information to permit judgement so were at unclear risk of detection bias (<a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a>; <a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>; <a href="./references#CD014592-bbs2-0003" title="ChiengthongK , RuanphooP , ChatsuwanT , BunyavejchevinS . Effect of vaginal estrogen in postmenopausal women using vaginal pessary for pelvic organ prolapse treatment: a randomized controlled trial. International Urogynecology Journal2022;33(7):1833-8. [DOI: 10.1007/s00192-021-04821-y]TCTR20180329001. Effect of vaginal estriol 0.03 mg with Lactobacillus acidophilus on incidence of bacterial vaginosis in patient using pessary for treatment of pelvic organ prolapse. thaiclinicaltrials.org/show/TCTR20180329001 (first received 29 March 2018). ">Chiengthong 2022</a>; <a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>; <a href="./references#CD014592-bbs2-0008" title="NunesJC , FeldnerPC , CastroRA , NaderHB , SartoriMF , GirãoMB . Uterine prolapse: evaluation of glycosaminoglycans in postmenopausal women after estrogen therapy. Climacteric2011;14(1):121-5. ">Nunes 2011</a>; <a href="./references#CD014592-bbs2-0012" title="TontivuthikulP , SanmeeU , Wongtra-NganS , PongnarisornC . Effect of local estrogen cream on vaginal health after pessary use for prolapsed pelvic organ: a randomized controlled trial. Journal of the Medical Association of Thailand2016;99(7):757-63. ">Tontivuthikul 2016</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>). In <a href="./references#CD014592-bbs2-0013" title="NCT00803335. The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse [The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse: a randomized control trial]. clinicaltrials.gov/ct2/show/NCT00803335 (first received 05 December 2008). VaccaroCM , CrispCC , EstanolMV , FellnerAN , MutemaGK , KleemanSD , et al. Administration of vaginal estrogen in women with vaginal atrophy prior to prolapse surgery: an assessment of quality of life outcomes and medication adherence (Abstract 286). International Urogynecology Journal2011;22(Suppl 3):S1839-40. [DOI: 10.1007/s00192-011-1521-1]VaccaroCM , CrispCC , FellnerAN , PaulsRN . Impact of preoperative vaginal estrogen on patient quality of life measures: a randomized controlled trial (Abstract 120). Female Pelvic Medicine and Reconstructive Surgery2012;18(8 Suppl 1):S151-2. [DOI: 10.1097/SPV.0b013e31826abf55]VaccaroCM , MutemaGK , FellnerAN , CrispCC , EstanolMV , KleemanSD , et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2013;19(1):34-9. [DOI: 10.1097/SPV.0b013e318278cc40]VaccaroCM , MutemaGK , FellnerAN , CrispCC , PaulsRN . The effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial (Abstract 02). Female Pelvic Medicine and Reconstructive Surgery2012;18(2 Suppl 1):S14. [DOI: 10.1097/SPV.0b013e31824bf52d]">Vaccaro 2013</a>, some outcomes appeared to be blinded but not all, so we judged the study at unclear risk. </p> </section> </section> <section id="CD014592-sec-0069"> <h4 class="title">Incomplete outcome data</h4> <p>Attrition was low in 10 studies, leading to a low risk of bias judgement (<a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a>; <a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>; <a href="./references#CD014592-bbs2-0003" title="ChiengthongK , RuanphooP , ChatsuwanT , BunyavejchevinS . Effect of vaginal estrogen in postmenopausal women using vaginal pessary for pelvic organ prolapse treatment: a randomized controlled trial. International Urogynecology Journal2022;33(7):1833-8. [DOI: 10.1007/s00192-021-04821-y]TCTR20180329001. Effect of vaginal estriol 0.03 mg with Lactobacillus acidophilus on incidence of bacterial vaginosis in patient using pessary for treatment of pelvic organ prolapse. thaiclinicaltrials.org/show/TCTR20180329001 (first received 29 March 2018). ">Chiengthong 2022</a>; <a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a>; <a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>; <a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>; <a href="./references#CD014592-bbs2-0008" title="NunesJC , FeldnerPC , CastroRA , NaderHB , SartoriMF , GirãoMB . Uterine prolapse: evaluation of glycosaminoglycans in postmenopausal women after estrogen therapy. Climacteric2011;14(1):121-5. ">Nunes 2011</a>; <a href="./references#CD014592-bbs2-0010" title="StipicI , PolasekO , VulicM , PundaH , GrandicL , StrinicT . Estrogen replacement therapy improves pulmonary function in postmenopausal women with genital prolapse. Rejuvenation Research2012;15(6):596-600. [DOI: 10.1089/rej.2012.1337]">Stipic 2012</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>; <a href="./references#CD014592-bbs2-0012" title="TontivuthikulP , SanmeeU , Wongtra-NganS , PongnarisornC . Effect of local estrogen cream on vaginal health after pessary use for prolapsed pelvic organ: a randomized controlled trial. Journal of the Medical Association of Thailand2016;99(7):757-63. ">Tontivuthikul 2016</a>). We judged <a href="./references#CD014592-bbs2-0004" title="CoelhoSC , GiraldoPC , BritoLG , Teatin JuliatoCR . Estrogen use on complications for women treating pelvic organ prolapse with vaginal pessaries (ESTRO-PESS)-a randomized clinical trial (Abstract 007). International Urogynecology Journal2020;31(Suppl 1):S4. [DOI: 10.1007/s00192-020-04555-3]RBR-23sqxz. Impact of cream vaginal use on complications in women using vaginal ring in treatment of genital prolapse: a randomized clinical trial [Impacto do uso do creme vaginal nas complicações em mulheres usuárias de anel vaginais no tratamento do prolapso genital: ensaio clínico randomizado] [Impact of estrogen use on complications in women using vaginal pessaries with genital prolapse: a randomized clinical trial [Impacto do uso do estrogênio nas complicações em mulheres usuárias de pessários vaginais com prolapso genital: ensaio clínico randomizado]]. ensaiosclinicos.gov.br/rg/RBR-23sqxz (first received 24 August 2018). ">Coelho 2020</a> at high risk of attrition bias because of the high rate of loss to follow‐up in both groups. <a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a> and <a href="./references#CD014592-bbs2-0013" title="NCT00803335. The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse [The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse: a randomized control trial]. clinicaltrials.gov/ct2/show/NCT00803335 (first received 05 December 2008). VaccaroCM , CrispCC , EstanolMV , FellnerAN , MutemaGK , KleemanSD , et al. Administration of vaginal estrogen in women with vaginal atrophy prior to prolapse surgery: an assessment of quality of life outcomes and medication adherence (Abstract 286). International Urogynecology Journal2011;22(Suppl 3):S1839-40. [DOI: 10.1007/s00192-011-1521-1]VaccaroCM , CrispCC , FellnerAN , PaulsRN . Impact of preoperative vaginal estrogen on patient quality of life measures: a randomized controlled trial (Abstract 120). Female Pelvic Medicine and Reconstructive Surgery2012;18(8 Suppl 1):S151-2. [DOI: 10.1097/SPV.0b013e31826abf55]VaccaroCM , MutemaGK , FellnerAN , CrispCC , EstanolMV , KleemanSD , et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2013;19(1):34-9. [DOI: 10.1097/SPV.0b013e318278cc40]VaccaroCM , MutemaGK , FellnerAN , CrispCC , PaulsRN . The effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial (Abstract 02). Female Pelvic Medicine and Reconstructive Surgery2012;18(2 Suppl 1):S14. [DOI: 10.1097/SPV.0b013e31824bf52d]">Vaccaro 2013</a> were also at high risk of attrition bias because of large differential dropouts between groups. <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a> was at unclear risk because it was unclear whether the study authors performed an intention‐to‐treat (ITT) analysis, and there was a small differential loss to follow‐up. </p> </section> <section id="CD014592-sec-0070"> <h4 class="title">Selective reporting</h4> <p>We judged five studies at low risk of selective reporting because they appeared to report all prespecified outcomes (<a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a>; <a href="./references#CD014592-bbs2-0003" title="ChiengthongK , RuanphooP , ChatsuwanT , BunyavejchevinS . Effect of vaginal estrogen in postmenopausal women using vaginal pessary for pelvic organ prolapse treatment: a randomized controlled trial. International Urogynecology Journal2022;33(7):1833-8. [DOI: 10.1007/s00192-021-04821-y]TCTR20180329001. Effect of vaginal estriol 0.03 mg with Lactobacillus acidophilus on incidence of bacterial vaginosis in patient using pessary for treatment of pelvic organ prolapse. thaiclinicaltrials.org/show/TCTR20180329001 (first received 29 March 2018). ">Chiengthong 2022</a>; <a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a>; <a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>). </p> <p>Four studies were at high risk of reporting bias. In <a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>, all participants underwent transvaginal scans for endometrial thickness, but the results were not reported. The trial registration for <a href="./references#CD014592-bbs2-0004" title="CoelhoSC , GiraldoPC , BritoLG , Teatin JuliatoCR . Estrogen use on complications for women treating pelvic organ prolapse with vaginal pessaries (ESTRO-PESS)-a randomized clinical trial (Abstract 007). International Urogynecology Journal2020;31(Suppl 1):S4. [DOI: 10.1007/s00192-020-04555-3]RBR-23sqxz. Impact of cream vaginal use on complications in women using vaginal ring in treatment of genital prolapse: a randomized clinical trial [Impacto do uso do creme vaginal nas complicações em mulheres usuárias de anel vaginais no tratamento do prolapso genital: ensaio clínico randomizado] [Impact of estrogen use on complications in women using vaginal pessaries with genital prolapse: a randomized clinical trial [Impacto do uso do estrogênio nas complicações em mulheres usuárias de pessários vaginais com prolapso genital: ensaio clínico randomizado]]. ensaiosclinicos.gov.br/rg/RBR-23sqxz (first received 24 August 2018). ">Coelho 2020</a> did not list the urinary outcomes assessed in the study, and the report provided no explanation for the addition of these outcomes. Furthermore, adherence and medication use were monitored and recorded but not reported. <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a> listed postoperative vaginal swab culture result as an outcome in its trial registration but did not report this in the results. <a href="./references#CD014592-bbs2-0013" title="NCT00803335. The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse [The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse: a randomized control trial]. clinicaltrials.gov/ct2/show/NCT00803335 (first received 05 December 2008). VaccaroCM , CrispCC , EstanolMV , FellnerAN , MutemaGK , KleemanSD , et al. Administration of vaginal estrogen in women with vaginal atrophy prior to prolapse surgery: an assessment of quality of life outcomes and medication adherence (Abstract 286). International Urogynecology Journal2011;22(Suppl 3):S1839-40. [DOI: 10.1007/s00192-011-1521-1]VaccaroCM , CrispCC , FellnerAN , PaulsRN . Impact of preoperative vaginal estrogen on patient quality of life measures: a randomized controlled trial (Abstract 120). Female Pelvic Medicine and Reconstructive Surgery2012;18(8 Suppl 1):S151-2. [DOI: 10.1097/SPV.0b013e31826abf55]VaccaroCM , MutemaGK , FellnerAN , CrispCC , EstanolMV , KleemanSD , et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2013;19(1):34-9. [DOI: 10.1097/SPV.0b013e318278cc40]VaccaroCM , MutemaGK , FellnerAN , CrispCC , PaulsRN . The effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial (Abstract 02). Female Pelvic Medicine and Reconstructive Surgery2012;18(2 Suppl 1):S14. [DOI: 10.1097/SPV.0b013e31824bf52d]">Vaccaro 2013</a> only reported cytological outcomes in the full‐text article, while the abstract reported quality of life; we found no explanation for this inconsistency. </p> <p>Four studies published after 2010 did not have an associated trial registration, so we were unable to judge which outcomes had been prespecified. We judged these studies at unclear risk of reporting bias (<a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>; <a href="./references#CD014592-bbs2-0008" title="NunesJC , FeldnerPC , CastroRA , NaderHB , SartoriMF , GirãoMB . Uterine prolapse: evaluation of glycosaminoglycans in postmenopausal women after estrogen therapy. Climacteric2011;14(1):121-5. ">Nunes 2011</a>; <a href="./references#CD014592-bbs2-0010" title="StipicI , PolasekO , VulicM , PundaH , GrandicL , StrinicT . Estrogen replacement therapy improves pulmonary function in postmenopausal women with genital prolapse. Rejuvenation Research2012;15(6):596-600. [DOI: 10.1089/rej.2012.1337]">Stipic 2012</a>; <a href="./references#CD014592-bbs2-0012" title="TontivuthikulP , SanmeeU , Wongtra-NganS , PongnarisornC . Effect of local estrogen cream on vaginal health after pessary use for prolapsed pelvic organ: a randomized controlled trial. Journal of the Medical Association of Thailand2016;99(7):757-63. ">Tontivuthikul 2016</a>). Although <a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a> reported all measures listed in its trial registration, it performed a post‐hoc analysis without explanation; for this reason, we also judged it at unclear risk of reporting bias. </p> </section> <section id="CD014592-sec-0071"> <h4 class="title">Other potential sources of bias</h4> <p>There was no indication of any other sources of bias in 11 studies (<a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a>; <a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>; <a href="./references#CD014592-bbs2-0003" title="ChiengthongK , RuanphooP , ChatsuwanT , BunyavejchevinS . Effect of vaginal estrogen in postmenopausal women using vaginal pessary for pelvic organ prolapse treatment: a randomized controlled trial. International Urogynecology Journal2022;33(7):1833-8. [DOI: 10.1007/s00192-021-04821-y]TCTR20180329001. Effect of vaginal estriol 0.03 mg with Lactobacillus acidophilus on incidence of bacterial vaginosis in patient using pessary for treatment of pelvic organ prolapse. thaiclinicaltrials.org/show/TCTR20180329001 (first received 29 March 2018). ">Chiengthong 2022</a>; <a href="./references#CD014592-bbs2-0004" title="CoelhoSC , GiraldoPC , BritoLG , Teatin JuliatoCR . Estrogen use on complications for women treating pelvic organ prolapse with vaginal pessaries (ESTRO-PESS)-a randomized clinical trial (Abstract 007). International Urogynecology Journal2020;31(Suppl 1):S4. [DOI: 10.1007/s00192-020-04555-3]RBR-23sqxz. Impact of cream vaginal use on complications in women using vaginal ring in treatment of genital prolapse: a randomized clinical trial [Impacto do uso do creme vaginal nas complicações em mulheres usuárias de anel vaginais no tratamento do prolapso genital: ensaio clínico randomizado] [Impact of estrogen use on complications in women using vaginal pessaries with genital prolapse: a randomized clinical trial [Impacto do uso do estrogênio nas complicações em mulheres usuárias de pessários vaginais com prolapso genital: ensaio clínico randomizado]]. ensaiosclinicos.gov.br/rg/RBR-23sqxz (first received 24 August 2018). ">Coelho 2020</a>; <a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a>; <a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>; <a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>; <a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>; <a href="./references#CD014592-bbs2-0012" title="TontivuthikulP , SanmeeU , Wongtra-NganS , PongnarisornC . Effect of local estrogen cream on vaginal health after pessary use for prolapsed pelvic organ: a randomized controlled trial. Journal of the Medical Association of Thailand2016;99(7):757-63. ">Tontivuthikul 2016</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>). </p> <p>There were major baseline differences between groups in <a href="./references#CD014592-bbs2-0008" title="NunesJC , FeldnerPC , CastroRA , NaderHB , SartoriMF , GirãoMB . Uterine prolapse: evaluation of glycosaminoglycans in postmenopausal women after estrogen therapy. Climacteric2011;14(1):121-5. ">Nunes 2011</a>, suggesting issues with the randomisation process and leading to a high risk judgement for other bias. We also judged <a href="./references#CD014592-bbs2-0013" title="NCT00803335. The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse [The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse: a randomized control trial]. clinicaltrials.gov/ct2/show/NCT00803335 (first received 05 December 2008). VaccaroCM , CrispCC , EstanolMV , FellnerAN , MutemaGK , KleemanSD , et al. Administration of vaginal estrogen in women with vaginal atrophy prior to prolapse surgery: an assessment of quality of life outcomes and medication adherence (Abstract 286). International Urogynecology Journal2011;22(Suppl 3):S1839-40. [DOI: 10.1007/s00192-011-1521-1]VaccaroCM , CrispCC , FellnerAN , PaulsRN . Impact of preoperative vaginal estrogen on patient quality of life measures: a randomized controlled trial (Abstract 120). Female Pelvic Medicine and Reconstructive Surgery2012;18(8 Suppl 1):S151-2. [DOI: 10.1097/SPV.0b013e31826abf55]VaccaroCM , MutemaGK , FellnerAN , CrispCC , EstanolMV , KleemanSD , et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2013;19(1):34-9. [DOI: 10.1097/SPV.0b013e318278cc40]VaccaroCM , MutemaGK , FellnerAN , CrispCC , PaulsRN . The effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial (Abstract 02). Female Pelvic Medicine and Reconstructive Surgery2012;18(2 Suppl 1):S14. [DOI: 10.1097/SPV.0b013e31824bf52d]">Vaccaro 2013</a> at high risk of other bias because one arm of the study was excluded and participants were evaluated at between two and 12 weeks of treatment rather than at a standardised follow‐up time. </p> <p>We considered <a href="./references#CD014592-bbs2-0010" title="StipicI , PolasekO , VulicM , PundaH , GrandicL , StrinicT . Estrogen replacement therapy improves pulmonary function in postmenopausal women with genital prolapse. Rejuvenation Research2012;15(6):596-600. [DOI: 10.1089/rej.2012.1337]">Stipic 2012</a> at unclear risk of other bias because it did not report any baseline respiratory variables, although the study's primary endpoint was lung function. </p> </section> </section> <section id="CD014592-sec-0072"> <h3 class="title" id="CD014592-sec-0072">Effects of interventions</h3> <p>See: <a href="./full#CD014592-tbl-0001"><b>Summary of findings 1</b> Oestrogen therapy alone versus no treatment or placebo</a>; <a href="./full#CD014592-tbl-0002"><b>Summary of findings 2</b> Oestrogen therapy alone versus pelvic floor muscle training</a>; <a href="./full#CD014592-tbl-0003"><b>Summary of findings 3</b> Oestrogen therapy alone versus devices such as vaginal pessaries</a>; <a href="./full#CD014592-tbl-0004"><b>Summary of findings 4</b> Oestrogen therapy alone versus surgery</a> </p> <section id="CD014592-sec-0073"> <h4 class="title">Oestrogen therapy alone versus no treatment or placebo</h4> <p>No studies evaluated oestrogen therapy alone versus no treatment or placebo.</p> </section> <section id="CD014592-sec-0074"> <h4 class="title">Oestrogen therapy alone versus pelvic floor muscle training</h4> <p>No studies evaluated oestrogen therapy alone versus PFMT.</p> </section> <section id="CD014592-sec-0075"> <h4 class="title">Oestrogen therapy alone versus devices such as vaginal pessaries</h4> <p>No studies evaluated oestrogen therapy alone versus devices such as vaginal pessaries.</p> </section> <section id="CD014592-sec-0076"> <h4 class="title">Oestrogen therapy alone versus surgery</h4> <p>No studies evaluated oestrogen therapy alone versus surgery.</p> </section> <section id="CD014592-sec-0077"> <h4 class="title">Oestrogen therapy in conjunction with pelvic floor muscle training versus pelvic floor muscle training alone </h4> <p>No studies evaluated oestrogen therapy in conjunction with PFMT versus PFMT alone.</p> </section> <section id="CD014592-sec-0078"> <h4 class="title">Oestrogen therapy in conjunction with vaginal pessaries versus vaginal pessaries alone</h4> <p>Three studies evaluated topical oestrogen therapy in conjunction with vaginal pessaries versus vaginal pessaries alone (<a href="./references#CD014592-bbs2-0003" title="ChiengthongK , RuanphooP , ChatsuwanT , BunyavejchevinS . Effect of vaginal estrogen in postmenopausal women using vaginal pessary for pelvic organ prolapse treatment: a randomized controlled trial. International Urogynecology Journal2022;33(7):1833-8. [DOI: 10.1007/s00192-021-04821-y]TCTR20180329001. Effect of vaginal estriol 0.03 mg with Lactobacillus acidophilus on incidence of bacterial vaginosis in patient using pessary for treatment of pelvic organ prolapse. thaiclinicaltrials.org/show/TCTR20180329001 (first received 29 March 2018). ">Chiengthong 2022</a>; <a href="./references#CD014592-bbs2-0004" title="CoelhoSC , GiraldoPC , BritoLG , Teatin JuliatoCR . Estrogen use on complications for women treating pelvic organ prolapse with vaginal pessaries (ESTRO-PESS)-a randomized clinical trial (Abstract 007). International Urogynecology Journal2020;31(Suppl 1):S4. [DOI: 10.1007/s00192-020-04555-3]RBR-23sqxz. Impact of cream vaginal use on complications in women using vaginal ring in treatment of genital prolapse: a randomized clinical trial [Impacto do uso do creme vaginal nas complicações em mulheres usuárias de anel vaginais no tratamento do prolapso genital: ensaio clínico randomizado] [Impact of estrogen use on complications in women using vaginal pessaries with genital prolapse: a randomized clinical trial [Impacto do uso do estrogênio nas complicações em mulheres usuárias de pessários vaginais com prolapso genital: ensaio clínico randomizado]]. ensaiosclinicos.gov.br/rg/RBR-23sqxz (first received 24 August 2018). ">Coelho 2020</a>; <a href="./references#CD014592-bbs2-0012" title="TontivuthikulP , SanmeeU , Wongtra-NganS , PongnarisornC . Effect of local estrogen cream on vaginal health after pessary use for prolapsed pelvic organ: a randomized controlled trial. Journal of the Medical Association of Thailand2016;99(7):757-63. ">Tontivuthikul 2016</a>). </p> <section id="CD014592-sec-0079"> <h5 class="title">Primary outcome</h5> <section id="CD014592-sec-0080"> <h6 class="title">Participant‐reported subjective improvement or cure of pelvic organ prolapse symptoms</h6> <p>No studies reported participant‐reported subjective improvement or cure of POP symptoms.</p> </section> </section> <section id="CD014592-sec-0081"> <h5 class="title">Secondary outcomes</h5> <section id="CD014592-sec-0082"> <h6 class="title">Improvement or cure of associated urinary symptoms</h6> <p>No studies reported improvement or cure of associated urinary symptoms.</p> </section> <section id="CD014592-sec-0083"> <h6 class="title">Improvement or cure of associated bowel symptoms</h6> <p>No studies reported improvement or cure of associated bowel symptoms.</p> </section> <section id="CD014592-sec-0084"> <h6 class="title">Improvement or cure of associated sexual symptoms</h6> <p>No studies reported improvement or cure of associated sexual symptoms.</p> </section> <section id="CD014592-sec-0085"> <h6 class="title">Objective improvement or cure of pelvic organ prolapse symptoms</h6> <p>No studies reported objective improvement or cure of POP symptoms.</p> </section> <section id="CD014592-sec-0086"> <h6 class="title">Condition‐specific quality of life</h6> <p>No studies reported condition‐specific quality of life.</p> </section> <section id="CD014592-sec-0087"> <h6 class="title">Generic quality of life or health status</h6> <p>No studies reported generic quality of life or health status.</p> </section> <section id="CD014592-sec-0088"> <h6 class="title">Psychological or emotional well‐being outcome measures and ability to cope with daily activities </h6> <p>No studies reported psychological or emotional well‐being outcome measures or ability to cope with daily activities. </p> </section> <section id="CD014592-sec-0089"> <h6 class="title">Participant adherence to the intervention</h6> <p>Only <a href="./references#CD014592-bbs2-0004" title="CoelhoSC , GiraldoPC , BritoLG , Teatin JuliatoCR . Estrogen use on complications for women treating pelvic organ prolapse with vaginal pessaries (ESTRO-PESS)-a randomized clinical trial (Abstract 007). International Urogynecology Journal2020;31(Suppl 1):S4. [DOI: 10.1007/s00192-020-04555-3]RBR-23sqxz. Impact of cream vaginal use on complications in women using vaginal ring in treatment of genital prolapse: a randomized clinical trial [Impacto do uso do creme vaginal nas complicações em mulheres usuárias de anel vaginais no tratamento do prolapso genital: ensaio clínico randomizado] [Impact of estrogen use on complications in women using vaginal pessaries with genital prolapse: a randomized clinical trial [Impacto do uso do estrogênio nas complicações em mulheres usuárias de pessários vaginais com prolapso genital: ensaio clínico randomizado]]. ensaiosclinicos.gov.br/rg/RBR-23sqxz (first received 24 August 2018). ">Coelho 2020</a> reported participant adherence to topical oestrogen through discontinuation of pessary use. Slightly more women in the control group discontinued pessary use (<a href="./references#CD014592-fig-0005" title="">Analysis 1.1</a>). </p> </section> <section id="CD014592-sec-0090"> <h6 class="title">Reduction in minor adverse events: urinary tract infection</h6> <p>No studies reported reduction in UTIs.</p> </section> <section id="CD014592-sec-0091"> <h6 class="title">Reduction in minor adverse events: vaginal events</h6> <p>All three studies reported reduction in vaginal events. Topical oestrogen therapy plus pessary may lead to a reduction in minor adverse vaginal events compared with pessary alone (RR 0.48, 95% CI 0.25 to 0.91; 3 studies, 185 participants; <a href="./references#CD014592-fig-0006" title="">Analysis 1.2</a>). </p> </section> <section id="CD014592-sec-0092"> <h6 class="title">Reduction in minor adverse events: urinary storage events</h6> <p>No studies reported reduction in urinary storage events.</p> </section> <section id="CD014592-sec-0093"> <h6 class="title">Reduction in minor adverse events: sexual adverse events</h6> <p>No studies reported reduction in sexual adverse events.</p> </section> <section id="CD014592-sec-0094"> <h6 class="title">Major adverse events</h6> <p>Two studies recorded the number of major adverse events experienced by women (<a href="./references#CD014592-bbs2-0004" title="CoelhoSC , GiraldoPC , BritoLG , Teatin JuliatoCR . Estrogen use on complications for women treating pelvic organ prolapse with vaginal pessaries (ESTRO-PESS)-a randomized clinical trial (Abstract 007). International Urogynecology Journal2020;31(Suppl 1):S4. [DOI: 10.1007/s00192-020-04555-3]RBR-23sqxz. Impact of cream vaginal use on complications in women using vaginal ring in treatment of genital prolapse: a randomized clinical trial [Impacto do uso do creme vaginal nas complicações em mulheres usuárias de anel vaginais no tratamento do prolapso genital: ensaio clínico randomizado] [Impact of estrogen use on complications in women using vaginal pessaries with genital prolapse: a randomized clinical trial [Impacto do uso do estrogênio nas complicações em mulheres usuárias de pessários vaginais com prolapso genital: ensaio clínico randomizado]]. ensaiosclinicos.gov.br/rg/RBR-23sqxz (first received 24 August 2018). ">Coelho 2020</a>; <a href="./references#CD014592-bbs2-0012" title="TontivuthikulP , SanmeeU , Wongtra-NganS , PongnarisornC . Effect of local estrogen cream on vaginal health after pessary use for prolapsed pelvic organ: a randomized controlled trial. Journal of the Medical Association of Thailand2016;99(7):757-63. ">Tontivuthikul 2016</a>). No major adverse events occurred in either group in either study (<a href="./references#CD014592-fig-0007" title="">Analysis 1.3</a>). </p> </section> <section id="CD014592-sec-0095"> <h6 class="title">Surgical outcomes: operative time</h6> <p>No studies reported operative time.</p> </section> <section id="CD014592-sec-0096"> <h6 class="title">Surgical outcomes: mesh exposure</h6> <p>No studies reported mesh exposure.</p> </section> </section> </section> <section id="CD014592-sec-0097"> <h4 class="title">Oestrogen therapy in conjunction with surgery versus surgery alone</h4> <p>Eleven studies evaluated topical or systemic oestrogen therapy in conjunction with surgery versus surgery alone (<a href="./references#CD014592-bbs2-0001" title="BaracatEC , SimõesMJ , SoaresJM , HaidarMA , Rodrigues de LimaG . Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clinical and Experimental Obstetrics and Gynecology2001;28(1):26-30. ">Baracat 2001</a>; <a href="./references#CD014592-bbs2-0002" title="CarusoS , CianciS , VitaleSG , MatarazzoMG , AmoreFF , CianciA . Effects of ultralow topic estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause2017;24(8):900-7. [DOI: 10.1097/GME.0000000000000851]NCT02906111. Vaginal estriol before and vaginal surgery for prolapse (VSaE) [Effects on vaginal health and quality of life in postmenopausal women using ultra low topic estriol before vaginal surgery for pelvic statics disorders]. clinicaltrials.gov/show/NCT02906111 (first received 19 September 2016). ">Caruso 2017</a>; <a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a>; <a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>; <a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>; <a href="./references#CD014592-bbs2-0008" title="NunesJC , FeldnerPC , CastroRA , NaderHB , SartoriMF , GirãoMB . Uterine prolapse: evaluation of glycosaminoglycans in postmenopausal women after estrogen therapy. Climacteric2011;14(1):121-5. ">Nunes 2011</a>; <a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a>; <a href="./references#CD014592-bbs2-0010" title="StipicI , PolasekO , VulicM , PundaH , GrandicL , StrinicT . Estrogen replacement therapy improves pulmonary function in postmenopausal women with genital prolapse. Rejuvenation Research2012;15(6):596-600. [DOI: 10.1089/rej.2012.1337]">Stipic 2012</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>; <a href="./references#CD014592-bbs2-0013" title="NCT00803335. The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse [The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse: a randomized control trial]. clinicaltrials.gov/ct2/show/NCT00803335 (first received 05 December 2008). VaccaroCM , CrispCC , EstanolMV , FellnerAN , MutemaGK , KleemanSD , et al. Administration of vaginal estrogen in women with vaginal atrophy prior to prolapse surgery: an assessment of quality of life outcomes and medication adherence (Abstract 286). International Urogynecology Journal2011;22(Suppl 3):S1839-40. [DOI: 10.1007/s00192-011-1521-1]VaccaroCM , CrispCC , FellnerAN , PaulsRN . Impact of preoperative vaginal estrogen on patient quality of life measures: a randomized controlled trial (Abstract 120). Female Pelvic Medicine and Reconstructive Surgery2012;18(8 Suppl 1):S151-2. [DOI: 10.1097/SPV.0b013e31826abf55]VaccaroCM , MutemaGK , FellnerAN , CrispCC , EstanolMV , KleemanSD , et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2013;19(1):34-9. [DOI: 10.1097/SPV.0b013e318278cc40]VaccaroCM , MutemaGK , FellnerAN , CrispCC , PaulsRN . The effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial (Abstract 02). Female Pelvic Medicine and Reconstructive Surgery2012;18(2 Suppl 1):S14. [DOI: 10.1097/SPV.0b013e31824bf52d]">Vaccaro 2013</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>). </p> <section id="CD014592-sec-0098"> <h5 class="title">Primary outcome</h5> <section id="CD014592-sec-0099"> <h6 class="title">Participant‐reported subjective improvement or cure of pelvic organ prolapse symptoms</h6> <p>Two studies reported subjective improvement or cure of POP symptoms, but we were unable to pool the data in a meta‐analysis (<a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>). Both studies found no evidence of a difference in subjective improvement of POP symptoms between topical oestrogen therapy plus surgery and surgery alone at six months (265 participants; <a href="./references#CD014592-fig-0008" title="">Analysis 2.1</a>) and at 12 months (263 participants; <a href="./references#CD014592-fig-0009" title="">Analysis 2.2</a>). </p> </section> </section> <section id="CD014592-sec-0100"> <h5 class="title">Secondary outcomes</h5> <section id="CD014592-sec-0101"> <h6 class="title">Improvement or cure of associated urinary symptoms</h6> <p>Only <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a> reported improvement or cure of associated urinary symptoms, finding that topical oestrogen therapy plus surgery compared with surgery alone may result in worse urinary symptoms, measured using the Urinary Impact Questionnaire (UIQ‐7) subscale of the PFIQ‐7, at six months (79 participants; <a href="./references#CD014592-fig-0010" title="">Analysis 2.3</a>). However, the same study reported no difference in urinary symptoms between the two groups at 12 months (79 participants; <a href="./references#CD014592-fig-0011" title="">Analysis 2.4</a>). There was no clinically important difference at either time point (six or 12 months). </p> </section> <section id="CD014592-sec-0102"> <h6 class="title">Improvement or cure of associated bowel symptoms</h6> <p>Only <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a> reported improvement of associated bowl symptoms, finding that topical oestrogen therapy plus surgery compared with surgery alone may result in worse bowel symptoms, measured using the Colorectal‐Anal Impact Questionnaire (CRAIQ‐7) subscale of the PFIQ‐7, at six months (79 participants; <a href="./references#CD014592-fig-0012" title="">Analysis 2.5</a>) and at 12 months (79 participants; <a href="./references#CD014592-fig-0013" title="">Analysis 2.6</a>). However, there was no clinically important difference at either time point (six or 12 months). </p> </section> <section id="CD014592-sec-0103"> <h6 class="title">Improvement or cure of associated sexual symptoms</h6> <p>Two studies reported improvement or cure of associated sexual symptoms (<a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>). At six months, topical oestrogen therapy plus surgery may result in a small improvement in sexual symptoms compared with surgery alone, although the difference is not considered to be clinically important (MD −1.02, 95% CI −3.52 to 1.48; 2 studies 211 participants; <a href="./references#CD014592-fig-0014" title="">Analysis 2.7</a>). It is uncertain whether topical oestrogen therapy with surgery has an effect on associated sexual symptoms compared with surgery alone after 12 months; the difference is not considered to be clinically important (MD −0.57, 95% CI −1.98 to 0.85; 2 studies, 207 participants; <a href="./references#CD014592-fig-0015" title="">Analysis 2.8</a>). </p> </section> <section id="CD014592-sec-0104"> <h6 class="title">Objective improvement or cure of pelvic organ prolapse symptoms</h6> <p>Three studies reported objective improvement or cure of POP symptoms (<a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>), though we were only able to pool data from <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a> and <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>. The meta‐analysis suggested there may be no difference between topical oestrogen therapy plus surgery and surgery alone in terms of objective improvement of POP symptoms at six months (RR 1.01, 95% CI 0.94 to 1.08; 241 participants; <a href="./references#CD014592-fig-0016" title="">Analysis 2.9</a>). <a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a> also found no evidence of a difference in objective improvement at six months (20 participants; <a href="./references#CD014592-fig-0017" title="">Analysis 2.10</a>). </p> <p><a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a> measured objective improvement or cure of POP symptoms at 12 months, finding no difference between topical oestrogen therapy plus surgery and surgery alone (186 participants; <a href="./references#CD014592-fig-0018" title="">Analysis 2.11</a>). </p> </section> <section id="CD014592-sec-0105"> <h6 class="title">Condition‐specific quality of life</h6> <p>Only <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a> reported condition‐specific quality of life, finding no difference between topical oestrogen therapy plus surgery and surgery alone at six months (186 participants; <a href="./references#CD014592-fig-0019" title="">Analysis 2.12</a>) or 12 months (186 participants; <a href="./references#CD014592-fig-0020" title="">Analysis 2.13</a>). </p> </section> <section id="CD014592-sec-0106"> <h6 class="title">Generic quality of life or health status</h6> <p>No studies reported generic quality of life or health status.</p> </section> <section id="CD014592-sec-0107"> <h6 class="title">Psychological or emotional well‐being outcome measures and ability to cope with daily activities </h6> <p>No studies reported psychological or emotional well‐being outcome measures or ability to cope with daily activities. </p> </section> <section id="CD014592-sec-0108"> <h6 class="title">Participant adherence to the intervention</h6> <p>Three studies reported participant adherence to the intervention (<a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a>; <a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>), but we were only able to pool data from <a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a> and <a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>). The meta‐analysis showed no difference in adherence to the intervention between women who received oestrogen therapy plus surgery compared with those who received surgery alone (RR 1.07, 95% CI 0.49 to 2.32; 2 studies, 114 participants; <a href="./references#CD014592-fig-0021" title="">Analysis 2.14</a>). </p> <p><a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a> reported that 20 of 28 women in the topical oestrogen group used the oestrogen pessaries at least 75% of the expected time (<a href="./references#CD014592-fig-0022" title="">Analysis 2.15</a>). </p> </section> <section id="CD014592-sec-0109"> <h6 class="title">Reduction in minor adverse events: urinary tract infection</h6> <p>Five studies reported reduction in UTIs (<a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a>; <a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>; <a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>). Topical oestrogen therapy plus surgery may lead to fewer cases of UTI compared with surgery alone (RR 0.49, 95% CI 0.26 to 0.90; 483 participants; <a href="./references#CD014592-fig-0023" title="">Analysis 2.16</a>). </p> </section> <section id="CD014592-sec-0110"> <h6 class="title">Reduction in minor adverse events: vaginal events</h6> <p>Four studies reported reduction in vaginal events (<a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>; <a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>; <a href="./references#CD014592-bbs2-0013" title="NCT00803335. The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse [The effects of local vaginal estrogen in postmenopausal women with pelvic organ prolapse: a randomized control trial]. clinicaltrials.gov/ct2/show/NCT00803335 (first received 05 December 2008). VaccaroCM , CrispCC , EstanolMV , FellnerAN , MutemaGK , KleemanSD , et al. Administration of vaginal estrogen in women with vaginal atrophy prior to prolapse surgery: an assessment of quality of life outcomes and medication adherence (Abstract 286). International Urogynecology Journal2011;22(Suppl 3):S1839-40. [DOI: 10.1007/s00192-011-1521-1]VaccaroCM , CrispCC , FellnerAN , PaulsRN . Impact of preoperative vaginal estrogen on patient quality of life measures: a randomized controlled trial (Abstract 120). Female Pelvic Medicine and Reconstructive Surgery2012;18(8 Suppl 1):S151-2. [DOI: 10.1097/SPV.0b013e31826abf55]VaccaroCM , MutemaGK , FellnerAN , CrispCC , EstanolMV , KleemanSD , et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Medicine and Reconstructive Surgery2013;19(1):34-9. [DOI: 10.1097/SPV.0b013e318278cc40]VaccaroCM , MutemaGK , FellnerAN , CrispCC , PaulsRN . The effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial (Abstract 02). Female Pelvic Medicine and Reconstructive Surgery2012;18(2 Suppl 1):S14. [DOI: 10.1097/SPV.0b013e31824bf52d]">Vaccaro 2013</a>). From the results of the meta‐analysis, it is uncertain whether topical oestrogen therapy plus surgery affects the occurrence of adverse vaginal events compared with surgery alone, as the 95% CI indicates both benefit and harm (RR 2.23, 95% CI 0.74 to 6.79; 371 participants; <a href="./references#CD014592-fig-0024" title="">Analysis 2.17</a>). </p> </section> <section id="CD014592-sec-0111"> <h6 class="title">Reduction in minor adverse events: urinary storage events</h6> <p>Two studies reported reduction in urinary storage events (<a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>). Meta‐analysis of their results showed no difference in risk of urinary storage issues between women who received topical oestrogen plus surgery and those who received surgery alone (RR 0.94, 95% CI 0.46 to 1.92; 289 participants; <a href="./references#CD014592-fig-0025" title="">Analysis 2.18</a>). </p> </section> <section id="CD014592-sec-0112"> <h6 class="title">Reduction in minor adverse events: sexual adverse events</h6> <p>Two studies reported sexual adverse events, but we were unable to pool their results (<a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>). <a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a> found little evidence of a difference between the groups in the number of partners experiencing discomfort during intercourse at six weeks (1/22 in the oestrogen therapy plus surgery group versus 2/43 in the surgery alone group; <a href="./references#CD014592-fig-0026" title="">Analysis 2.19</a>). <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a> found that the number of women with dyspareunia was slightly lower in the oestrogen therapy plus surgery group compared with the surgery alone group at one year (17/93 versus 21/93; <a href="./references#CD014592-fig-0026" title="">Analysis 2.19</a>). </p> </section> <section id="CD014592-sec-0113"> <h6 class="title">Major adverse events</h6> <p>Five studies reported major adverse events (<a href="./references#CD014592-bbs2-0005" title="FeldingC , MikkelsenAL , ClausenHV , LoftA , LarsenLG . Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas1992;15(3):241-9. MikkelsenAL , FeldingC , ClausenHV . Clinical effects of preoperative oestradiol treatment before vaginal repair operation. A double-blind, randomized trial. Gynecologic and Obstetric Investigation1995;40(2):125-8. ">Felding 1992</a>; <a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a>; <a href="./references#CD014592-bbs2-0009" title="GoodMM , ShiH , KellerP , RoshanravanSM , WordA , RahnDD . Local estrogen treatment prior to pelvic reconstructive surgery decreases collagenases and elastases in the vaginal wall: a double-blind randomized controlled study in postmenopausal women with prolapse (Abstract 06). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]GoodMM , WaiC , SchafferJI , CortonMM , WhiteA , ShiH , et al. Patient compliance &amp; safety with use of preoperative local estrogen treatment in postmenopausal women with prolapse: Analysis from a double-blind randomized controlled study (Abstract 15). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S85. [DOI: 10.1097/SPV.0b013e3182a5ddf0]NCT01778985. Effect of preoperative estrogen treatment on connective tissues of the pelvic floor (PET) [Effect of preoperative estrogen treatment on connective tissues of the pelvic floor]. clinicaltrials.gov/show/NCT01778985 (first received 29 January 2013). RahnDD , GoodMM , RoshanravanSM , ShiH , SchafferJI , SinghRJ , et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. Journal of Clinical Endocrinology and Metabolism2014;99(10):3728-36. [DOI: 10.1210/jc.2014-1216]RahnDD , GoodMM , ShiH , KellerP , RoshanravanSM , WordA . Effects of preoperative local estrogen treatment on connective tissues of the vaginal wall in postmenopausal women with prolapse: a double-blind randomized controlled study (Abstract 05). Female Pelvic Medicine and Reconstructive Surgery2013;19(Suppl 5):S47. [DOI: 10.1097/SPV.0b013e3182a5ddf0]">Rahn 2014</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>; <a href="./references#CD014592-bbs2-0014" title="EudraCT2014-000179-18. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) – feasibility study]. www.clinicaltrialsregister.eu/ctr-search/trial/2014-000179-18/results (first received 10 March 2015). ISRCTN46661996. Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery [Local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS) feasibility study]. isrctn.com/ISRCTN46661996 (first received 28 May 2015). Middleton 2021. Middleton L [Re: study query: randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial [personal communication]]. Email to: E Johnson 2 November 2021. VergheseTS , MiddletonL , CheedV , LeightonL , DanielsJ , LatthePM . Randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS): a pilot study to assess feasibility of a large multicentre trial. BMJ Open2020;10(9):e025141. [DOI: 10.1136/bmjopen-2018-025141]VergheseTS , MiddletonLJ , CheedV , LeightonL , DanielsJP , LatthePM . A randomised controlled trial to investigate the effectiveness of local oestrogen treatment in postmenopausal women undergoing pelvic organ prolapse surgery (LOTUS)-a pilot study to assess feasibility of a large multi-centre trial (Abstract 026). International Urogynecology Journal2018;29(Suppl 1):S15-6. [DOI: 10.1007/s00192-018-3752-x]">Verghese 2020</a>). It is uncertain whether topical or systemic oestrogen therapy plus surgery affects the occurrence of major adverse events compared with surgery alone, because the 95% CI indicates both benefit and harm (RR 1.02, 95% CI 0.39 to 2.66; 453 participants; <a href="./references#CD014592-fig-0027" title="">Analysis 2.20</a>). </p> </section> <section id="CD014592-sec-0114"> <h6 class="title">Surgical outcomes: operative time</h6> <p>Only <a href="./references#CD014592-bbs2-0007" title="EUCTR2016-000410-30-AT. Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: influence on subjective and objective parameters [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome: a prospective randomized, double-blind, placebo-controlled study]. www.clinicaltrialsregister.eu/ctr-search/trial/2016-000410-30/results (first received 19 October 2016). MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Sexual function in postmenopausal women with symptomatic pelvic organ prolapse treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Sexual Medicine2022;19(7):1124-30. [DOI: 10.1016/j.jsxm.2022.04.007]MarschalekML , BodnerK , KimbergerO , MorgenbesserR , DietrichW , ObrucaC , et al. Surgical assessment of tissue quality during pelvic organ prolapse repair in postmenopausal women pre-treated either with locally applied estrogen or placebo: results of a double-masked, placebo-controlled, multicenter trial. Journal of Clinical Medicine2021;10(11):2531. [DOI: 10.3390/jcm10112531]MarschalekML , BodnerK , KimbergerO , ZehetmayerS , MordenbesserR , DietrichW , et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG2021;128(13):2200-8. [DOI: 10.1111/1471-0528.16894]NCT03779633. Preoperative oestrogen in postmenopausal women with pelvic organ prolapse [Preoperative locally applied oestrogen in postmenopausal women with pelvic organ prolapse: changes in subjective and objective outcome – a prospective, randomized, double-blind, placebo-controlled, multicenter study]. clinicaltrials.gov/show/NCT03779633 (first received 19 December 2018). ">Marschalek 2021</a> reported operative time. Operative time in minutes may be slightly longer for women receiving topical oestrogen plus surgery compared with those receiving surgery alone (103 participants; <a href="./references#CD014592-fig-0028" title="">Analysis 2.21</a>). </p> </section> <section id="CD014592-sec-0115"> <h6 class="title">Surgical outcomes: mesh exposure</h6> <p>Two studies reported mesh exposure, but we were unable to pool their results (<a href="./references#CD014592-bbs2-0006" title="KarpD , Jean-MichelM , PetersonT , JohnstonY , SuciuG , AguilarV , et al. Optimizing post-operative healing following vaginal reconstructive surgery: a triple arm randomized clinical trial of an estradiol-releasing vaginal ring (Abstract 55). Neurourology and Urodynamics2010;29(6):887-8. KarpDR , Jean-MichelM , JohnstonY , SuciuG , AguilarVC , DavilaGW . A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery. Female Pelvic Medicine and Reconstructive Surgery2012;18(4):211-5. [DOI: 10.1097/SPV.0b013e31825e6401]">Karp 2012</a>; <a href="./references#CD014592-bbs2-0011" title="SunZ , ZhuL , XuT , ShiX , LangJ . Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause2016;23(7):740-8. [DOI: 10.1097/GME.0000000000000614]ZhuL , SunZ , ChiCTR-TRC-13003481. A Randomized, controlled trial of intravaginal promestriene in women with a risk of mesh exposure associated with transvaginal implantation for pelvic organ prolapse [阴道局部应用雌激素对预防网片重建手术网片暴露的效果研究]. chictr.org.cn/showproj.aspx?proj=6079 (first received 15 August 2013). ">Sun 2016</a>). Both studies found little or no difference in the number of women with mesh exposures between the topical oestrogen plus surgery and surgery alone groups (<a href="./references#CD014592-fig-0029" title="">Analysis 2.22</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD014592-sec-0116" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD014592-sec-0116"></div> <p>A previous Cochrane Review evaluated oestrogens for treatment or prevention of POP in postmenopausal women (<a href="./references#CD014592-bbs2-0064" title="IsmailSI , BainC , HagenS . Oestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal women. Cochrane Database of Systematic Reviews2010, Issue 9. Art. No: CD007063. [DOI: 10.1002/14651858.CD007063.pub2]">Ismail 2010</a>). To aid clarity, it was decided to divide the topic into two separate reviews covering prevention and treatment. This review covers the treatment of POP with oestrogen therapy in postmenopausal women. </p> <section id="CD014592-sec-0117"> <h3 class="title" id="CD014592-sec-0117">Summary of main results</h3> <p>We identified 14 studies including a total of 1002 women in this version of the review. No studies assessed the effects of oestrogen therapy alone versus no treatment or placebo, versus PFMT, versus devices such as vaginal pessaries, or versus surgery. However, three studies assessed topical oestrogen therapy in conjunction with vaginal pessaries versus vaginal pessaries alone, and 11 studies evaluated oestrogen therapy in conjunction with surgery versus surgery alone. </p> </section> <section id="CD014592-sec-0118"> <h3 class="title" id="CD014592-sec-0118">Overall completeness and applicability of evidence</h3> <p>We conducted a comprehensive search for studies, conducted citation chaining, and attempted to obtain unpublished data where necessary (e.g. by contacting study authors). However, the 14 studies included in this review only covered two of our prespecified comparisons, and none contributed to any of our four main comparisons. </p> <p>Many studies were small, and the number of participants ranged from six to 186. Although the studies were set in a mix of high‐income countries and low‐ and middle‐income countries, three were conducted in Brazil, and three in the USA. As we identified only 14 studies, the applicability of our findings to different populations may be limited. In addition, many studies did not report the ethnicities of participants. </p> <p>The studies were clinically heterogenous in terms of the outcomes assessed, the tools used, and the time points of measurement. Additionally, many studies focused on Vaginal Maturation Index (VMI) and cytological outcomes that are associated more with genitourinary symptoms of menopause (GSM) than with POP, or used as surrogate markers for outcomes. </p> <p>Furthermore, we were unable to perform our prespecified subgroup analyses owing to insufficient data. Because we could not analyse the results of topical and systemic oestrogen therapy separately, some of our findings may not take into account the route of administration. Although there is evidence of a difference in the effect of systemic and local oestrogen on urinary symptoms (<a href="./references#CD014592-bbs2-0041" title="CodyJD , JacobsML , RichardsonK , MoehrerB , HextallA . Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database of Systematic Reviews2012, Issue 10. [DOI: 10.1002/14651858]">Cody 2012</a>), similar evidence is not available for POP. Benefits from systemic oestrogen such as improvement of vaginal dryness and vaginal epithelial quality may also be relevant for POP symptoms (<a href="./references#CD014592-bbs2-0084" title="RahnDD , WardRM , SansesTV , CarberryC , MamikMM , MeriwetherKV , et al, on behalf of the Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen use in postmenopausal women with pelvic floor disorders: systematic review and practice guidelines. International Urogynecology Journal2015;26(1):3-13.">Rahn 2015</a>). </p> </section> <section id="CD014592-sec-0119"> <h3 class="title" id="CD014592-sec-0119">Quality of the evidence</h3> <p>In general, the evidence on oestrogen therapy for treating POP is uncertain. We were unable to assess the evidence using GRADE, as no studies evaluated our main comparisons of interest. </p> <p>The meta‐analyses we performed often included too few participants to give a precise result; this imprecision was reflected in wide CIs. In terms of risk of bias, many studies were at high risk of performance bias because they did not blind participants or personnel, and we also had some concerns about selective reporting. </p> </section> <section id="CD014592-sec-0120"> <h3 class="title" id="CD014592-sec-0120">Potential biases in the review process</h3> <p>We made every effort to minimise bias within the review process. This included conducting a comprehensive literature search, including citation chaining, and having two review authors independently screen studies, extract data, and assess risk of bias. Had data allowed, two independent review authors would have performed the GRADE assessment. </p> <p>However, we changed the PICO from that prespecified in the protocol, particularly surrounding outcome measures (see <a href="#CD014592-sec-0139">Differences between protocol and review</a>). We made most of these changes after starting data extraction. Our intention was to make the review more clinically useful and accessible for stakeholders (including patients, the public, and clinicians) by focusing on outcomes that would be more consistent across our prespecified comparisons. We made every attempt not to be data‐driven when making these decisions. </p> </section> <section id="CD014592-sec-0121"> <h3 class="title" id="CD014592-sec-0121">Agreements and disagreements with other studies or reviews</h3> <p>Two previous reviews investigated the role of oestrogen in the treatment of POP (<a href="./references#CD014592-bbs2-0084" title="RahnDD , WardRM , SansesTV , CarberryC , MamikMM , MeriwetherKV , et al, on behalf of the Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen use in postmenopausal women with pelvic floor disorders: systematic review and practice guidelines. International Urogynecology Journal2015;26(1):3-13.">Rahn 2015</a>; <a href="./references#CD014592-bbs2-0097" title="WeberMA , KleijnMH , LangendamM , LimpensJ , HeinemanMJ , RooversJP . Local oestrogen for pelvic floor disorders: a systematic review. PLOS One2015;10(9):e0136265.">Weber 2015</a>). Both concluded that the available evidence was scarce and of low quality, and the included studies assessed vaginal signs and symptoms of atrophy or hypo‐oestrogenisation rather than specifically signs and symptoms of POP. </p> </section> <section id="CD014592-sec-0122"> <h3 class="title" id="CD014592-sec-0122">Brief economic commentary</h3> <p>To supplement the main systematic review of oestrogen therapy for treating POP in postmenopausal women, we sought to identify relevant economic evaluations. We found no economic studies that analysed the use of oestrogen therapy in this population. The apparent shortage of relevant economic evaluations indicates a paucity of economic evidence on the efficiency of oestrogen therapy as a management strategy for treating POP in postmenopausal women. It should be noted that one potentially relevant ongoing trial includes an economic evaluation (<a href="./references#CD014592-bbs2-0096" title="VodegelEV , ZwolsmanSE , VollebregtA , DuijnhovenRG , BosmansJE , SpeksnijderL , et al. Cost-effectiveness of perioperative vaginally administered estrogen in postmenopausal women undergoing prolapse surgery (EVA trial): study protocol for a multicenter double-blind randomized placebo-controlled trial. BMC Women's Health2021;21:439.">Vodegel 2021</a>). The ongoing trial is a multicentre, double‐blind, randomised, placebo‐controlled trial based in the Netherlands, comparing the administration of vaginal oestrogen cream or placebo cream from four to six weeks after surgery until 12 months after surgery. The economic evaluation will include a cost‐effectiveness analysis (with the outcomes measured by the PFDI‐20) and a cost‐utility analysis (with the outcomes measured by quality adjusted life years (QALYs)). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD014592-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/urn:x-wiley:14651858:media:CD014592:CD014592-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA diagram – clinical effectiveness searches." data-id="CD014592-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_t/tCD014592-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA diagram – clinical effectiveness searches.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/full#CD014592-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014592-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/urn:x-wiley:14651858:media:CD014592:CD014592-FIG-02" target="_blank"><b></b></a></p> </div><img alt="PRISMA diagram – cost effectiveness searches." data-id="CD014592-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_t/tCD014592-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>PRISMA diagram – cost effectiveness searches.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/full#CD014592-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014592-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/urn:x-wiley:14651858:media:CD014592:CD014592-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD014592-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_t/tCD014592-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/full#CD014592-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014592-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/urn:x-wiley:14651858:media:CD014592:CD014592-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD014592-fig-0004" src="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_t/tCD014592-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/full#CD014592-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014592-fig-0005"> <p> <div class="table" id="CD014592-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Participant adherence to the intervention (including discontinuation of pessary use and declining surgical procedures) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>OT + pessary</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pessary alone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time‐point</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Nature of adherence</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Coelho 2020</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinued pessary</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Oestrogen therapy (OT) in conjunction with vaginal pessaries versus vaginal pessaries alone, Outcome 1: Participant adherence to the intervention (including discontinuation of pessary use and declining surgical procedures) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-fig-0005">Navigate to figure in review</a></div> </div> <div class="figure" id="CD014592-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/urn:x-wiley:14651858:media:CD014592:CD014592-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oestrogen therapy (OT) in conjunction with vaginal pessaries versus vaginal pessaries alone, Outcome 2: Reduction in minor adverse events: vaginal events" data-id="CD014592-fig-0006" src="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_t/tCD014592-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Oestrogen therapy (OT) in conjunction with vaginal pessaries versus vaginal pessaries alone, Outcome 2: Reduction in minor adverse events: vaginal events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014592-fig-0007"> <p> <div class="table" id="CD014592-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Major adverse events</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>OT + pessary</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Pessary alone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time‐point</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of adverse event</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Coelho 2020</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major adverse events</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tontivuthikul 2016</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major adverse events</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Oestrogen therapy (OT) in conjunction with vaginal pessaries versus vaginal pessaries alone, Outcome 3: Major adverse events </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-fig-0007">Navigate to figure in review</a></div> </div> <div class="figure" id="CD014592-fig-0008"> <p> <div class="table" id="CD014592-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Participant‐reported subjective improvement or cure of pelvic organ prolapse symptoms: 6 months </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>OT + surgery</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Surgery alone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tool used</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tool direction</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sun 2016</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.5%</p> <p>n = 93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90.3%</p> <p>n = 93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rate of satisfaction on Patient Global Impression of Change (PGI‐C)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Good response on PGI‐C: at month 12, defined as "much better" or "a little better" when participants were asked "compared with how you were doing before your recent pelvic floor operation, would you say that now you are much better/a little better/about the same/a little worse/much worse?" </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Verghese 2020</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.4 ± 43.8</p> <p>n = 38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.0 ± 37.1</p> <p>n = 41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pelvic Floor Impact Questionnaire (PFIQ‐7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Higher score = worse outcome</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 1: Participant‐reported subjective improvement or cure of pelvic organ prolapse symptoms: 6 months </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-fig-0008">Navigate to figure in review</a></div> </div> <div class="figure" id="CD014592-fig-0009"> <p> <div class="table" id="CD014592-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Participant‐reported subjective improvement or cure of pelvic organ prolapse symptoms: 12 months </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>OT + surgery</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Surgery alone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tool used</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tool direction</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sun 2016</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97.8%</p> <p>n = 93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95.7%</p> <p>n = 93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rate of satisfaction on Patient Global Impression of Change (PGI‐C)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Good response on PGI‐C: at month 12, defined as "much better" or "a little better" when participants were asked "compared with how you were doing before your recent pelvic floor operation, would you say that now you are much better/a little better/about the same/a little worse/much worse?" </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Verghese 2020</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49.8 ± 44.1</p> <p>n = 36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.1 ± 47.7</p> <p>n = 41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pelvic Floor Impact Questionnaire (PFIQ‐7) summary score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Score 0–300; higher score = worse outcome</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 2: Participant‐reported subjective improvement or cure of pelvic organ prolapse symptoms: 12 months </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-fig-0009">Navigate to figure in review</a></div> </div> <div class="figure" id="CD014592-fig-0010"> <p> <div class="table" id="CD014592-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Improvement or cure of associated urinary symptoms: 6 months</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>OT + surgery</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Surgery alone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tool used</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tool direction</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Verghese 2020</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.6 ± 21.7</p> <p>n = 38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.9 ± 11.2</p> <p>n = 41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urinary Impact Questionnaire (UIQ‐7); score 0–100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Higher score = worse outcome</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 3: Improvement or cure of associated urinary symptoms: 6 months </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-fig-0010">Navigate to figure in review</a></div> </div> <div class="figure" id="CD014592-fig-0011"> <p> <div class="table" id="CD014592-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Improvement or cure of associated urinary symptoms: 12 months</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>OT + surgery</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Surgery alone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tool used</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tool direction</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Verghese 2020</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.9 ± 16.8</p> <p>n = 37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.0 ± 13.9</p> <p>n = 42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urinary Impact Questionnaire (UIQ‐7); score 0–100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Higher score = worse outcome</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 4: Improvement or cure of associated urinary symptoms: 12 months </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-fig-0011">Navigate to figure in review</a></div> </div> <div class="figure" id="CD014592-fig-0012"> <p> <div class="table" id="CD014592-tblf-0007"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Improvement or cure of associated bowel symptoms: 6 months</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>OT + surgery</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Surgery alone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tool used</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tool direction</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Verghese 2020</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.9 ± 13.1</p> <p>n = 38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4 ± 6.1</p> <p>n = 41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colorectal‐Anal Impact Questionnaire (CRAIQ‐7); score 0–100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Higher score = worse outcome</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 5: Improvement or cure of associated bowel symptoms: 6 months </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-fig-0012">Navigate to figure in review</a></div> </div> <div class="figure" id="CD014592-fig-0013"> <p> <div class="table" id="CD014592-tblf-0008"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Improvement or cure of associated bowel symptoms: 12 months</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>OT + surgery</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Surgery alone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tool used</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tool direction</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Verghese 2020</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.5 ± 16.3</p> <p>n = 36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9 ± 6.1</p> <p>n = 42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Colorectal‐Anal Impact Questionnaire (CRAIQ‐7); score 0–100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Higher score = worse outcome</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 6: Improvement or cure of associated bowel symptoms: 12 months </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-fig-0013">Navigate to figure in review</a></div> </div> <div class="figure" id="CD014592-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/urn:x-wiley:14651858:media:CD014592:CD014592-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 7: Improvement or cure of associated sexual symptoms: 6 months" data-id="CD014592-fig-0014" src="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_t/tCD014592-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 7: Improvement or cure of associated sexual symptoms: 6 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014592-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/urn:x-wiley:14651858:media:CD014592:CD014592-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 8: Improvement or cure of associated sexual symptoms: 12 months" data-id="CD014592-fig-0015" src="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_t/tCD014592-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 8: Improvement or cure of associated sexual symptoms: 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014592-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/urn:x-wiley:14651858:media:CD014592:CD014592-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 9: Objective improvement or cure of pelvic organ prolapse: 6 months (meta‐analysis)" data-id="CD014592-fig-0016" src="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_t/tCD014592-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 9: Objective improvement or cure of pelvic organ prolapse: 6 months (meta‐analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014592-fig-0017"> <p> <div class="table" id="CD014592-tblf-0009"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Objective improvement or cure of pelvic organ prolapse: 6 months (other data)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>OT + surgery</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Surgery alone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tool used</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Rahn 2014</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Postoperative anterior compartment stage</p> <p>Median: 0.5</p> <p>IQR: 0.5, 0.8</p> <p>n = 8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Postoperative anterior compartment stage</p> <p>Median: 1.0</p> <p>IQR: 0.0, 1.3</p> <p>n = 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Assumed Pelvic Organ Prolapse Quantification System (POP‐Q); not clear from paper</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 10: Objective improvement or cure of pelvic organ prolapse: 6 months (other data) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-fig-0017">Navigate to figure in review</a></div> </div> <div class="figure" id="CD014592-fig-0018"> <p> <div class="table" id="CD014592-tblf-0010"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Objective improvement or cure of pelvic organ prolapse: 12 months</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>OT + surgery</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Surgery alone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tool used</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sun 2016</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> <p>n = 93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98.9%</p> <p>n = 93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anatomic success rate % measured by Pelvic Organ Prolapse Quantification System (POP‐Q) stage &lt; 2 </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 11: Objective improvement or cure of pelvic organ prolapse: 12 months </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-fig-0018">Navigate to figure in review</a></div> </div> <div class="figure" id="CD014592-fig-0019"> <p> <div class="table" id="CD014592-tblf-0011"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Condition‐specific quality of life: 6 months</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>OT + surgery</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Surgery alone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tool used</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Direction of tool</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sun 2016</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.4 ± 5.7</p> <p>n = 93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.8 ± 5.6</p> <p>n = 93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pelvic Floor Impact Questionnaire (PFIQ‐7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Higher score = better result</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 12: Condition‐specific quality of life: 6 months </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-fig-0019">Navigate to figure in review</a></div> </div> <div class="figure" id="CD014592-fig-0020"> <p> <div class="table" id="CD014592-tblf-0012"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Condition‐specific quality of life: 12 months</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>OT + surgery</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Surgery alone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Tool used</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Direction of tool</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sun 2016</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2 ± 3.4</p> <p>n = 93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.8 ± 4.3</p> <p>n = 93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pelvic Floor Impact Questionnaire (PFIQ‐7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Higher score = better result</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 13: Condition‐specific quality of life: 12 months </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-fig-0020">Navigate to figure in review</a></div> </div> <div class="figure" id="CD014592-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/urn:x-wiley:14651858:media:CD014592:CD014592-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 14: Participant adherence to intervention (meta‐analysis)" data-id="CD014592-fig-0021" src="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_t/tCD014592-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 14: Participant adherence to intervention (meta‐analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014592-fig-0022"> <p> <div class="table" id="CD014592-tblf-0013"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Participant adherence to intervention (other data)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>OT + surgery</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Surgery alone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Definition of compliance</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time‐point</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Verghese 2020</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable (no oestrogen therapy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pessaries used ≥ 75% of the expected time</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 months</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 15: Participant adherence to intervention (other data) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-fig-0022">Navigate to figure in review</a></div> </div> <div class="figure" id="CD014592-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/urn:x-wiley:14651858:media:CD014592:CD014592-CMP-002.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 16: Reduction in minor adverse events: urinary tract infection" data-id="CD014592-fig-0023" src="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-CMP-002.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_t/tCD014592-CMP-002.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 16: Reduction in minor adverse events: urinary tract infection </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-CMP-002.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014592-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/urn:x-wiley:14651858:media:CD014592:CD014592-CMP-002.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 17: Reduction in minor adverse events: vaginal events" data-id="CD014592-fig-0024" src="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-CMP-002.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_t/tCD014592-CMP-002.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 17: Reduction in minor adverse events: vaginal events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-CMP-002.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014592-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/urn:x-wiley:14651858:media:CD014592:CD014592-CMP-002.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 18: Reduction in minor adverse events: urinary storage events" data-id="CD014592-fig-0025" src="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-CMP-002.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_t/tCD014592-CMP-002.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 18: Reduction in minor adverse events: urinary storage events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-CMP-002.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014592-fig-0026"> <p> <div class="table" id="CD014592-tblf-0014"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Reduction in minor adverse events: sexual adverse events</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>OT + surgery</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Surgery alone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Symptom</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Time‐point</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Karp 2012</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Partner discomfort with intercourse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 weeks</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sun 2016</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dyspareunia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any time within 1 year</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 19: Reduction in minor adverse events: sexual adverse events </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-fig-0026">Navigate to figure in review</a></div> </div> <div class="figure" id="CD014592-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/urn:x-wiley:14651858:media:CD014592:CD014592-CMP-002.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 20: Major adverse events: total number of events" data-id="CD014592-fig-0027" src="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-CMP-002.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_t/tCD014592-CMP-002.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 20: Major adverse events: total number of events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/media/CDSR/CD014592/image_n/nCD014592-CMP-002.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014592-fig-0028"> <p> <div class="table" id="CD014592-tblf-0015"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Surgical outcomes: operative time</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>OT + surgery</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Surgery alone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Measurement</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Marschalek 2021</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88.73 ± 30.3</p> <p>n = 51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.46 ± 32.3</p> <p>n = 52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minutes</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 21: Surgical outcomes: operative time </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-fig-0028">Navigate to figure in review</a></div> </div> <div class="figure" id="CD014592-fig-0029"> <p> <div class="table" id="CD014592-tblf-0016"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Surgical outcomes: mesh exposure</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>OT + surgery</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Surgery alone</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Measurement</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Karp 2012</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of mesh exposures on examination at 12 weeks after surgery</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sun 2016</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesh exposures ≤ 1 cm within 1 year</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2: Oestrogen therapy (OT) in conjunction with surgery versus surgery alone, Outcome 22: Surgical outcomes: mesh exposure </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-fig-0029">Navigate to figure in review</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD014592-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Oestrogen therapy alone versus no treatment or placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oestrogen therapy alone versus no treatment or placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women with POP </p> <p><b>Setting:</b> primary or secondary care </p> <p><b>Intervention:</b> oestrogen therapy </p> <p><b>Comparison:</b> no treatment or placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with oestrogens</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no treatment or placebo</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subjective improvement or cure of POP symptoms</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement or cure of associated sexual symptoms</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Objective improvement or cure of POP symptoms</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Generic quality of life measures</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant adherence to intervention</b><br/>Follow‐up: various time points </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Minor adverse effects: vaginal events</b><br/>Follow‐up: longest time point reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major adverse events</b><br/>Follow‐up: longest time point reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>POP:</b> pelvic organ prolapse. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Oestrogen therapy alone versus no treatment or placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/full#CD014592-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014592-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oestrogen therapy alone versus pelvic floor muscle training</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oestrogen therapy alone versus pelvic floor muscle training</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women with POP </p> <p><b>Setting:</b> primary or secondary care </p> <p><b>Intervention:</b> oestrogen therapy </p> <p><b>Comparison:</b> pelvic floor muscle training </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with oestrogens</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with PFMT</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subjective improvement or cure of POP symptoms</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement or cure of associated sexual symptoms</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Objective improvement or cure of POP symptoms</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Generic quality of life measures</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant adherence to intervention</b><br/>Follow‐up: various time points </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Minor adverse effects: vaginal events</b><br/>Follow‐up: longest time point reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major adverse events</b><br/>Follow‐up: longest time point reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>PFMT:</b> pelvic floor muscle training; <b>POP:</b> pelvic organ prolapse. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oestrogen therapy alone versus pelvic floor muscle training</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/full#CD014592-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014592-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oestrogen therapy alone versus devices such as vaginal pessaries</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oestrogen therapy alone versus devices such as vaginal pessaries</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women with POP </p> <p><b>Setting:</b> primary or secondary care </p> <p><b>Intervention:</b> oestrogen therapy </p> <p><b>Comparison:</b> devices such as vaginal pessaries </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with oestrogens</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no treatment or placebo</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subjective improvement or cure of POP symptoms</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement or cure of associated sexual symptoms</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Objective improvement or cure of POP symptoms</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Generic quality of life measures</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant adherence to intervention</b><br/>Follow‐up: various time points </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Minor adverse effects: vaginal events</b><br/>Follow‐up: longest time point reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major adverse events</b><br/>Follow‐up: longest time point reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>POP:</b> pelvic organ prolapse. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oestrogen therapy alone versus devices such as vaginal pessaries</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/full#CD014592-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD014592-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Oestrogen therapy alone versus surgery</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oestrogen therapy alone versus surgery</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> women with POP </p> <p><b>Setting:</b> primary or secondary care </p> <p><b>Intervention:</b> oestrogen therapy </p> <p><b>Comparison:</b> surgery </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with oestrogens</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no treatment or placebo</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subjective improvement or cure of POP symptoms</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement or cure of associated sexual symptoms</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Objective improvement or cure of POP symptoms</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Generic quality of life measures</b><br/>Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant adherence to intervention</b><br/>Follow‐up: various time points </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Minor adverse effects: vaginal events</b><br/>Follow‐up: longest time point reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major adverse events</b><br/>Follow‐up: longest time point reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>POP:</b> pelvic organ prolapse. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Oestrogen therapy alone versus surgery</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/full#CD014592-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014592-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oestrogen therapy (OT) in conjunction with vaginal pessaries versus vaginal pessaries alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Participant adherence to the intervention (including discontinuation of pessary use and declining surgical procedures) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Reduction in minor adverse events: vaginal events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.25, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Major adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oestrogen therapy (OT) in conjunction with vaginal pessaries versus vaginal pessaries alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014592-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oestrogen therapy (OT) in conjunction with surgery versus surgery alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Participant‐reported subjective improvement or cure of pelvic organ prolapse symptoms: 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Participant‐reported subjective improvement or cure of pelvic organ prolapse symptoms: 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Improvement or cure of associated urinary symptoms: 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Improvement or cure of associated urinary symptoms: 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Improvement or cure of associated bowel symptoms: 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Improvement or cure of associated bowel symptoms: 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Improvement or cure of associated sexual symptoms: 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.02 [‐3.52, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Improvement or cure of associated sexual symptoms: 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.57 [‐1.98, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Objective improvement or cure of pelvic organ prolapse: 6 months (meta‐analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.94, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Objective improvement or cure of pelvic organ prolapse: 6 months (other data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Objective improvement or cure of pelvic organ prolapse: 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Condition‐specific quality of life: 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Condition‐specific quality of life: 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 Participant adherence to intervention (meta‐analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.49, 2.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.15 Participant adherence to intervention (other data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.16 Reduction in minor adverse events: urinary tract infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.26, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.17 Reduction in minor adverse events: vaginal events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.23 [0.74, 6.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.18 Reduction in minor adverse events: urinary storage events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.46, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.19 Reduction in minor adverse events: sexual adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.20 Major adverse events: total number of events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.39, 2.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.21 Surgical outcomes: operative time <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.22 Surgical outcomes: mesh exposure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Oestrogen therapy (OT) in conjunction with surgery versus surgery alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014592.pub2/references#CD014592-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD014592.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD014592-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD014592-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD014592-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD014592-note-0010">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD014592-note-0007">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD014592-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD014592-note-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD014592-note-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD014592-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014592\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014592\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014592\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014592\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014592\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014592\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014592\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014592\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014592\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014592\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014592\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014592\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014592\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014592\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014592\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014592\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014592\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014592\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7LavyS58&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014592.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014592.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD014592.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD014592.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014592.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740720080822"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014592.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740720080825"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014592.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918df870794f9368',t:'MTc0MDcyMDA4MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 